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Abstract
Biological networks have been employed as prior knowledge to identify robust molecular
signatures. Many studies integrate protein-protein interaction(PPI) network with gene
expression data, where the network is often used to guide the search in the feature space to
select the important nodes or subnetworks as signatures. As multiple types of omics data
become more and more available, it brings the questions of which data types contain better
molecular signatures and whether it is beneficial to use multiple omics data simultaneously.
We investigated this topic with the task of cancer prognosis prediction. After con-
ducting a comprehensive literature review, we selected 10 representative feature selection
algorithms. Five of them integrate network information and the other five algorithms use
only omics data. On single-omics levels, we performed feature selection alternatively on
mRNA and miRNA expression data, DNA methylation data, and copy number alteration
data. Then we evaluated the prediction performance of these features, as well as their
stability, network properties, and biological interpretation. To obtain multi-omics signa-
tures, we first combined the selected features from single-omics levels and evaluated the
prediction performance of different combinations. Then we extended network-based fea-
ture selection algorithms to incorporate multi-omics data using a multiplex structure. For
the feature selection algorithms that do not use network information, we employed them
on concatenated data. Last but not least, we evaluated the predictive performance of both
single-omics and multi-omics signatures on independent lung cancer multi-omics data.
One of the major challenges in biomarker discovery is the curse of dimensionality, which
contributes to the low reproducibility of many proposed molecular signatures. Even with
network-based feature selection algorithms, significant improvements are hard to achieve
as the networks are often of large sizes. To avoid this issue and find biologically meaningful
signatures, we propose to construct phenotype relevant gene regulatory networks based on
Epithelial Mesenchymal Transition (EMT), which is demonstrated as highly relevant to
the metastasis and prognosis of epithelial cancers. We integrated different types of omics
data with EMT networks to select prognostic signatures. Although the dimensionality was
reduced to less than 2.5% of the original, EMT-based feature selection gave even better
prediction performance than selecting features from the original data. Frequently selected
features achieved average AUC value of 0.83. The features were able to stratify patients
into significantly different prognostic groups on both the training data and the independent
testing data. Using combinations of single-omics signatures and using multiplex-based
feature selection further improved the prediction performance.
Since biological data have large volume, high velocity, and wide varieties, it becomes
necessary to employ database systems that meet the need of integrative omics data analysis.
Therefore, we tested the performance of a few relational and non-relational databases for
storing and retrieving omics data. Based on the results, we provided a few advices on
building scalable omics data infrastructures.
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1.1 Rich Omics Data and the Curse of Dimensionality
Cancer is a generic term for a large group of diseases characterized by uncontrollable
cell growth and divisions, promotion of blood vessel construction, and the capability of
invading other tissues, organs and forming metastases. Cancer accounts for more than 8
million deaths worldwide annually. According to the National Cancer Institute, there are
more than 100 types of cancer, which are usually named after the organs or tissues where
the cancer origins. The major cancer types are lung, liver, colorectal, breast cancer, etc.
Cancers are also described by the type of cell that forms them, such as an epithelial cell
or a squamous cell. Cancers that are formed by epithelial cells are called carcinomas. It is
the most common type of cancer. Carcinomas that begin in different epithelial cell types
have specific names. Adenocarcinoma is a cancer that forms in epithelial cells that produce
fluids or mucus. Lung cancer is a leading cancer type, which causes more than 1.5 million
deaths [222] per year. It is an aggressive, heterogeneous cancer type [60] and its long-term
survival rate remains low despite the advances in surgery, radiotherapy, and chemotherapy
[222]. As adenocarcinoma is the most common lung cancer histological subtype, accounting
for almost half of all lung cancers, in this study we take Lung Adenocarcinoma as the
example [50].
While it is difficult to cure a cancer patient at a late stage, it is very important to
choose the right therapy according to the risk/prognosis of the patients. If we can pre-
dict the prognosis of cancer patients at diagnosis, e.g., classifying patients into high and
low risk groups, it can help the clinicians and patients to make decisions between active
versus supportive treatment in order to balance the benefits and toxicities. Traditional
cancer prognosis prediction is based on clinical variables such as tumor stage, age, and
disease history. The information of a patient is compared against population cancer re-
gistries [104]. However, these clinical parameters are insufficient to accurately predict the
risk of patients [232]. Overwhelming evidence shows that histologically similar tumors can
be of completely different diseases at the molecular level, each with different clinical be-
havior [143, 226, 255]. In addition, some medical tests such as computed tomography and
biopsy can be harmful. The National Lung Screening Trial conducted a randomized trial
using low-dose CT to screen lung cancer among high-risk persons. While the screening sig-
nificantly reduced lung cancer mortality, the false positive rate is high (96%) [241]. Since
cancer is a heterogeneous disease, more individualized prognosis prediction is necessary.
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Fortunately, ’Omic’ technologies provide detailed characterization of patients’ molecular
profiles to advance the clinical management of cancer.
Omics refers to the aggregate of studies in biology ending in omics, such as genomics,
transcriptomics, epigenomics, proteomics, etc. The related suffix -ome is used to address
the object under these studies - genome, transcriptome, epicurean, proteome, respectively.
For example, genomics involves sequencing and the analysis of entire genome, which is
the complete set of genetic material. It studies phenomenon such as heterosis, epistasis,
and copy number variation (CNV) using technologies of DNA sequencing. Transcriptomics
studies all RNA transcripts, including mRNAs and non-coding RNAs. The commonly used
techniques are microarray and RNA sequencing (RNA-Seq). Epigenetics studies epigenetic
modifications such as DNA methylation and histone modification on the genome. These
modifications are heritable traits that affect gene activity and expression. These multiple
levels of gene regulation interplay and lead to complex phenotypes, as shown in Figure 1.1,
where we illustrated five gene regulation mechanisms (in reality there are much more) that
happen within or between omics levels:
1. Single-nucleotide polymorphism (SNP). It is a variation in a single nucleotide at
specific positions of a genome. It is present to a certain degree in a population and
it underlies differences in our susceptibility to disease.
2. Epigenomic regulations such as DNA methylation and histone modification. The
former adds methyl groups to the DNA molecule and typically acts to repress gene
transcription. The latter contributes to the accessibility of genes for transcription.
3. Alternative splicing. On the transcriptome level a precursor mRNA can produce
different mRNAs, which is regulated by trans-acting splicing activator and splicing
repressor proteins. In this way, a single gene can code multiple proteins.
4. miRNA-related gene silencing. miRNA-related gene silencing: miRNAs bind to the
target mRNA via base-paring to silence mRNA molecules by mechanisms such as
cleavage and destabilization.
5. Transcription factor regulation. Transcription factors are proteins that bind to a
specific DNA sequence (TFbs: transcription factor binding site) to control the tran-
scription rate of genes.
6. The enzymes catalyze all catabolic pathways to break nutrients into cellular building
blocks, produce energy and heat; and all anabolic pathways to synthesize complex
molecules from simpler ones using energy.
It is not hard to acknowledge that biological systems are complex and dynamic, consid-
ering the gene regulations that happen at multiple Omics levels simultaneously. Therefore,
heterogeneous molecular data, as mentioned above, can offer tremendous insights into the
molecular changes in cancer pathogenesis. It is also necessary for building robust models
to predict clinical outcomes. Thanks to technological advances, obtaining multiple levels
of omics data becomes cheaper and more feasible. As one of the large-scale projects, the
Cancer Genome Atlas (TCGA) project has generated genomic, transcriptomic, epigenomic,
and proteomic data from more than 11,000 cases in 33 cancer types and subtypes [271].
1.1 Rich Omics Data and the Curse of Dimensionality 3
Figure 1.1: Multiple -omes interact with each other and jointly contribute to the phenome.
The data have been used for different applications such as prognosis prediction [303], cancer
subtypes classification [30,305] and cancer driver genes identification [305].
In prognosis prediction with omics data, machine learning is a widely applied technique
to generate predictive models. Machine learning can be generally understood as learning
from data using computer programs. It follows the procedure of induction and deduction.
In the inductive step it learns the model from data (training set) and in the deductive step
the model is employed to make predictions on new data (testing data). In data-driven
applications, it is often a very good alternative to manual model construction, which is
in some cases very time consuming or not feasible. The commonly accepted operational
definition of a machine learning program is given by Tom M. Mitchell ”A computer program
is said to learn from experience E with respect to some class of tasks T and performance
measure P if its performance at tasks in T, as measured by P, improves with experience
E” [172]. It shows that the computer program captures the patterns in the existing data
so that it can generalize in unseen data. We would like to give an example of spam filter
here to convey this idea. The task T is to classify emails into two classes: spam or not
spam. This is a type of machine learning named classification and it is the most mature
and most often used type. A simple classifier is illustrated in Figure 1.2. Given a good
amount of spam and normal emails, there are mainly five steps:
1. Decide how to represent each email as a feature vector. We build a representative
word list from a dictionary and use a Boolean vector to represent each email in terms
of whether these words are present in the email.
2. Extract the Boolean features from all emails to generate the training set.
3. Train a decision tree classifier using these features where the leaf nodes give the most
likely labels for the emails that reach the nodes.
4 Chapter 1 Introduction
Figure 1.2: A simple machine learning application - spam classifier.
4. Test the classifier on new emails by extracting the same Boolean features and predict
their labels using the decision tree.
5. Compare the prediction with the true labels to evaluate the classifier.
By its definition, machine learning applications depend on data, specifically, the amount
of data and the quality of features. In extreme cases, when there are no data or no relevant
data, it is infeasible to train a machine learning model. Compared with the application
of classifying emails, classifying cancer patients into good and poor prognostic groups is
more difficult due to the facts listed in Table 1.1. The class labels of patients are not
so straightforward as emails. This is because usually one does not have the follow-up
information for all samples. This happens when the patients withdraw the study or the
event (death) has not occurred at the end of the study so their prognostic data are only
partly known. In this case, right-censoring is present. If right-censoring happens in many
samples, e.g., due to a short follow-up time, it can affect the reliability of analysis. In
studies that try to identify prognostic biomarkers, censoring is usually handled in two
ways, either by dichotomizing the samples into good and poor prognostic groups based
on a threshold or by doing survival analysis that can take into account the censoring
information. The feature noise is common in Omics data due to batch effect, which refers
to technical sources of variation that have been added to the samples during handling.
Factors include different experiment times, handlers, reagent lots, etc [81]. It can be
detected and adjusted using batch effect correction algorithms [32, 144, 234]. The most
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Table 1.1: Comparison of the applications of spam filter and cancer prognosis prediction.
Spam filter Prognosis prediction





Around 20,000 features (genes)
p >>n
# class noise avoidable censoring of clinical data
# feature noise hardly any common
critical issue for building predictive prognostic model is, however, the high dimensionality
of data, where the number of features overwhelms the number of samples (p » n). This
brings lots of concerns in fitting machine learning models.
When the data lie in high-dimensional space, analyzing and organizing the data become
challenging. It is because the sample density decreases exponentially with the increase of
the dimensionality. For example, suppose we have 100 samples and the 1D space has a
width of 50 unit intervals. The sample density is 100/50 = 2 samples/interval. The samples
can completely cover the space. In the 2D space of 50*50 = 2500 unit squares, the sample
density becomes 100/2500=0.04 samples/unit square. In the 3D space, spreading the
samples onto the 50*50*50=1.25e5 unit cubes yields a sample density of only 100/125000
= 8e-4 samples/unit cube. If we keep increasing the dimensionality, the samples lie expo-
nentially sparser in the space. We know that statistically sound analysis requires certain
levels of sample density. When the data is too sparse in high-dimensional space, it is
problematic for any method that requires statistical significance. It not only applies in
machine learning, but also in numerical analysis, combinatorics, optimization, etc. These
phenomena are in general called the curse of dimensionality.
In machine learning, each sample is represented by n features (variables). The word
feature space refers to the n-dimensions where the features live. The high dimensionality
of the feature space can lead to undesired consequences such as overfitting. Here we would
like to give the intuition with the following example. Suppose we have 100 samples in
the training set to train a classifier. When the dimensionality is low, with 2 features, the
samples cannot be separated well and thus the patterns in the data are not recognized.
This is called underfitting. As more features are added, the samples are described in
higher dimensional space, one can find the hyperplane to separate the samples better. The
underlying patterns in the data are captured. Note that when the dimensionality further
increases, e.g., by constructing more features such as taking the polynomials, it becomes
much easier to find a hyperplane that can separate the training samples perfectly into two
classes (it is know that any dataset that lie in N dimensional space can be separated in N-1
dimensions). However, this may not bring the desired benefit. If we project the samples in
low, moderate, and high dimensional spaces back to a two-dimensional space, the decision
boundaries typically look like the ones shown Figure 1.3. It is clear that the trained
model in high dimensional space overfits the data. In other words, the model is overly
complex. It shows that the classifier can no longer differentiate between exceptions and
0Note that Figure 1.3 is only for giving an intuition of how the dimensionality may affect the performance,
in reality machine learning has much trial and error. One can tune parameters and use techniques such as
regularization to decrease overfitting to some extent.
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(b) A good fit


















Figure 1.3: An illustration of underfitting, a good fit, and overfitting in terms of the
dimensionality of the feature space.
the appearance of certain training samples and the real patterns. This needs to be avoided
because it makes the model sensible to minor fluctuations in the training data and results
in poor predictive performance on the testing data. Depending on the underlying model of
the machine learning algorithm, e.g., linear or non-linear, the overfitting can happen earlier
or later with increasing number of features. Note that the performance of the classifier is
evaluated by how well it can generalize on the testing set and not how well the classifier
can fit the training data.
Mathematically, theoretical analysis shows that distance metrics which are used to
measure the similarity between samples show different behavior in high dimensional space











where d is the dimensionality of the feature space. It shows that the ratio of the
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difference between the maximum and minimum distances to the origin, and the minimum
distance, tends to be zero. One can imagine that on a high dimensional hypercube, most of
the data points lie on the corners of the cube and far from the origin. Therefore, distance
measures lose their effectiveness. Since distance metrics are widely used in machine learning
algorithms, high dimensionality makes it difficult to train machine learning models.
It is safe to say that the number of available samples limits the number of features to
use without overfitting. With p » n, omics data are far from ideal for training machine
learning models. If we use the data directly, the classifier will not able to find the true
patterns, thus generalizing correctly becomes exponentially hard or even impossible, since
the samples cover only a dwindling fraction of the feature space. The trained models will
then give more random predictions. However, this does not put training machine learning
models on omics data to an end because not all the features are necessary to use. In
cancer biology it is acknowledged that only a small fraction of these features (the true
signals) contribute to the phenotype of interest. It we can find these important features
out of all features and train a predictive model with only these features, it can help prevent
overfitting and lead to more interpretable models. This process is named feature selection
and the identified feature subset is called molecular signatures. It is supposed to represent
the footprint of the phenotype so that it can be used to predict the phenotype of new
samples given their signatures. Selecting robust molecular signatures from Omics data,
however, is challenging. Many feature selection algorithms have been proposed in the past
decades. However, the robustness and the predictive capability of the biomarkers are not
yet satisfactory [16, 171, 258]. In the next section we are going to have an overview of
existing feature selection algorithms, many of which are proposed for identifying cancer
prognostic signatures.
1.2 Methods for Identifying Molecular Signatures
Identifying disease signature (biomarkers) from omics data is one of the major endeavors
in systems biology. Predictive, robust, and interpretable molecular signatures are gener-
ally considered as an important step towards personalized medicine. Since the emergence
of gene expression microarray techniques, methods have been developed to find disease
signatures - the set of genes whose expression values are indicative of a phenotype. The
aim is to improve our understanding of disease by finding disease driver gene and help
develop effective models to predict disease outcome [59,113,281]. From a machine learning
perspective, identifying disease biomarkers is formulated as a feature selection task. The
high-dimensional data is recorded as a matrix Xn×p = {xi,j} containing the information of
p genes in n samples, where xi,j is the expression level of gene j in sample i and p n. In
a classification problem, the n samples originate from different phenotype groups, which
are denoted by a target variable y = {y1, ..., yn}. The entries of y are either 0 or 1. Feature
selection is to find the subset of genes across all samples Sn×k ∈ Xn×p, k  p, which can
best discriminate the samples into their groups. Unlike other dimensionality reduction
techniques that are based on projection (e.g., principle component analysis) or compres-
sion, feature selection techniques do not alter the original features, but only select a subset
of them. Thus, it offers the advantage of interpretability of the molecular signatures.
Finding the optimal feature subset to give the best prediction performance is NP hard
8 Chapter 1 Introduction
Figure 1.4: An overview of feature selection algorithms for prognosis prediction. The
methods are first divided into three broad categories based on their information sources. In
each category, we give three representative branches based on the algorithm or application.
(nondeterministic polynomial-time hard). In bioinformatics, different algorithms are pro-
posed to improve the prediction accuracy of the machine learning models trained using
these features. Since the early development on mainly microarray data, the methods have
been developed from using single type of omics data (typically gene expression data) to
the integration of data with biological network, and to the integration of multiple types of
omics data, thanks to the accumulation of genetic regulation knowledge and improvements
in sequencing techniques.
Following this trend of increasing integration of biological knowledge and multiple data
sources in biomarker discovery (and more or less in ascending chronological order), we
would like to give the introduction in three parts according to whether and how data are
integrated for feature selection. The first part involves methods that use only one type
of omics data without network. The data is usually gene expression data. The second
part introduces methods that integrate gene expression data with biological network. The
third part introduces studies that employ multiple types of omics data (with or without
biological network), with the goal to compare different omics data, cluster samples or
perform predictive tasks. In each part we will give the motivations, some representative
methods, and the potential advantages and drawbacks. For advanced readers, Figure 1.4
gives a high-level summary of the methods included. In the following text, we will use
the word feature in the context of machine learning, and use the corresponding terms of
biological entities, e.g., genes, molecules, when we talk about applications.
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1.2.1 Feature Selection on Single-omics Data
This part concerns the earliest and the more frequently used feature selection algorithms.
Features are selected only based on the intrinsic property of the data without considering
their biological roles. Gene expression microarray (GEM) is the earliest high-dimensional
omics data that captures expression level of many genes simultaneously. Most of the earlier
feature selection studies used GEM data. As is generally accepted, these methods are
divided into three categories: filter, wrapper, and embedded methods [101, 145, 209, 237].
They differ from each other in how they search in the space of feature subsets:
• Filter methods select features by their statistical and information theoretical meas-
ures without the use of machine learning model. Based on a predefined criterion,
such as t-statistic, feature relevance scores are calculated for individual features with
a higher score indicative of a more important feature. The features are then ranked
by the scores and top ranked features are selected. A few other commonly used cri-
terion include chi-squared statistic, the p-value of univariate cox proportional hazard
model, information gain, and Fisher score [88]. Most of the filter methods are uni-
variate. Several multivariate methods also exist, such as correlation-based feature
selection [95,295], Markov blanket filter [135], etc.
• Wrapper methods utilize a specific classifier to evaluate the quality of feature subsets,
in order to guide feature selection. Wrapper methods generate various feature subsets
and evaluate them by training a classifier and testing its performance. There are two
types of wrappers: deterministic and randomized. The former uses search techniques
such as sequential forward selection, sequential backward selection. The added or
eliminated features in the previous step are not changed in later steps [200]. The
latter often uses genetic algorithms and simulated annealing to obtain feature subsets
[195,208].
• Embedded methods embed feature selection with classifier construction. They can
be divided into three types [237]: 1) pruning methods such as recursive feature
elimination [90] 2) build-in mechanisms for feature selection, typically for tree-based
classifiers and 3) regularization methods, which are shown to give good performance
and are increasingly employed [159].
Filters are simple, fast, and independent of classifiers. They can easily handle high-
dimensional data. Sometimes it is used as an initial gene selection step before more com-
plicated feature selection algorithms are applied [77, 146, 255]. Despite its simplicity, it is
shown to be able to achieve comparable or even better performance [97, 106, 215]. The
disadvantage of filter methods is that feature dependencies are usually ignored, which may
result in good features but worse classifier performance. For example, highly correlated
features have been shown to undermine the stability of classifiers [251]. Another disad-
vantage is that it ignores the effect of selected features on the performance of the classifier,
which is dependent on the biases and the heuristics of the classifier [97]. For example, the
performance of Naive-Bayes classifier improves with the removal of irrelevant features, but
not every filter is able to select the relevant features.
Wrappers can take into account feature dependencies and avoid the representational
bias of the classifier. This renders the selected features to be specific for a classifier.
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However, as the dimensionality of the data grows, the space of feature subsets grows
exponentially. Wrapper methods become much more expensive. In this case, randomized
search strategies are often applied instead of deterministic search. Compared with filter
methods, wrapper methods are prone to over-fitting, especially if the classifier is complex.
[157] shows that the more exhaustively the feature subset space is searched the greater the
likelihood of finding a feature subset that has a high training accuracy while generalizing
poorly. It is necessary to control the depth of search, and use strategies such as post-
pruning of decision trees, adding noise to the training data [134], and early stopping [157]
to decrease overfitting.
Embedded methods address the disadvantages of both filter and wrapper methods. It
includes the interaction with the classification model and is far less computationally costly
than wrapper methods. This is achieved by having an objective function that minimizes
both the fitting error of the machine learning algorithm and a penalization term that is
used to shrink the model coefficients. Taking the example of a regularization method with




where penalty(w) is the regularization term and α is the regularization parameter con-
trolling the trade-off between c(.) and the penalty [237]. For example, a well-known regu-
larization algorithm Lasso [250] penalizes the l1-norm of the coefficient w: penalty(w) =∑p
i=1 |wi|. Lasso method is very widely applied [159] on high-dimensional omics data,
although its consistency cannot be guaranteed when certain conditions are not met [302].
Regularization-based feature selection has attracted attention in recent years. The different
combinations of model fitting and regularization terms can give rise to different embedded
feature selection methods, such as group Lasso [114], bridge regularization [108], regular-
ized Cox regression [224], regularized decision trees [56,57], etc.
Although many algorithms are proposed and can be easily applied as off-the-shelf tools,
it is still difficult to identify robust biomarkers. This is because while it is easy to identify
a set of features that fits the training data very well, it is hard to find features that
generalize well on independent data. Due to the properties of the data shown in Table
1.1, a good generalization is very hard to achieve. Indeed, as more molecular patterns
are reported, the low reproducibility of many reported gene signatures has been criticized.
It was noticed that there is hardly considerable overlap among biomarkers identified in
different studies for the same disease, and biomarkers identified using one dataset may
not work well on other datasets [66, 67, 171]. It is shown that there exist many feature
subsets that perform similarly well, making it difficult to find the true signals. Even
taking random sets of features from the entire feature space is shown to give comparable
prediction performance [258]. To tell which set of features can generalize well seems to be
very puzzling.
Another challenge is to produce feature sets that have good biological interpretation to
assist biological research [62,66]. Given multiple sets of features that do not have significant
difference in their prediction performance, it is impossible to tell from the data alone which
set of features is more biologically meaningful, e.g., more relevant to cancer progression.
In another scenario when a set of features does have good prediction performance, but the
features have no relations with each other in gene regulations, it would also be reluctant
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(a) Data-network mapping
(b) Subnetwork features
Figure 1.5: An illustration of the integration of gene expression data with molecular net-
work. (a) shows the correspondence between features and network nodes (b) shows subnet-
work features - the aggregation of features in red and blue circles can better differentiate
between two sample groups.
to tell why this set of features is a set of good disease signatures. This is very likely to
happen given the noise and the sample heterogeneity in omics datasets. The typical low
reproducibility of molecular signatures and the difficulty to interpret them necessitate the
integration of domain knowledge in biomarker discovery [169]. Various feature selection
methods that integrate biological knowledge have been proposed and we are going to
address it in the next part.
1.2.2 Network-based Feature Selection on Single-omics Data
Biological knowledge has been applied to assist feature selection in a few directions such as
the integration of biological network or pathways, Gene-Set Enrichment Analysis (GSEA),
and text mining. GSEA is a method to identify whether classes of genes (e.g., based on
gene ontology terms) are statistically over-represented or deleted in a set of genes. This
can be associated with disease phenotypes. It is usually used to help assess the potential
biological indications of a set of features. Text mining employs natural language processing
techniques to relate basic biomedical research to clinical practice, e.g., to find potential
associations among genes from literature that are very time consuming for humans. Most
of the effort so far has been made in network or pathway-based feature selection where
biological knowledge is represented as a network of genes. The networks of interacting
molecules have been placed between genotypes and phenotypes in systems biology and it is
acknowledged that the properties of the network as a whole determine the phenotypes [17].
The underlying motivation is that the features (genes) are not isolated (independent) but
regulate each other in a network (dependent) via various mechanisms. This property should
be considered in a way so as to find features that act jointly to contribute to the phenotype.
Figure 1.5a shows intuitively how the omics data and network relate to each other.
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It shows that molecular profiling of a group of patients can be put to a table, where the
rows correspond to different patients and the columns correspond to molecules. If one only
looks at the table and try to identify the signatures, it falls into the methods in section
1.2.1. However, the features and the nodes in a gene network have correspondence. It is
very likely that the role that a gene plays in the network has something to do with the
importance of the gene and its interactions with other features. By taking into account both
the features and the underlying network structure, various feature selection methods have
been proposed. Our scope is within the studies that try to identify molecular signatures
for making predictions and does not include the studies that only identify active modules
without building predictive models. While it is difficult to mention all important methods,
we summarized three representative categories based on their methodologies.
The first category is network structure guided searching. This group of methods aims
to identify subnetworks, instead of single nodes, that can best differentiate phenotype
groups, as shown in Figure 1.5b. Each of the identified subnetworks is aggregated to
produce one feature (the metagene) and these metagene features are used for training
predictive models. The search is guided by a predefined scoring function which takes the
input of a subnetwork (several connected feature vectors) and outputs a real value, which
is used to rank the subnetwork. Because finding the maximal-scoring connected module is
NP-hard, greedy search is frequently applied by starting at each network node and adding
its neighbors incrementally until constraints are not satisfied. For example, the increase
of the score does not meet a predefined threshold. Different methods can differ in their
scoring functions, how metagene was calculated from individual genes, and the biological
networks used. For example, [40] used mutual information as the scoring function and the
addition operator to aggregate subnetworks. [152, 167] used the p-value of Cox PH model
in defining the scoring functions. [190] dichotomized features and defined a scoring function
based on information theory. [8] tested different aggregation operators on their effects on
the prediction performance.
The second category is network-based regularization. Recall the regularization methods
in section 1.2.1. where a penalty term is included to avoid overfitting, here the penalty term
additionally takes into account the network structure. Adjacency matrix A and Laplacian
matrix L are frequently used to represent a network G to be included in the penalty term.
Since the majority of the methods in this category are based on linear classifiers, it can be
written in the following form:
wˆ = min
w
c(wTX, Y ) + αpenalty(w, G)
where G denote the network structure. For example, in graph Lasso penalty(w, G) =
λ||w||1 + (1− λ)∑i,j Ai,j(wi −wj), which forces connected nodes to have similar weights
[237, 287]. Using similar formulations, [149] proposed a network-constrained regulariza-
tion and feature selection methods on genomic data. [299] added a network regularization
term to the log-likelihood function of the Cox proportional hazard model. [35] developed
a network-constrained support vector machine method, where the network-based regular-
ization term is added to the objective function of SVM.
The third category of methods involves iteratively updating node importance scores
on the network. Frequently used methods include network propagation and random walk.
[175, 274] adapted Google’s PageRank algorithm to rank genes in a network. PageRank
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is used to rank the importance of web pages based on the links among pages. Pages are
assigned an initial rank r[0] ∈ RN . This rank is updated iteratively depending on the rank
of pages that are linked to it. For page j, its rank from r[n−1]j to r
[n]











, 1 ≤ j ≤ N
where degi is the degree of the ith page and d is a fixed parameter. By iterating until
convergence, a page will be highly ranked if it is linked to other highly ranked pages. This
process has an alternative interpretation in terms of random walk theory [142]. [49] used
random walk kernel to smooth gene-wise t-statistics over the network. This is achieved by
assigning each node an initial score based on t-test and then multiply it with the random
walk kernel. The p-step random walk kernel is used as a similarity measure to capture the
relatedness of two nodes in the network. It is defined as:
K = (αI − Lnorm)p = ((α− 1)I +D−1/2AD−1/2)p
where Lnorm is the normalized graph Laplacian matrix, α is constant, and p is the
number of random walk steps. The network-smoothed t-statistic t˜ = tTK is used to meas-
ure node importance. Similarly, random walk-based scoring of network components is also
applied in [136] to prioritize functional networks. [207] used network propagation method
to score genes based on their proximity to mutated genes and differentially expressed genes
in the network. The method is shown to be able to better prioritize known cancer driver
genes and predict potential cancer genes. Both mutation and expression data are mapped
on the network to jointed identify important genes.
Having discussed about the feature selection methods, we think it is also necessary to
introduce the molecular interaction networks. The network mostly comes from biological
knowledge on gene regulations, protein-protein interaction, etc. Different networks have
been used, as listed in Table 1.2. Given the variability of options, it seems that before
choosing which feature selection algorithm to use, one of the first step is to consider which
network, or which combination of networks to use. Apparently, the results are network
dependent. Intuitively, one may choose to use as much network information as possible
because it enriches the information. However, it meanwhile increases the search space, and
this makes it harder to differentiate signals and noises.
It is shown in many studies, e.g., from Table 1.2, that features selected based on a
network outperform features that are selected based on the data alone, in terms of their
prediction performance and biological interpretation. There was at one point a significant
increase in network-based feature selection methods. However, in recent years, several
studies show that network-based feature selection methods do not always show better
prediction performance, but mainly improve the biological interpretation of the signa-
tures [48, 228, 229]. [48] compared fourteen published gene selection methods, including 6
single gene methods and 8 network-based feature selection methods, on six breast cancer
datasets with respect to prediction accuracy, signature stability and biological interpretab-
ility. The biological interpretability is measured by enrichment analysis of disease related
genes, KEGG pathways and known drug targets. They found that network-based features
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Table 1.2: Frequently used molecular/gene interaction networks in network-based feature
selection studies. We list the networks, their sizes and information sources, as well as
exemplary studies that use the networks. With STRING database, we only considered the
edges with confidence score ≥ 0.9. Note that when the database includes many species, only
Homo sapiens is considered. Data means the network size is dependent on the dimension
of data. App means the network size is dependent on the application.
Idx interacting structures Database Version |E(G)| |V (G)|
1 Protein-protein STRING v10.5 547621 19578
2 Protein-protein HPRD Release 9 41327 30047
3 Biological pathways KEGG Release 84.0 App App
4 Biological pathways Pathway Commons v7 1912848 14863
5 miRNA-gene miRTarBase v7.0 502651 16822
6 transcription factor - target TRANSFAC v7.0 public - 1648
7 Gene co-expression None None Data Data
8 Gene Functional linkage Multiple None App App
9 Gene ontology Gene ontology None GO GO
Idx Information Studies
1 binary PPIs, including predicted interactions [51,91,118]
2 binary, and complex PPIs, PTMs, protein-DNA interactions [35,152,167,190]
3 Very broad, including systems information, genomic information,chemical information, and health information [149,215]
4 Biochemical reactions, gene regulations, interactions involvingproteins, DNA, RNA, and small molecules. [176]
5 microRNA-target interactions [118]
6 Transcription factor binding sites [111,274]
7 Pearson correlation [175,299]
8 Multiple database resources [40,277,299,300]
9 Gene ontology [175]
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in most cases cannot improve prediction accuracy significantly but can improve the inter-
pretability of gene signatures. [229] tested single gene and network-based algorithms on six
breast cancer datasets in predicting breast cancer prognosis. They also found out that the
composite feature classifiers do not outperform single gene classifiers. What’s more, the
randomization of the network structure, which destroys the biological information, does not
result in a deterioration in the performance of composite feature classifiers. [228] extended
the experiments in [229] by including more gene signatures and drew consistent conclu-
sions. [228, 229] also show that when a proper correction of feature set size is performed,
the stability of composite features is not higher than single gene features. Based on their
experiments, the argument to prefer network-based features over single gene features does
not hold true.
It now seems controversial whether network-based methods are superior to feature
selection methods without network. In the first sight, this may seem puzzling - because by
integrating biological network we give more relevant input to the algorithms and normally
the outcome should be better as well. In our opinions, there could be several reasons that
contribute to the puzzle.
1. There is no exact mapping from gene expression data to PPI network. Ideally, one
would map protein expression value to the protein network, or the corresponding
functional molecules to a molecular interaction network. For example, in the case of
transcription factor - DNA interaction, the entities are protein and gene expression,
but instead, only gene expression values are used. In fact, it is reluctant to represent
protein levels by gene expression levels as there are several steps from gene expression
to a functional protein, which are regulated by multiple mechanisms (as will be
mentioned in Chapter 5.
2. There is not enough investigation in meta-gene operators - how individual gene ex-
pression levels are aggregated into composite features. A recent study [8] has ad-
dressed this issue by evaluating multiple operators to summarize genes into meta-
genes and choose the best operator. This significantly improves the stability of the
signatures. Since there are still no available rules of how to combine features based
on a biological network, this area potentially needs more efforts.
3. The curse of dimensionality is present in both no network methods and network-based
methods. As there are many irrelevant signals in the omics data, the signals are also
present in the network when the data are mapped to it. When the network is, e.g.,
searched from each node alternatively, many irrelevant nodes could be selected. Due
to the high-dimensionality and heterogeneity of samples, which create great difficulty
to differentiate signals and noise, the performance difference of single gene features
and composite features cannot be determined.
While the first issue cannot be resolved at the moment (as will be mentioned in Chapter
5) and the second issue could be explored by trail-and-error, we think the last issue is by far
the most critical one, which hinders the advantages of data integration to be seen in feature
selection. As observed from both studies in section 1.2.1 and section 1.2.2, when different
algorithms are compared on multiple datasets with the same experimental settings, the
conclusions can be different than the studies where the algorithms were proposed. This
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shows that the algorithms are sensitive to changes in the data and networks. It resembles
overfitting, where the information (both signals and noise) is overwhelming for the small
set of samples at hand and the feature selection algorithms are not able to pick the signals.
As discussed previously, to have good performance we need to reduce the dimensionality
of data and select features with biological significance.
Some researchers have approached this question by integrating information from mul-
tiple omics data sources. The motivation is that these different sources of information
depict the multiple dimensions of gene activity and thus can complement each other, al-
though the dimensionality is not necessarily reduced. While selecting molecular signatures
using only one type of data can have much bias, taking into account multiple omics data
can better prioritize candidate genes [203]. In recent years, data integration-based feature
selection has attracted more and more attention and it will be introduced in the following
part. Due to the limited number of methods compared with the previous two method cat-
egories, we will not limit our introduction to feature selection in prognosis prediction, but
also include methods that use multiple omics data in other relevant tasks such as patient
clustering, disease gene prioritization, etc.
1.2.3 Multi- and Integrative Omics Data Analysis
It is demonstrated that the molecular portrait of a tumor manifests at multiple omic
levels [181]. The typical focus on one single omic level at a time thus can only explain
a modest portion of complex disease. Thanks to the recent efforts in collecting multi-
omics data in the same groups of individuals, integrative analysis has been developed
to study complex diseases in a more comprehensive manner. For example, besides finding
molecular patterns from one type of omics data, which can have certain bias, multiple types
of omics data can be considered simultaneously to find more robust disease signatures.
Later in Chapter 4 we proposed to use a multiplex structure to selected mixed features
from multiple omic layers. In fact, for many questions in disease research, such as how
genomic changes affect genetic pathways that drive cancer phenotypes, it is necessary to
simultaneously look at multiple molecular data levels. In this part, we introduce some
studies that employ multiple omics data. We decide not to limit our scope to cancer
prognosis prediction studies (the number of studies is by far limited), but also include
studies that use integrative approaches for other relevant tasks such as patient clustering,
gene prioritization, etc.
A comprehensive study [296] compared the predictive capability of multiple levels of
omics data: CNA, DNA methylation, mRNA expression, miRNA expression, and protein
expression data, and their combination with clinical features, on four cancer types from
TCGA. Using the same feature selection algorithms and classifiers, different omics data
are used to train predictive models for prognosis prediction and their performance was
evaluated by cross-validation. The results show that the prediction performance varies sig-
nificantly across data types and cancer types while the effect of different machine learning
algorithms is moderate. They show that clinical features in many cases outperform mo-
lecular features, while combining molecular features with clinical features can significantly
improve the performance. [303] conducted a similar comparative study to compare the
predictive capability of four types of omics data and their combinations. In addition, they
evaluated the performance of the omics data combinations with clinical features. Their
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experimental results show that clinical features and mRNA expression features are the
most informative. Adding other omics features does not give substantial improvement in
predictions. [163] employed four omics data types (mRNA, DNA methylation, CNA, and
miRNA) to identify prognostic signatures for serous ovarian cancer. Features are selec-
ted individually from these data types using regularized Cox model [188] and the selected
features are combined to give integrative features. The integrated features were shown
to outperform individual data in stratifying patients into significantly different prognostic
groups. While these straightforward methods of combining multiple omics data are help-
ful and necessary, there are other studies that use more complex integration methods in
different aspects of disease research.
One category of studies aims to cluster patients into different prognostic groups based
on patient similarities defined on multiple omic levels. A simple illustration is given in
Figure 1.6a. [128, 264] use similarity network fusion methods to cluster patients into dif-
ferent survival groups. [128] used the same four types of omics data and constructed a
patients’ k-nearest neighbor graph using each data type, where edges represent similarities
and nodes represent patients. Then these four graphs are integrated using graph-based
semi-supervised learning algorithms [252, 307]. They show that the integrative approach
(using the best combination of model parameters) significantly outperforms individual data
types. [264] proposed a network fusion algorithm on patient similarity networks construc-
ted using mRNA expression, DNA methylation, and miRNA expression data. It iterative
updates each of the networks with information from the other networks, making them
more similar with each iteration and eventually obtaining the fused network. Based on
the fused network, spectral clustering is applied to stratify patients into clusters. They
tested this method on five cancer types and showed significant improvement in stratify-
ing patients into different prognostic groups, compared with using individual data types.
Similarity can also be defined on the pathway level. In [257], curated pathway interactions
are incorporated to define the levels of pathway activities using different types of omics
data. Grouping patients based on their pathway perturbations leads to subgroups that
have significantly different survival outcomes.
While the similarity network clustering above is composed of separate clustering fol-
lowed by network integration, there are methods proposed to incorporate all data types
simultaneously and produce a single integrated cluster assignment. [227] applied unsuper-
vised multiple kernel learning method on multiple omics data which reduces the dimen-
sionality and meanwhile performs data integration. One or multiple kernels are generated
from individual omics data and these kernels are linearly combined to give a unified kernel
matrix. K-means clustering is applied on the unified kernel matrix to stratify patients into
clusters. It is shown that these clusters have significantly different clinical outcome. [219]
developed iCluster algorithm that used joint latent variable to associate different omic data
types. The idea is to use the tumor subtypes vector as the latent variable that connects
a set of models, which induces dependencies across different types of omics data. The
algorithm is tested on breast and lung cancer samples to identify tumor subtypes. Com-
pared with the patient stratification results in these studies, we will show in chapter 3 and
4 that using a much smaller but phenotype relevant biological network, one can achieve
remarkably good patient stratification.
The second category of study aims to prioritize candidate genes using heterogeneous
data sources. A simple illustration is given in Figure 1.6b. [2] developed Endeavour to
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(a) Similarity network fusion (b) Gene prioritization
Figure 1.6: An illustration of integrating multiple omics data sources to improve predic-
tions. (a) Multiple omics data are used to build patient similarity networks and these
networks are fused into one similarity network. (b) Heterogeneous data sources are used to
rank candidate genes based on their similarity with known disease genes. The individual
ranks are aggregated into an overall rank.
prioritize genes that are involved in specific diseases or signaling pathways. The individual
rankings using different data sources such as literature, functional annotation, and pathway
membership are integrated into a single overall ranking using order statistics. This overall
ranking is shown to significantly outperform individual rankings. [54] used kernel fusion
technique to more accurately prioritize disease genes. They computed multiple kernel
matrices based on different data sources to measure the similarities between candidate genes
and diseases genes. These kernels are convexly combined to give an overall similarity matrix
that can better capture gene similarities. [49] prioritized candidate genes for prognosis
prediction using random walk kernel on a gene network. It first calculated the t-statistics
of individual genes and miRNAs using prognostic information. Then a random walk kernel
is used to smooth the t-statistics over the network structure. The details of the algorithm
are given in Chapter 3. [36] proposed the method MAXDRIVER to identify potential cancer
driver genes. It first constructed a fused gene functional similarity network where the edge
weights are derived from protein-protein interaction, gene co-expression, gene sequence
similarities, and pathway co-occurrence. Then this network was combined with a disease
phenotypic similarity network and gene-disease associations to construct a heterogeneous
network. Then an information flow method was applied on the heterogeneous network to
find the relationships among cancers and candidate genes. This method was shown to be
able to accurately rank known disease genes. [207] and [6] also used multiple data sources
to discover potential cancer driver genes.
Methods have also been proposed for finding relationships among heterogeneous data
sources. [158] proposed to find synergistic effect of DNA methylation and CNA on gene
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expression using statistical approach. They showed that for several oncogenes both hypo-
methylation and copy number amplification are present. [153] introduced a sparse multi-
block partial least squares regression model to identify multi-dimensional regulatory mod-
ules from multiple omics data. It identified sets of features from gene expression data, DNA
methylation data, and miRNA expression data that jointly contributed to the expression
of a set of genes. They showed that the identified modules had significant functional en-
richment and coupled impact on oncogenes. [155] predicted gene-phenotype relationships
by using random walk method on a heterogeneous network. The network was constructed
by connecting gene network (PPI) and phenotype network using a bipartite graph. The
transition matrix was defined based on network connectivity. The steady state probability
of finding the walker at each node was used to measure the proximity of network nodes to
seed nodes. The results showed that compared with using random walk on gene network
only, the accuracy of gene-phenotype link prediction was significantly improved with het-
erogeneous network. Besides the above discussed applications, heterogeneous data sources
have also been applied in gene regulatory network (GRN) inference [308].
As we have seen, many studies integrate multiple omics data sources to better cluster
samples, prioritize disease genes, and find the relationships between features of different
omic levels. This is usually achieved by integrating similarity measures (kernels, random
walk distance), using joint latent variables, and applying multiple statistical tests. How-
ever, so far, few methods have been developed to integrate multiple omics data sources for
feature selection in cancer prognosis prediction. In addition, integrating multiple omics
data sources and meanwhile utilizing biological network structure has not been well invest-
igated. This is mainly because integrating several high-dimensional data will worsen the
curse of dimensionality and make it more difficult to find the important features. Taking
all features into account increases irrelevant information dramatically and thus diminishes
the advantages of information enrichment. For network-based feature selection algorithms,
finding composite features by mapping these data on a biological network would be hard
to implement and evaluate.
1.3 Thesis Overview
1.3.1 Motivations
Biological systems are usually complex and high-dimensional by nature. It is recognized
that the bottleneck for life science studies has shifted from generating data to the inter-
pretation of data so as to derive insights into biological mechanisms [169]. When dealing
with omics data, the problems of high-dimensionality and limited number of samples cre-
ate great challenges [10]. How to select important features has been investigated since
decades. Not only does it apply to the data, but also to the underlying gene interaction
networks, where not all network components are relevant for the phenotype of interest.
As introduced, feature selection algorithms have developed from using single omics data,
typically microarray data, to the integration of omics data with biological network, and to
the integration of multiple types of omics data and other biological information. In line
with the innovation of network and multiple data resources integration, we identified some
research gaps:
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1. Biological networks are mostly mapped with only one type of omics data. It would be
very interesting to know how the prediction performance differs when the networks
are mapped with different omics data types alternatively. In addition, what are the
relationships among the features that are selected using different omics data.
2. Data integration has not been realized directly on the networks. In our opinion,
this is mainly due to the large network size, which makes this integration very costly.
What’s more, not all parts of the network are equivalent for the phenotype to predict.
Usually a small fraction of the network plays a key role in a phenotype.
3. The integration of biological knowledge has not been detailed. The integration con-
siders either the whole biological knowledge-base (e.g., a PPI network) or none. The
specific information of which genes are important for a phenotype/disease that are
discovered in biological research has not been utilized.
State-of-the-art studies have shown that feature selection, biological network integra-
tion, and multiple omics data integration are all important components for discovering
robust cancer prognostic biomarkers. However, how to bring these elements under one
framework for building predictive models remains to be investigated. Since the problem of
high dimensionality hinders the discovery of robust molecular signatures, by far the poten-
tial clinical utility of the aggregate of these data remains largely unknown. In this thesis
we propose a Phenotype Relevant Network-based Feature Selection (PRNFS) framework
and demonstrates its superior performance with the use case of cancer prognosis predic-
tion. Within this framework, we have successfully integrated four types of omics data with
GRNs to identify robust molecular signatures. We show that significantly better prediction
performance can be achieved using <2.5 % of the original dimensionality.
Concretely, we used biological knowledge to build a specific GRN for cancer prognosis
prediction. We constructed an Epithelial Mesenchymal Transition (EMT) network by re-
viewing EMT literature and putting the genes and regulatory relationships to a graph.
EMT process has long been demonstrated as closely related to cancer progression [245].
Many important EMT regulators such as SNAIL1 and SNAIL2 genes have been shown to
correlate significantly with disease relapse and survival in patients with breast, colorectal,
and ovarian carcinoma, where it is shown that EMT development can lead to poor clinical
outcomes [96, 246]. In lung cancer, [214] demonstrated that mesenchymal gene expression
signatures (genes that encode mesenchymal proteins) can divide early stage LUAD pa-
tients into significantly different survival groups. Since mesenchymal gene expression has
a predictive value, their regulations are therefore important for prognosis. This is because
the gene regulations in cancer progression have been widely acknowledged as a network
consisting of multiple dysregulated pathways [14, 137, 240, 268]. The details of how the
EMT networks are constructed are given in Chapter 2.
By using EMT networks and their composing molecules for feature selection, we aim
to select highly relevant features for cancer prognosis prediction. As we narrow down the
number of features dramatically, the dimensionality is reduced, and biologically important
features are kept. On EMT networks, we mapped multiple types of omics data either
alternatively or simultaneously to select single-omics features and multi-omics features.
This is not only useful for building predictive models, but also for the analysis of molecular
signatures. Since the process of EMT is complex and coordinately regulated by multiple
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pathways and regulatory levels, it is interesting to see which genes play important roles on
different omics levels.
1.3.2 Thesis Outline
Finding important features from a reservoir of features is difficult. To ensure that the
molecular signatures identified on one dataset will generalize well on other samples, it is
necessary to guide the feature selection by using cancer domain knowledge. Currently,
the domain knowledge - mainly protein-protein interaction networks, are either used as a
whole, or not used at all. In depth domain knowledge has not been integrated with the
identification of prognosis biomarkers. This lack of direction when integrating biological
network thus could not be as fruitful as expected. This is supported by recent studies,
which show that integrating biological network does not bring benefits in improving the
prediction accuracy of molecular signatures. Based on these motivations, we aim to identify
robust prognosis signatures using EMT networks. The thesis is organized into four parts:
Part I: Constructing EMT Gene Regulatory Networks
We introduce the biological background of EMT, e.g., what it is, where does it happen, and
how it is related to cancer prognosis. Then we go further and introduce the key regulatory
events during EMT and the genes and miRNAs that play important roles. Afterwards
we show how EMT gene regulations are modeled using networks and provide network
visualizations.
Part II: Identifying Single-omics Prognostic Signatures
We applied state-of-the-art feature selection algorithms - both network-based and none
network-based algorithms, to select molecular signatures on individual omics data levels
using EMT networks. We used three data levels alternatively - gene expression (including
mRNA expression and miRNA expression), DNA methylation, and copy number alteration.
We mapped each data level to the EMT networks, selected the features, and evaluated
the prediction performance of the features using multiple evaluation metrics. To provide
objective evaluations, we compared the performance of EMT features with that of several
other groups such as random features. We also evaluated the prediction performance of
frequently selected features, the combination of molecular features with clinical features,
and the effect of classification thresholds. Additionally, the selected features were analyzed
in terms of their stability, network properties and biological interpretations. At last, we
related our results with state-of-the-art studies, where consistent findings were pointed out
and new insights were addressed.
Part III: Identifying Multi-omics Prognostic Signatures
We identified multi-omics prognostic signatures and compared it with single-omics ones.
We first obtained multi-omics signature by combining signatures from single data levels.
The combined features showed significant improvement in patient stratification. Then we
proposed an integrative feature selection algorithm based on multiplex networks, which
is able to directly identify multi-omics signatures. Compared with feature selection on
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single-layer networks, we have obtained significantly better prediction performance with
multiplex-based feature selection. We have also analyzed the feature compositions of the
identified multi-omics signatures. Last but not least, we tested EMT signatures - both
single- and multi-omics ones, on an independent dataset consisting of both gene expression
and DNA methylation data for a cohort of patients. We showed that EMT signatures can
stratify the independent samples into significantly different prognostic groups.
Part IV: Database Applications for Proteomics Data
Having focused on discovering and evaluating prognostic signatures, we are also concerned
about how to effectively manage large biological data to support data integration and
the development of individualized medicine. Here we take the example of proteomics
data because of its complexity and large size. We benchmarked several relational and
non-relational databases on their performance of storing and querying Mass Spectrometry
(MS) and Tandem Mass Spectrometry (MS/MS) data. Based on the results we provided
some advice on building omics data infrastructures.
Chapter 2
Epithelial Mesenchymal Transition in Can-
cer Progression
As introduced in Chapter 1, epithelial mesenchymal transition (EMT) gene regulations
are highly relevant to cancer progression, which is what we aim to predict using feature
selection and machine learning algorithms. We proposed to select features from EMT
networks so that the molecular signatures can be more robust and biologically meaningful.
However, we have not yet explained what is EMT and why it is relevant to cancer prognosis.
This is the theme of this chapter. We will first introduce what is EMT. Then we describe
the central EMT gene regulations that occur on multiple interconnected gene regulatory
networks and pathways. Afterwards we explain how we represent EMT gene regulations
in a network model. In the end we provide visualizations and basic information of the
networks.
2.1 Biological Background
EMT is originally defined by a series of experiments where differentiated epithelial cells
can convert into mesenchymal cells [84, 85]. It is a biological process that allows a polar-
ized epithelial cell to obtain mesenchymal cell phenotypes including increased migratory
capacity, invasiveness, and elevated resistance to apoptosis, etc [120]. Based on the biolo-
gical context in which EMT occurs, it has been categorized into three subtypes [119, 121]
1) embryogenesis, implantation and organ development 2) tissue regeneration and organ
fibrosis, and 3) cancer progression and metastasis. Here we put the emphasis on subtype
3.
In normal epithelial tissues, the cells are tightly connected laterally by cell junction
structures, including adherence junctions, desmosomes, tight junctions, and gap junctions
[285], as illustrated in Figure 2.1 from the book [26] (on page 1036 in chapter 19). The
cells have an apical-basal polarity and anchor to the basement membrane. It ensures that
the cells can only migrate laterally but not entering the underlying extracellular matrix
(ECM). In contrast, mesenchymal cells are front-back polarized and rarely contact directly
with neighboring cells [100]. They can invade as individual cells through ECM. In epithelial
cancers, the activation of EMT program has been proposed as the critical mechanism for
the acquisition of malignant phenotypes [245] because the epithelial cells undergoing EMT
become invasive and can migrate to distant sites. At the distant site, the migrated cancer
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Figure 2.1: An illustration of cell junctions in epithelial cells. Figure source [26].
Figure 2.2: Contribution of EMT to cancer progression. It illustrates the process of normal
epithelial cells losing their polarity and becoming invasive carcinoma, invading remote sites
and establishing secondary tumors. Figure source [121].
cells can establish subsequent colonies via a MET (Mesenchymal Epithelial Transition, the
reverse of EMT) process under the local micro-environments of distant organs [20, 116].
This is well illustrated by Figure 2.2 from Figure 5 in [121].
Many molecular processes are engaged in the EMT process such as the activation of
transcription factors, expression of cytoskeletal proteins, expression changes of miRNAs,
etc. [121] reviewed the potential pathways and transcription factors that induce EMT.
In a later review study [24], the authors give an overview of the four different regulat-
ory layers involved in EMT process including transcriptional control, Non-coding RNAs,
EMT-associated differential splicing, translational and post-translational regulations. It
reviewed the important molecules in each layer. In review paper [140], it is described the
main changes that occur in cells that undergoes EMT, the roles of major EMT transcrip-
tion factors, and signaling pathways involved in EMT. In review paper [285], the authors
described the signaling pathways related to EMT and put these pathways in a molecular
network to show their interactions. In the following we introduce in detail these molecular
regulations, starting with hallmarks of EMT process and key transcriptional factors that
mediate this process, then how these transcriptional factors are regulated at transcrip-
tional, translational, and post-translational level, and ending up with a summary from the
perspective of network and pathways.
A hallmark of EMT is the down-regulation of E-cadherin expression, which is essential
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for maintaining cell-cell adhesion [289]. Functional loss of E-cadherin has been associated
with cancer progression and poor prognosis in human tumors [261]. In addition, genes
encoding claudin and occludin are also repressed, which stabilizes the dissolution of apical
tight junctions and desmosomes [109]. While the genes encoding epithelial cell junction
proteins are repressed, the genes encoding proteins that promote mesenchymal adhesion
are activated [74,291]. Specifically, the expression of N-cadherin is increased which provides
a mechanism for trans-endothelial migration of cancer cells. Thus the ’cadherin switch’
drastically changes the adhesive properties of cells and provokes cell migration and invasion
[244,272].
2.2 EMT Gene Regulations
As summarized in [24], EMT is regulated by four major interconnected regulatory net-
works - transcriptional control, non-coding RNA regulation, differential splicing and post-
translational control. In the following paragraphs, we are going to follow this framework
and describe the gene regulations in each layer. Although we could refer the readers to [24]
without further explanations, we think it is necessary to provide the following gene reg-
ulations learned from this article. Because we are going to construct an EMT network,
which is used in the following chapters as the basis for identifying molecular signatures
for prognosis prediction, we think it is better to give the gene regulations in the following
text. Different from the original article, we are going to introduce the gene regulations in
a more concise way, only to make it sufficient for supporting this study.
At the transcription level, there are a few master transcription factors that repress the
expression of cell-cell junction proteins [193]. SNAI1 and SNAI2 down-regulate CDH1 gene
(encodes E-cadherin) by binding to CDH1 promoter [15, 29, 55, 93, 174]. ZEB1 [65], ZEB2
[41] and E47 [174,196] also bind to CDH1 promoter and down-regulate CDH1 expression.
SNAI1 and SNAI2 also down-regulate claudins and occludin [112], and other epithelial
genes such as MUC1 and cytokeratin 18 [89]. ZEB1 also represses MUC1 expression
[89]. ZEB2 down-regulates also P-Cadherin. Meanwhile SNAI1, SNAI2, [174] ZEB2 [254]
and TWIST1 [182] up-regulate N-cadherin expression. SNAI1 is reported to induce the
expression of mesenchymal markers fibronectin [29], LEF1 and the transcription repressor
ZEB1 [89]. SNAI2 can induce the expression of mesenchymal marker vimentin [263]. LEF1
is shown to be an essential molecule for EMT [170]. It can facilitate the nuclear trans-
location of β-catenin, which drives the gene expression programme of cell cycle proteins
and oncogenes that favor EMT [117].
The master transcription factors can also interact with epigenetic modifiers and cause
genome-wide gene expression changes. DNA methyltransferase 1 (DNMT1) maintains the
expression of E-cadherin in a methylation-independent way by interacting with SNAI1 and
thereby preventing it from binding CDH1 promoter [68]. SNAI1 can also induce repressive
histone modifications at CDH1 promoter by its interactions with HDAC1, HDAC2 and
Sin3A [192]. ZEB1 recruits deacetylase sirtuin 1 (SIRT1) to the E-cadherin promoter region
to deacetylate histone H3 and reduce the transcription of E-cadherin [27]. Similarly, ZEB1
interacts with the SWI/SNF chromatin-remodeling protein BRG1 to repress E-cadherin
expression [212]. TWIST1 cooperates with BMI1 and EZH2 to down-regulated CDH1 [286].
In addition to transcriptional regulations, post-transcriptional gene regulations such
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Figure 2.3: Construction of a small EMT network involving 14 genes and miRNAs. Two
double-negative feedback loops - miR-200 family and ZEB family, miR-34 family and
SNAIL1, are shown.
as pre-mRNA alternative splicing also contribute to EMT [24]. Many genes have differ-
ent splicing isoforms and the balance between these isoforms is related to whether EMT
will occur [78, 183]. Epithelial splicing regulatory protein 1 (ESRP1) and ESRP2 are in-
volved in controlling the specific splicing of epithelial isoforms of many proteins such as
CTNND1, CD44, etc [269, 284]. ESRP genes are found to be directly down-regulated by
EMT transcription factors SNAI1, ZEB1 and ZEB2 [102,202]. At the post-transcriptional
level, miRNAs also regulate EMT gene expression. miRNAs are small non-coding RNA
molecules that can bind to complementary sequences of mRNA molecules and thus silence
the mRNAs. miRNA-200 family, including miR-200a, miR-200b, miR-200c, miR-141 and
miR-429, and miR-205 repress the expression of ZEB family [87]. ZEB family also repress
the expression of miR-200 family. The loop between these two families of transcription
factors controls both EMT and MET [25,87,189]. miR-34 family members including miR-
34a, miR-34b, and miR-34c also form a double-negative feedback loop with SNAI1 that
regulates EMT [131,223]. Tumor suppressor p53 inhibits EMT by activating miR-200 and
miR-192 family members, which suppress ZEB1 and ZEB2. [31, 131]. EZH2 represses the
expression of E-cadherin. miR-101 represses EZH2 and thus help maintaining E-cadherin
expression [256]. To give a brief illustration of the regulatory network among these mo-
lecules, we have drawn a regulatory network including 14 central molecules, as shown in
Figure 2.3.
The regulations of EMT also occur at translational and post-translational level. In-
creased expression of YB1 protein is shown to induce EMT [69]. It can stimulate the
translation of SNAI1, ZEB2, LEF1, and TWIST1 [69]. Post-translational regulation of
SNAI1 is also important for its protein level and sub-cellular localization. In the GSK3β
dependent mechanism of SNAI1 regulation, SNAI1 is phosphorylated by CK1 and then
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phosphorylated by GSK3β for degradation [282, 293, 306]. TNFα stabilizes SNAIL by
activating the NF-κB pathway [278]. GSK3β independent ubiquitin ligases MDM2 and
FBXL14 can also target SNAI1 and SNAI2 for degradation. In contrast, LOXL2 inter-
acts with SNAI1 and stabilizes it [194]. The subcellular location of SNAI1 also affects its
activity as nuclear SNAI1 degrades slower than cytosolic SNAI1. PKD1 phosphorylates
SNAI1 and facilitates its nuclear export, which decreases its effect on inducing EMT [63].
PAK1 and LATS2 phosphorylate SNAI1 and favor its nuclear retention, thus enhancing
its activity [288,298].
As is widely acknowledged, EMT involves the corporation of multiple pathways [140].
They often regulate these EMT master transcription factors such as SNAI1, ZEB1 [193].
As mentioned above, GSK3β phosphorylates SNAI1 for degradation. GSK3β also phos-
phorylates p53 and activates is transcriptional activity [253]. WNT pathway increases
SNAI1 activity by inhibiting GSK3β. PI3K-AKT pathway also inhibits GSK3β [294].
When GSK3β is inhibited, β-catenin can accumulate in the cytoplasm and eventually
translocate into the nucleus to activate TCF/LEF transcription factors and induce EMT
[161, 276]. JAK/stat3 signaling pathway increases the expression of SNAI1 and TWIST1
[37, 283]. Growth factors that act through receptor tyrosine kinases such as EGF, FGF
and VEGF can activate RAS-RAF-MEK-ERK MAPK signaling cascade. When activated,
ERK2 can increase the expression of ZEB1, ZEB2, SNAI1, SNAI2 [39, 220]. Notch sig-
naling pathway upregulates SNAI1 and SNAI2 [211]. In Hedgehog signaling pathways,
GLI1 can induce SNAI1 expression [154]. Last but not least, TGFβ signaling pathway
also contributes to EMT. In response to TGFβ1, SMAD2 and SMAD3 are phosphorylated
and then combine with SMAD4 to form SMAD complexes. SMAD3 and SMAD4 activate
HMGA2, which activates SNAI1 expression [249]. SNAI1 induces the nuclear translocation
of ETS1, which is required for ZEB1 expression [52]. These pathways are not isolated but
interconnected. TGF-beta/Smad signaling and Wnt signaling pathways are reported in
developmental and pathological events. In EMT, Smad2 and Smad4 form a complex with
LEF1 at the E-cadherin promoter, resulting in its transcriptional repression. In the TGFβ
pathway, TGFβ receptor TGFBR1 can phosphorylates SHCA protein which activates SOS
protein and then initiates the RAS-RAF-MEK-ERK MAPK pathway.
There are different perspectives with regard to EMT induction. Some propose that
the convergence of signaling pathways is essential for EMT; Some say that the balance
of different regulatory layers decides whether EMT will occur. Both are relevant to the
network perspective of cancer. The EMT gene regulatory network is complex and how its
components interact with each other to induce EMT is not yet well understood [247]. What
is certain is that EMT is a crucial program for the invasion and metastasis of epithelial
tumors which involves the loss of cell-cell adhesion and increase of cell mobility.
2.3 A Novel EMT Network Model
We constructed the EMT network based on the literature review above. It consists of 74
genes and miRNAs and their interactions. In our previous work [216], where EMT network
was used to find molecular signatures for prognosis prediction, we showed that this EMT
network did not give a good prediction performance as expected. One of the reason we
consider is that the genes in the EMT network are mainly driver genes, which affect the
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expression of many downstream target genes that are usually more differentially expressed
than the driver genes [66]. In this scenario, using only the driver genes to build predictive
models is not a good option, especially when the data are noisy.
To compensate for it, we extended the EMT network by including the molecules that
directly interact with or being regulated by the molecules in the network. In this way, the
network not only contains driver genes but also some important downstream genes. We
used NetworkAnalyst tool [279] to find these interactions. NetworkAnalyst is a compre-
hensive web-based tool for biological network analysis. One of its component is to take
the input of gene or protein names and return their interacting partners in protein-protein
interaction, miRNA-gene interaction, and TF-gene interactions. We thereby name the ori-
ginal network as Core network and the following extended versions of networks as Extended
network and Filtered network.
• Extended network. We uploaded the official gene symbols of the core EMT network
to the NetworkAnalyst web interface and obtained the first-order network of these
core EMT genes and miRNAs using STRING interactome (confidence score cutoff:
900) [235], ENCODE transcription factor and gene target data [266], and miRNA-
gene interaction data [105] respectively. Since we are only interested in aberrant
pathways in cancer, for each obtained network we only kept the genes that belong to
the Pathways in cancer term according to the KEGG pathway enrichment analysis.
Note that we applied this selection criteria only to the newly added genes. None
of the molecules in the core EMT network is removed. Accordingly, we obtained 3
new networks (one from each information source) and each network includes the core
EMT network, the newly added genes and all interactions among them. Then we
took the union of the three networks and generated the Extended network.
• Filtered network. Upon analysis of the extended EMT network, we notice that many
genes have low variance and they are not useful for differentiating different sample
groups. Thus, we removed the nodes (genes or miRNAs) whose variance are below
a certain threshold, no matter whether the nodes belong to the core EMT network
or not. We choose to remove nodes according to their variance because it is an
unsupervised criterion. For example, we could also remove nodes based on univariate
Cox proportional hazards model. However, as it is a supervised criterion, it would
be hard to apply in reality because it requires the response information beforehand.
Even though it is applicable, modifying the network in a supervised manner may
lead to overfitting of subsequent analysis.
In biological literature the molecules are often referred to as, e.g., the corresponding
kinases, transcription factors, or other functional molecules. However, for the convenience
of mapping different types of omics data to the EMT network, we represent the molecules
in the network using the names of their corresponding genes or miRNAs. For example,
E-Cadherin, which is an epithelial cell marker, is represented using the name of its coding
gene CDH1. The names of the molecules in the core EMT network are provided in Table
2.1. Their interactions are given in Table 7.1. The basic information of the three networks
(as undirected) are given in Table 2.2. For the convenience of the readers, we visualized
the three networks using R package igraph [47]. The networks are shown in Figure 2.4,
Figure 2.5, and Figure 7.1.
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Figure 2.4: Core EMT Network. The names of genes and miRNAs are given on the nodes.
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Figure 2.5: Filtered EMT Network. The names of genes and miRNAs are given on the
nodes.
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AKT1 ESRP2 LEF1 miR-205 SIRT1 TGFB1
BMI1 ETS1 LOXL2 miR-215 SMAD2 TNF
BTRC EZH2 MAP2K1 miR-34a SMAD3 TP53
CDH1 FBXL14 MAP2K2 miR-34b SMAD4 TWIST1
CDH2 FN1 MAPK1 miR-34c SMARCA4 VIM
CDH3 GSK3B MDM2 miR-429 SNAI1 WNT1
CLDN3 HDAC1 miR-101-1 MUC1 SNAI2 YBX1
CLDN4 HDAC2 miR-130b NFKB1 SOS1 ZEB1
CSN2 HMGA2 miR-141 NOTCH1 STAT3 ZEB2
CSNK1A1 HRAS miR-192 OCLN TCF3
CTNNB1 KRAS miR-200a PAK1 TCF7
DNMT1 KRT18 miR-200b PIK3CA TCF7L1
ESRP1 LATS2 miR-200c RAF1 TCF7L2
Table 2.1: The list of gene names in the core EMT network.
Table 2.2: Basic information of the three EMT networks
Different EMT networks |V (G)| |E(G)|
Core EMT network 74 113
Filtered EMT network 123 253
Extended EMT network 455 2620
In the next two chapters, we are going to use these three EMT networks for extracting
features for prognosis prediction in lung cancer. In fact, as shown by the experiments in
the next chapters, both the extended network and the filtered networks can significantly
outperform the core network. Many important features selected in the extended network
and filtered network are not included in the core network.

Chapter 3
Single-omics Prognostic Signatures for Lung
Adenocarcinoma
In this chapter, we apply state-of-the-art features selection algorithms on several omics
data levels to identify molecular signatures for lung cancer prognosis prediction. The data
levels include transcriptomics (including mRNA expression and miRNA expression), DNA
methylation, and copy number alteration (CNA). We will employ 10 feature selection al-
gorithms on each data level separately and evaluate their prediction performance using
three evaluation metrics: ROC-AUC values, ROC-PR values and classification accuracy.
All the evaluations are based on 30 times stratified 10-fold cross-validation. We will also
analyze the selected features in terms of their stability, network properties, biological inter-
pretations, and whether they can stratify the samples into significantly different prognostic
groups. We begin with introducing the feature selection algorithms. Then we describe the
experiments and analyze the results.
3.1 State-of-the-art Algorithms
There are mainly two types of studies for identifying prognostic signatures based on how
follow-up data is used. In the original data, the survival times of individuals are either
uncensored or right-censored. Right-censoring means that the individual was followed
until time t, at which the individual was still alive, but then takes no further part in
the study. Thus, we only know that the individual survived at least up to time t. The
first type of algorithms is based on classification. The samples are firstly divided into
two prognosis groups: a group that survived above a threshold and a group that did not.
The goal of an algorithm is to find features that can discriminate the two groups. The
second type of algorithms directly uses survival data and involved either Cox’s proportional
hazard model or survival analysis to select features and evaluate the predictions. The goal
of an algorithm is to find features to better predict the risk of death. We included 10
algorithms for comparison, 6 from type one and 4 from type two. We also try to cover
different underlying methodologies when we select algorithms. Since we will evaluate these
algorithms using the same gene regulatory networks (GRN) - EMT networks, algorithms
that are based on co-expression networks are excluded. We also excluded dimensionality
reduction algorithms such as PCA because our goal is to select a subset of the original
features. All the algorithms perform feature selection by selecting an optimal subset of
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Table 3.1: Categorization of the 10 feature selection algorithms
Algorithm Methodology Network Output Ref
t-test t-statistic No feature ranking [97,215]
Lasso regularized regression No coefficients [250]
NetLasso network-based regularization Yes coefficients [149]
AddDA2 subnetwork scoring and searching Yes subnetworks [8, 40]
NetRank feature importance on network Yes feature ranking [274]
stSVM random walk on network Yes feature ranking [49]
Cox Cox PH model No feature ranking [43,181]
RegCox regularized Cox PH model No coefficients [224]
MSS random sampling No feature ranking [150]
Survnet subnetwork scoring and searching Yes subnetworks [152]
features or by providing a rank of the features. Table 3.1 gives an overview of these
algorithms.
Before describing these algorithms, we would like to give the necessary notations to
be used in the following descriptions. Suppose that we have a training set X with m
individuals and p features, X ∈ Rm×p, Xi = (Xi1,Xi2, ...,Xip)′. For the purpose of
exposition, we assume that X is gene expression data, although it can denote any type of
omics measurement. The survival data for individual i is represented by (ti, δi). ti is the
time at which death or censoring occurred to individual i. δi is the indicator of censoring.
δi = 1 if i is uncensored and δi = 0 if censored. The response variable y ∈ {0, 1}. yis are
the class label for the corresponding Xis indicating whether individual i has survived up
to a certain threshold. The right-censored samples with ti below the threshold are thrown
away because their class cannot be determined. The EMT network has p genes, which
correspond to the p predictors. It is represented by a simple graph G = (V,E)1, where V
is the set of vertices that correspond to the p predictors and E is the set of edges. A is
the adjacency matrix of the graph G. It is a square matrix such that its element Aij is
one when there is an edge from vertex i to vertex j, and zero when there is no edge. The
diagonal elements of A are all zero, since there are no edges from a vertex to itself (loops)
in the simple graph G. D is the degree matrix of graph G.
Feature selection based on classes
1. t-test. The intuition is that genes that are differentially expressed between the two
sample groups are likely to be useful for sample classification. The more a gene
is differentially expressed, the less likely that the difference of the mean expression
values between the two groups is zero. For each feature vector x, let x0 denotes
the values of x where the samples belong to class 0 and x1 denotes the values of x
where the samples belong to class 1. Assuming unequal sample sizes and unequal
1Note that there is a directed edge from gene g1k to gene g2 if g1 regulates g2. However, in the case
of gene product interactions, e.g., protein-protein interaction, it is hard to define a direction. Since the
algorithms under comparison do not use edge direction information, we treated the graph as undirected.
Likewise, since we could not find a good definition of the weight of each edge, we leave the graph edges as
unweighted or with equal weight 1.
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variances, we used Welch’s t test to test whether the population means are different.
The t statistic is calculated as:







It is then used for significance testing under Student’s t distribution with the degree




(s21/n1)2/(n1 − 1) + (s22/n2)2/(n2 − 1)
The resulting p-values of the test are used to provide the feature ranking. Although
this is a simple feature selection method, it has been shown to outperform many
more sophisticated feature selection algorithms [97,215].
2. Lasso (least absolute shrinkage and selection operator) [250]. It is a regression ana-
lysis method that performs both feature selection and regularization. It shrinks the
coefficients of some features to zero, thus producing a sparse model. Let regression
coefficient vector βˆ = (βˆ1, ..., βˆp)T , the Lasso estimate (βˆ0, βˆ) is defined by [250] as:











|βj | ≤ t.
We used glmnet R package [73] to find the optimal coefficients via penalized maximum

















over a range of λ values. The l(y, η) is the negative log-likelihood contribution of
observation i. α controls the elastic net penalty. α = 1 is Lasso and α = 0 is ridge
regression. We set α = 0.95. We used glmnet to perform 10-fold cross-validation on
the training set to select the best λ value and the corresponding feature sets (features
with nonzero coefficients).
3. Network-constrained regularization and variable selection [149]. It is a linear re-
gression model that incorporates network information as a graph represented by its
Laplacian matrix. The algorithm takes similar form as elastic net which fits a linear
regression model that penalizes the L1-norm and L2-norm of the coefficients. Mean-
while, it adds a network-constrained penalty using the Laplacian matrix L of the
graph. Such penalties can select subgroups of correlated features in the network and
offer global smoothness of the coefficients over the network. The aim is to not only
select a subset of important features but also potential subnetworks that are related
to yis. Given graph G, its Laplacian matrix Ln×n is defined as:
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L = D −A
The symmetric normalized Laplacian matrix L is defined as:
Lnorm := D−1/2LD−1/2
The elements of L are given by
Lnormi,j :=

1, if i = j and deg(vi) 6= 0
− 1√
deg(vi)deg(vj)
, if i 6= j and vi is adjacent to vj
0 otherwise.
For any fixed non-negative λ1 and λ2, [149] defines the network-constrained regular-
ization criterion as




||β1|| is the L1 norm, the same as used in Lasso. The third term λ2βTLβ induces a
smooth solution of β on the network. The goal is to find the estimator βˆ to minimize
L(λ1, λ2, β). The author has rewritten the optimization problem as the following:
βˆ = arg minβ{|~y −Xβ|2},












w(i, j) ≤ t
From this network-constrained penalty one can see that if vertices vi and vj are
neighbors in graph G, then βi and βj tend to be assigned similar values. We use the
implementation of this algorithm in Grace R package. It selects λ1 and λ2 values by
doing cross-validation on the training set.
4. Subnetwork aggregation algorithm [40]. This algorithm first overlaid the gene ex-
pression data on the corresponding proteins in the PPI (protein-protein interaction)
network. Then it performs searching from each node and adds its neighbors until the
mutual information between the aggregated gene expression of the subnetwork and
the class vector does not increase above a rate r. When adding a neighbor, it selects
the neighbor that maximizes the mutual information between the aggregation of the
subnetwork and the class vector. After selecting all subnetworks, the algorithm picks
out all significant subnetworks based on statistical tests using the null distributions of
subnetwork scores of random networks and permuted data. This algorithm takes the
averages of gene expressions within individual subnetworks as new features. However,
this aggregation may not be appropriate when the genes exhibit opposite association
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with the class label because then the predictive contributions can be canceled out. [8]
investigated 11 operators to aggregate gene expressions. Many of them showed better
prediction performance than the average operator. Here we adopted the Direction







where Ψg is the gene set of seed gene g. X∗j is the expression values of gene j. cj is
the correlation value of gene j with the class vector. We therefore implemented the
original algorithm but replaced the average operator with the DA2 operator. The
pseudo-code is shown in Algorithm 1.
5. NetRank [274]. NetRank algorithm follows the idea of Google’s PageRank algorithm
[187], which decides the relevance of web documents based on the number of highly
ranked documents that point to it. In the context of biological network, the rank of
a gene is influenced by the ranks of genes that link to it. The rank can be computed
iteratively:







, 1 ≤ j ≤ |V (G)|,
where rnj denotes the ranking of gene j after n iterations, cj is the absolute Pearson
correlation of gene j expression values with the class vector, and d ∈ (0, 1) is a
parameter describing the influence of the network on the ranking of genes. Iterating
to convergence corresponds to solving the following equation [175,274]:
(I − dATD−1)~r = (1− d)~c
The parameter d is set using Monte Carlo cross-validation on the training set. Values
of d ranging from 0 to 1 with step size of 0.1 are tested. We followed the procedure
described in [274].
6. Feature selection using network smoothed t-statistic (stSVM) [49]. This algorithm
uses random walk kernel to characterize the degree of relatedness between network
nodes. The p-step random walk kernel is defined as:
K = (αI − Lnorm)p
where α is a constant and p is the number of random walk steps. We used α = 1
and p = 2, as proposed in this article. stSVM assesses the differential expression
of each network gene by obtaining the t-statistic for each network node i. The t
statistics ti, i = 1, ..., |V | are summarized into a vector ~t. The final scores of nodes
are calculated as: t˜ = tTK. The features are ranked based on the scores.
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Algorithm 1 Subnetwork searching and aggregation algorithm
Input: X ∈ Rm×p, G = (V,E), y = {0, 1}m, and rate r.
Output: Ksubnet, Scores //the selected subnetworks and their scores.
Sign of node = {0}p
for each node u ∈ V do
Sign of nodeu = sgn(cor(X∗u, y)) //the sign of Spearman correlation
end for
X ′ = {1}m × Sign of nodeT ◦X
for each node u ∈ V do
Mutinfo seed = mutual information(X ′∗u, y)
Mutinfo = {0}|NG(u)|
for each node v ∈ NG(u) //get neighbors do
aggrevec = X ′∗v +X ′∗u
Mutinfov = mutual information(aggrevec, y)
end for
maxindex = arg maxi(Mutinfoi)
if Mutinfomaxindex > Mutinfo seed× (1 + r) then





Function extend subnet (X ′, y, snode, aggrevec){
Mutinfo current = mutual information(aggrevec, y)
Mutinfo = {0}|NG(snode)|
for each node v ∈ NG(snode) do
if v /∈ snode then
aggrevec = X ′∗v + aggrevec
Mutinfov = mutual information(aggrevec, y)
end if
end for
maxindex = arg maxi(Mutinfoi)
if Mutinfomaxindex > Mutinfo current× (1 + r) then
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Feature selection based on survival data
In this part, the algorithms use censored survival data directly instead of dividing it into
two classes. The goal of these algorithms is not to classify patients into two distinct groups
but to assess how much more at risk one individual is than another. Since these algorithms
share common components such as survival analysis and Cox proportional hazards model
(Cox PH) [43], we would like to first describe these components before going into the details
of each algorithm.
In survival analysis, usually one would estimate the survival function S(t). If T is the
time of death, then S(t) = p(T > t). It is the probability of surviving at least to time t.
It can be estimated non-parametrically in the presence of censoring using Kaplan-Meier
estimate [124]. Assuming d(t) is the number of deaths at time t, q(t) is the number of
right-censoring at time t, and n(t−) is the total number of individuals at risk an instant
before time t, the Kaplan-Meier estimate of S(t) is
Sˆ(t) = Sˆ(t−)pˆ(T > t|T ≥ t)
If no failures occur at time t, pˆ(T > t|T ≥ t) = 1.
If one or more failures occur at time t,
pˆ(T > t|T ≥ t) = n(t
−)− d(t)
n(t−)
Note that the Kaplan-Meier curve only drops at the time when failures occur. If we
write t(i) as the ith time point, and d(i), q(i), and n(i−) accordingly. Then the Kaplan-Meier






,with Sˆ(t) = 1 for t < t(1)
The confidence interval of Sˆ(t) can be estimated, e.g., using Greenwood’s estimator [86]
or the Tsiatis/Aalen formula [1]. In prognostic biomarker evaluation, one typically wants
to know whether a biomarker can separate the individuals to groups that have significantly
different survival functions. In other words, we need to compare different Kaplan-Meier
curves. It is illustrated in Figure 3.1, where the survival functions of two groups of in-
dividuals, e.g., case and control, are plotted with confidence intervals. This comparison
can be accomplished using log-rank test. It is a nonparametric test and appropriate to use
when the data are censored. The basic idea is that if the two groups have the same survival
distributions, then the ratio between the number of events and the number of individuals
at risk at the beginning of the time period for each observed time point should be the same
between the two groups.
To explain this using notations, let t = 1, ..., T be the distinct times of observed events
in either group. For each time t, let N1j and N2j be the number of individuals at risk at the
start of period j in the two groups. Let O1j and O2j be the number of deaths in the groups
at time j. Nj = N1j +N2j , Oj = O1j +O2j . Under the null hypothesis that S1(t) = S2(t),
O1j has a hypergeometric distribution with parameters Nj , N1j , and Oj , and the expected
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Figure 3.1: An example of estimated survival curves using Kaplan-Meier estimator and
the result of log-rank test.




N1j , with variance Vj =
Oj(N1j/Nj)(1−N1j/Nj)(Nj −Oj)
Nj − 1 . The log-rank







for some weights wj . If the null hypothesis is true, q ∼ χ21 asymptotically. The p-value,
p = p(Q > q|H0), follows the CDF of the χ21 distribution. For log-rank test, wi = 1. Thus,
emphasis is put on larger values of time. For the generalized Wilcoxon test, wi = n(i−),
where emphasis is put on smaller values of time.
From the test above, one can know whether there is a significant difference between
the survival distributions of the two groups based on a categorical covariate. But it is not
known how much more at risk one group is than the other. When dealing with continuous
covariate, depending on how the covariate is binned into groups, the test results can be
different. Cox’s proportional hazards model (Cox PH) [43] can be used to incorporate
continuous covariates into survival analysis and analyze their effect on survival.
Cox PH employs hazard function h(t). Hazard function is defined as the instantaneous
rate for the event to occur at time t conditional on survival until time t or later:
h(t) = lim
4t→0
p[(t ≤ T < t+4t)|T ≥ t]
4t








The hazard function in Cox PH takes the form:
h(t,x) = h0(t,α)exp(βTx) ,
where h0(t) is the baseline hazard function, α are parameters that influence the baseline
hazard function. β = (β1, ...βp)′ is a vector of regression coefficients. The baseline hazard
function depends on time but not covariates. The second term depends on the covariates
but not time.
Considering two individuals with covariate x1 and x2 (x1 and x2 are scalars). Then the
ratio of their hazards at time t is:
h(t, x1)
h(t, x2)
= exp{β(x1 − x2)}
As shown above, the hazard ratio does not depend on time. One can use the notion of
hazard ratio to test whether a covariate influences survival. The coefficient β is estimated
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where ti is the observed or censored survival time for ith individual. δi is the censoring
indicator. δi = 1 if i is observed and δi = 0 if censored. R(ti) is the risk set at time ti -
the set of patients who survived prior to time ti. β can be estimated without knowing the
baseline hazard function. According to Cox, the partial likelihood is valid when there are
no ties in the survival data [44]. In case there are ties, Efron approximation is used.
Below we introduce the details of each feature selection algorithm.
1. Univariate Cox PH model. We use each feature to fit a Cox PH model to obtain the
effect of each feature on survival. Given covariate x and parameter β. The hazard
rate at time t is given by:
h(t, x) = h0(t)exp(βx),
where β is the regression coefficient and h0(t) is the baseline hazard function. In-
creasing x by one unit scales the hazard rate by eβ. Thus β can be interpreted
as the increase in log hazard per unit of x. We use survival R package to fit the
univariate Cox PH model for each feature and obtain the p-value. Then we rank
the features by their p-values. Although straightforward, this approach has been
widely applied in many studies to obtain a preliminary set of features for prognosis
prediction [46,181,201,267].
2. Regularized Cox PH model [224]. This algorithm employs cyclical coordinate des-
cent to fit the Cox PH model with elastic net penalties. Assuming there are no
ties in death/censoring time, the optimization problem is to find β that maximizes
Cox’s log-partial likelihood given above, subject to the constraint: α∑pj=1 |βj |+ (1−
α)∑pj=1 β2j ≤ c. The algorithm is implemented in R package glmnet.
3. Multiple Survival Screening (MSS) algorithm [150]. This algorithm mainly addresses
the issue of high variability of tumor gene expression profiles. It means that in
tumour cells, there are many ’passenger signals’ and they differ among individual
samples. These signals may ’bury’ the real cancer gene expression signals. MSS
algorithm addresses this issue by using random samplings of random gene set (RGS)
and random data set (RDS). It aims to select more stable markers by using genes
that are consistently good predictors in randomly sampled data sets. We adjusted
the original algorithm to our experiment. The pseudocode is given in Algorithm 2.
4. Survnet [152]. This algorithm is similar to [40] where a scoring function is defined,
and a searching algorithm is employed to find subnetworks as molecular signatures.
Different from [40], Survnet evaluates each node using a Cox PH model and a search-
ing criterion is defined accordingly. Specifically, each gene i is assigned a score si,
which is transformed from the p-value of the univariate cox PH model pi.
si = Φ−1(1− pi) ,
where Φ−1 is the inverse standard normal cumulative distribution function. The








Algorithm 2 Multiple survival screening algorithm
Input: X ∈ Rm×p, survival data of m individuals, the number of RDS nD, the number
of RGS nG.
Output: The ranking of the p features.
Initialize a matrix S = {0}nG×nD to store the p-values of log-rank tests.
Generate the indices idx D and idx G for nD RDS and nG RGS respectively.
for i = 1 to nD do
for j = 1 to nG do
Extract the datasets M consisting of idx D[i] samples and idx G[j] genes.
Apply fuzzy clustering algorithm to divide samples in M into two clusters.
Fit survival curves for the individuals in each cluster.
Apply log-rank test to compare the two curves and assign the p-value to S[i, j].
end for
end for
Keep the gene sets whose p-values are less than 0.05 in at least 25% of all RDS.
Derive the ranking of genes based on their frequencies in these gene sets.
. A greedy search algorithm [40] is employed to find the subnetworks.
3.2 Experiments
3.2.1 Data Pre-processing
We obtained the following types of data for LUAD from the FIREHOSE Broad GDAC
website (Broad Genome Data Analysis Center [http://gdac.broadinstitute.org]). The data
were from TCGA data version 28/01/2016.
1. Level 3 normalized mRNA-Seq data - the calculated expression signals of genes per
sample. The data are generated with Illumina HiSeq 2000 RNA Sequencing Version2
analysis platform using RSEM (RNA-Seq by Expectation-Maximization) quantifica-
tion [148].
2. Level 3 CNA data - copy number alterations for aggregated/segmented regions of
chromosomes per sample. It is generated with Affymetrix Genome-Wide Human
SNP Array 6.0 platform with Human Genome version 19 (hg19) reference.
3. Level 3 DNA methylation data - the calculated Beta-values mapped to the genome
per sample. Beta-value is a methylation level measurement of an interrogated CpG
site. It is calculated as the ratio of the methylated probe intensity and the sum of
methylated and unmethylated probe intensities. The data is additionally prepro-
cessed by calculating the mean Beta-values of the probes among each gene (GDAC
Methylation Preprocessor Pipeline).
4. Level 3 miRNA-Seq data - the calculated expression for all reads aligning to miRNAs
per sample. The data is generated with Illumina Genome Analyzer miRNA Sequen-
cing platform using RPKM (Reads Per Kilobase exon Model per million mapped
reads) quantification.
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Table 3.2: The description of single-level datasets. This table shows (1) sample sizes for
labeled data, (2)sample sizes for censored data and (3) the total number of features on
each data level.
labeled data censored data
good prognosis poor prognosis total Total # features
Level GE 84 99 183 497 19290
Level DM 74 93 167 447 20074
Level CNA 73 76 149 503 21456
5. Clinical and follow-up data of patients.
The CNA data we obtained contain the segment mean values of different regions on the
chromosomes. To enable the mapping of CNA data to the network, we calculated the
gene-level CNA values using the function ProcessCNAData() in the TCGA-Assembler R
package [292]. In detail, for each gene on the reference genome hg19, the regions in the
CNA data that overlap this gene were found. Then the function takes the sum of the
element-wise products of the regions’ length and the regions’ segment mean values. This
value is then divided by the total length of the overlapping regions to give the gene level
CNA values. This calculation is performed for every sample to generate gene-level CNA
values. In the end, we normalized each of the four data types feature-wise by subtracting
the mean and dividing by the standard deviation. We removed the features with >20%
missing values among the samples for each type. For the remaining features, missing values
are imputed using the mean of the corresponding features.
We normalized each omics data feature-wise. We combined mRNA-Seq data and
miRNA-Seq data as transcriptomics data. Since these data levels are multi-dimensional de-
scription of genes, for the convenience of the following text, we abbreviate transcriptomics
data, DNA methylation data, and CNA data as GE, DM, and CNA respectively.
We mapped each data level to the EMT networks with corresponding features. For
each data level we have 6 datasets: 3 for the data mapping with labeled samples, and 3
for the data mapping with censored samples. The datasets with labels have less samples
than the dataset with censored samples because for many samples the labels are unknown
and thus are removed. The information of the datasets is given in Table 3.2, together
it is shown the total number of features from each data level. For CNA data, there are
missing values for some nodes in the EMT network, thus we took subnetworks of the EMT
networks such that each node in the network is mapped with real-valued features. The
sizes of networks for CNA data are 70 for the core EMT network, 445 for the extended
EMT network, and 117 for filtered EMT network.
3.2.2 Evaluation Metrics
We have employed multiple evaluation metrics for evaluating the classifiers trained using
the selected features. This is because the performance can be sensitive to the evaluation
metrics [34]. We used accuracy, AUC-ROC, PR-ROC to evaluate classifiers as they ad-
dress different aspects of the performance. The accuracy metric imposes a threshold for
continuous classifiers and evaluates the resulting classifications. Classification accuracy is
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often a poor metric in the real world when the data is skewed [198,199]. In our study, the
datasets are balanced and stratified sampling techniques are applied in cross-validations.
Therefore, the issue of imbalanced data is not of concern.
ROC curve measures the capability of a classifier to rank the positive samples relative
to the negative samples. We use ROC (Receiver operating characteristic) curve to evaluate
the prognostic potential of different feature sets. Let X denotes the predicted values, with
higher value more prone to short survival, and C denotes the binary outcome of short or
long survival, then the ROC curve forX is a plot of the True Positive Rate (TPR, also called
sensitivity) associated with the dichotomized test X > c versus the False Positive Rate
(FPR) for all possible threshold values c. The ROC curve is a monotone increasing function
in [0, 1]. It plots the value pairs of {P (X > c|C = 1), P (X > c|C = 0)} for c ∈ (−∞,∞).
ROC curves are often used to measure the prognostic capability of biomarkers. It is shown
that a perfect ROC curve with AUC equals 1 does not guarantee a perfect classification,
which depends on the threshold [72]. Compared with accuracy measure, it has several
advantages. First, a ROC curve captures the inherent discrimination capability of a test
without relying on any specific threshold while using accuracy measure one often has to
decide a threshold for the algorithms that output the probabilities of class values. Second,
ROC curve can depict the relative trade-offs between TPR and FPR. Third, ROC curve
provides a valid approach to compare different markers even when they are on different
scales. Last, the area under a ROC curve (AUC-ROC) can be interpreted as the probability
that the marker value from a randomly chosen positive individual exceeds the marker value
of a randomly chosen negative individual. In this way, AUC-ROC values can be used to
compare different ROC curves from different biomarkers.
Given the prediction vector X and a threshold c, one can derive from the prediction
probabilities the confusion matrix, and calculate the TPR, FPR, prediction, and recall
metrics, as shown in Figure 3.2. As proposed in [53], one can treat these metrics as
functions that map the confusion matrix to a point in either ROC space or PR space. In
the ROC space, the goal is to be closer to the upper-left corner. While in the PR space, the
goal is to be closer to the upper-right corner. As shown in Figure 3.2, the red curve is the
best one in both ROC and PR space. [53] has proven that for a given dataset of positive
and negative samples, there exists a one-to-one correspondence between a curve in ROC
space and a curve in PR space. Meanwhile, the authors also show that among different
ROC curves, a higher AUC-ROC value does not always lead to a higher AUC-PR value.
By the definition of PR curve, the prediction needs to achieve a high precision at low recall
values to achieve high AUC-PR values. Since ROC and PR curves are both derived from
the confusion matrix but cannot replace each other, we think it is necessary to evaluate
the above algorithms using both ROC and PR curves.
The area under the curve is used as a metric to define how an algorithm performs
over the whole space. The area under the ROC curve (AUC-ROC) is now commonly
used to evaluate biomarker performance. It can be calculated using the trapezoidal areas
created among ROC points. There are a few R packages for ROC analysis. Comparisons
of these packages, with regard to their support of smoothing, partial AUC, confidence
interval, and statistical tests are provided in [204,230]. According to these studies, pROC
R package is shown to have advantages over the other packages and we will employ it for the
ROC analysis. In PR space, linear interpolation cannot be applied because it yields over-
optimistic estimate of performance [53]. Therefore, we cannot directly calculate the area
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Figure 3.2: Evaluation metrics. In (a) and (b) we give the definitions of a few common
probabilities used in machine learning. In (c) and (d) we plotted curves in ROC and PR
spaces. The curves illustrate very good, good, and poor predictions. The curves with the
same color are generated using the same values.
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under the PR curve using linear interpolation. [23, 125] proposed fine-grained, continuous
interpolation between the PR points. The latter method has been implemented in the
PRROC R package [83]. We will use this package for AUC-PR calculation.
3.2.3 EMT-based Feature Selection
As introduced in Chapter 2 we constructed three EMT networks: core EMT network,
filtered EMT network, and extended EMT network. These networks and the features in
the network will be used for feature selection. We would like to address three motivations
of using EMT networks instead of the entire PPI network. The first motivation is from
a biological perspective. Although numerous biological evidence has shown that EMT
gene regulations play important roles in cancer prognosis, it has not been directly used for
prognosis prediction. Therefore, it is necessary to test the predictive capabilities of EMT
networks. The second motivation is that using EMT network can dramatically reduce the
cost of the experiments. Compared with the original datasets which have >20,000 features,
EMT networks have only 74, 123, and 455 features. High dimensionality is a major obstacle
in selecting biomarkers. The PPI network has around >20,000 nodes, which cannot help
with the dimensionality issue. The irrelevant parts of the network can cause high variance
in selected features. Last but not least, we objectively compared different algorithms with
the same network. As shown in the summary Table 1.2, the feature selection algorithms
usually used different sources of underlying network. This makes it difficult to directly
compare these algorithms. We tested all algorithms using the same data partitions, the
same networks, and evaluated them using the same metrics.
In our previous work [216], where we decomposed the EMT network into network mo-
tifs and selected network motif features, the predictive performance was not as good as
expected. Sometimes the EMT features were even performed worse than random features.
This does not agree with the biological facts that EMT is highly relevant to cancer pro-
gnosis. We have found two potential reasons for it. One is the limited information in the
core EMT network. We have resolved it by extending the EMT network to include down-
stream genes, as introduced in Chapter 2. The second and more critical reason is that
we used Lasso feature selection on each of the feature sets, which may have overwhelmed
the effects of different feature selection methods. Research also shows that Lasso could be
biased when the features are highly correlated [251]. As we used network motif scores as
new features, the overlap of many network motifs can cause high correlation among the
features. In this case, Lasso cannot give stable predictions. To change it, we abandoned
the idea of decomposing EMT network into network motifs and instead included many
state-of-the-art feature selection algorithms that do not depend on network motifs. Lasso
is only included as one of the algorithms.
Work Flow
The work flow of the experiments is shown in Figure 3.3. We take the processed data
from the three data levels and map the data to the three EMT networks, which yields 9
combinations of data and networks. For each combination we performed 30 times 10-fold
cross-validation to evaluate the 10 feature selection algorithms. Note that the indices for
training and testing samples in each fold are kept identical across all algorithms. In the
48 Chapter 3 Single-omics Prognostic Signatures for Lung Adenocarcinoma
Figure 3.3: Experiment flow. This figure illustrates the combination of data levels with
different networks and shows how the feature selection algorithms are evaluated in each
cross-validation fold.
lower part of the figure, we show how the evaluation was performed in each cross-validation
fold. As written in section 2.2.2, we have both labeled data and censored data for each
data type. We divide both of them into 10 folds, use 9 folds for training and the fold left for
testing. This gives training set A1 and testing set A2 for labeled data, and training set B1
and B2 for censored data. For the training phase, we apply type 1 algorithms on A1 and
type 2 algorithms on B1 to select features. This gives feature sets F1 to F10. Each of these
feature sets is used to train classifiers on A1. For the testing phase, we use each trained
classifier to make predictions on A2. As A2 is labeled data, we evaluate the prediction
performance using AUC, AUPR, and classification accuracy at different cutoffs.
There are a few commonly used accuracy estimation methods such as holdout, k-
fold cross-validation, stratified k-fold cross-validation, leave-one-out cross-validation, and
bootstrap. We used stratified 10-fold cross-validation because it is demonstrated to give a
more stable accuracy estimation [133]. We have noticed that in our experimental design
some of the testing samples in A2 could appear in the training set of B1 and interfere
with the evaluation. Therefore, we have tried another experimental setting (setting 2) to
separate the data in a stricter way to make sure that A2 and B1 have no overlap in each
cross-validation run. We have compared the results of setting 2 with the original setting
and found that this did not cause significant effect on the evaluation. We think this is
because both labeled data and censored data are divided into 10 folds independently and
randomly. The fraction of overlapping samples between A2 and B1 is rather small and
random. This could also be inferred from the data description in Table 3.2.
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Comparative Groups
We have proposed to employ feature selection algorithms on the EMT networks, which
contain at most 2.5% features from the original features. This is an original and very bold
assumption we have made based on biological domain knowledge. Consequently, we are
urged to compare the performance of EMT features with that of considering all features
from the corresponding data levels to intuitively assess how much ”performance loss” is
caused due to the assumption. This can tell us how useful EMT networks are in selecting
prognostic signatures. Therefore, we included the following four comparative groups:
1. Random networks. A random network has the same structure as an EMT network
but with randomly selected features on each node. We have used the same samples
and the same cross-validation folds to select features on the random networks. This
is to enable paired statistical tests between EMT networks and random networks.
In total, 150 random networks were generated, each was tested using 10-fold cross-
validation.
2. All features that are in the EMT networks. We include all features in the EMT
networks as features.
3. All features from the corresponding data levels (>19,000 features).
4. Take all features from the corresponding data levels and select a subset of features
using Lasso.
Additionally, we used clinical features for prediction. We used 9 clinical features from
patient data. The features are: age at initial diagnosis, gender, overall pathologic stage,
the variables T and N using the TNM cancer staging system 1, smoking history (discrete
variables denoting the heaviness of smoking), radiation therapy indicator and molecular
therapy indicator. We have also combined clinical features with frequently selected molecu-
lar features for prediction on the samples that have both clinical features and the corres-
ponding molecular features. What’s more, we tested the effect of thresholds in prediction
performance, which is usually omitted in most of the studies where only one arbitrary
threshold was chosen.
3.3 Results
In this section we present our results into five parts:
1. The comparison of EMT features with random features.
2. The AUC, AUPR, and accuracy of EMT features.
3. Frequently selected EMT features.
4. The effect of adding clinical features.
5. The effect of classification thresholds.
1TNM Classification of Malignant Tumor (TNM) is the most widely used cancer staging system. T
refers to the size and extend of the main tumor. N refers to the number of nearby lymph nodes that have
cancer. M refers to whether the cancer has spread from the primary tumor to other parts of the body.
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3.3.1 EMT Features vs. Random Features
We compared the prediction performance of EMT features with that of randomly chosen
features using AUC, AUPR and prediction accuracy metrics. We chose two combinations
of data levels and network sizes for the comparison. For each combination, 150 sets of
random features were sampled to estimate the overall prediction performance, each with
stratified 10-fold cross-validation. Figure 3.4 shows the distributions of AUC, AUPR, and
prediction accuracies for DNA methylation data with core EMT network. Figure 3.5 shows
the distributions of the metrics for gene expression data with filtered EMT network. In
each figure, the probability density functions of the evaluation metrics are estimated using
kernel density estimation method with Gaussian kernel.
Since our goal here is to compare random features with EMT features, we only included
5 feature selection algorithms and one comparative group (use all EMT features). The data
folds used in 30 times 10-fold cross-validation are kept the same for both EMT features
and random features. This enabled us to perform paired t-tests between EMT features and
random features for each feature selection algorithm. Since we have sampled 150 random
networks, each tested with 1 time 10-fold cross-validation, we randomly chose 30 random
networks for the statistical tests. Note that the probability density functions of random
networks are estimated using all 150 random networks. In each sub-figure we give the
p-value of the paired t-test. We observe that EMT features obtained significantly better
prediction performance for every feature selection algorithm and evaluation metric.
3.3.2 AUC, AUPR and Accuracy of EMT Features
In Figure 3.6 we show the boxplot of AUC values of the 10 feature selection algorithms,
with 3 different data levels and 3 different EMT networks using SVM classifier. The
comparative groups 2, 3, and 4 are included. In Figure 3.7 we give the boxplot for AUPR
values. Table 3.3 shows the average AUC and AUPR values. All results are averaged from
30 times stratified 10-fold cross-validation. We observe multiple interesting comparisons
that are consistent among the majority of the algorithms.
1. GE and DM data gave more accurate predictions than CNA data.
2. Larger network does not necessarily give better predictions. For example, with GE
data, filtered network in general gives better predictions than the core network and
the extended network. With DM data, the core network is in general the one with
higher AUC values. With CNA level, the advantage of larger network size is almost
negligible.
3. Compared with the first column, where all features within the EMT network were
used without feature selection, many feature selection algorithms do not show im-
proved performance. Some combinations of algorithms and networks significantly
outperform EMT features while some others gave worse performance.
4. Compared with using all features from GE data (19290 features), EMT network-
based features achieved significantly higher AUC values. Compared with using all
features of DM data (20074 features) and CNA data (21456 features), EMT network-






















































































Features EMT Features Random Features
Figure 3.4: The AUC, AUPR, and accuracies of EMT features versus random features using
DNA methylation data with the core EMT network. Gaussian kernel is used to estimate
the density functions based on results from 30 times 10-fold cross-validation. For each
cross-validation fold, EMT features and random features are tested on the same training
and testing samples. The comparisons on five feature selection algorithms together with
the comparative group of using all EMT features are shown. The p-values of paired t-tests
are provided.
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Figure 3.5: The AUC, AUPR, and accuracies of EMT features versus random features using
gene expression data with filtered EMT network. Gaussian kernel is used to estimate the
density functions based on results from 30 times 10-fold cross-validation. For each cross-
validation fold, EMT features and random features are tested on the same training and
testing samples. The comparisons on five feature selection algorithms together with the
comparative group of using all EMT features are shown. The p-values of paired t-tests are
provided.
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Table 3.3: The average AUC and AUPR values of the 10 feature selection algorithms using
SVM classifier. For each algorithm, we evaluated its prediction performance using 3 data
levels. Within each data level, we used 3 different sizes of EMT networks.
Data Level Gene expression DNA Methylation CNA Metric
|V (G)| 74 123 455 74 123 455 70 117 445
EMT 0.662 0.728 0.691 0.698 0.679 0.671 0.616 0.645 0.608 AUC0.627 0.719 0.651 0.666 0.648 0.652 0.521 0.608 0.506 AUPR
t-test 0.658 0.709 0.677 0.688 0.675 0.669 0.616 0.626 0.621 AUC0.612 0.702 0.650 0.654 0.645 0.647 0.570 0.603 0.578 AUPR
Lasso 0.616 0.703 0.620 0.697 0.666 0.667 0.615 0.619 0.617 AUC0.565 0.680 0.577 0.658 0.624 0.646 0.565 0.592 0.578 AUPR
NetLasso 0.659 0.718 0.686 0.700 0.678 0.677 0.619 0.635 0.621 AUC0.623 0.706 0.649 0.666 0.647 0.672 0.553 0.615 0.580 AUPR
addDA2 0.650 0.675 0.651 0.699 0.661 0.702 0.597 0.626 0.616 AUC0.611 0.636 0.607 0.662 0.610 0.678 0.530 0.616 0.579 AUPR
Netrank 0.656 0.691 0.668 0.695 0.685 0.693 0.615 0.619 0.610 AUC0.610 0.675 0.637 0.670 0.652 0.674 0.569 0.590 0.564 AUPR
stSVM 0.651 0.693 0.639 0.669 0.668 0.687 0.608 0.617 0.616 AUC0.617 0.669 0.591 0.621 0.631 0.664 0.531 0.554 0.552 AUPR
Cox 0.673 0.705 0.712 0.703 0.707 0.696 0.620 0.664 0.675 AUC0.623 0.686 0.673 0.667 0.673 0.671 0.541 0.642 0.659 AUPR
RegCox 0.648 0.698 0.729 0.696 0.717 0.666 0.645 0.669 0.653 AUC0.614 0.676 0.689 0.652 0.674 0.607 0.613 0.642 0.621 AUPR
MSS 0.662 0.694 0.659 0.674 0.654 0.640 0.608 0.627 0.625 AUC0.625 0.679 0.626 0.636 0.601 0.580 0.509 0.584 0.555 AUPR
Survnet 0.646 0.661 0.679 0.702 0.688 0.680 0.626 0.693 0.682 AUC0.611 0.650 0.654 0.664 0.637 0.628 0.574 0.673 0.645 AUPR
It is shown that applying Lasso feature selection on all the dimensions improved the
predictions for DM data, but not for GE and CNA data.
5. Core EMT network gives more accurate predictions than the other two networks using
DM data while filtered or extended EMT networks give more accurate predictions
using GE data. Since the latter networks include the downstream genes of the core
network, it is interesting to investigate the relationships between network scope and
the data level that is more predictive.
To test the effect of classifiers on the prediction performance, we also applied ran-
dom forest classifier using the selected features of each algorithm. The boxplot is shown
in Figure 3.8. The average AUC and AUPR values are given in Table 7.2. We observe
that with GE data both classifiers give similar performance, while random forest classifier
performs better with using all 19290 features, which is still equivalent or lower than the
prediction performance of EMT network-based features. With DM data, we observed less
difference among the three EMT networks than using SVM classifier. The AUC values
of all algorithms, especially when using the core EMT network, are lower than that of
SVM classifier. With CNA data, we again observed similar performance as SVM classifier.

























































Networks Core Network Filtered Network Extended Network All Features from the Data Level
All Features + Lasso
Figure 3.6: The AUC values of 10 feature selection algorithms using SVM classifier. The
three panels correspond to three data levels. Within each panel, the AUC values of the
10 algorithms are plotted. Each algorithm has three boxes of different colors denoting the
3 EMT networks. The blue and red dotted lines within each panel are the median AUC
values of two comparative groups: 1) using all data level features and 2) Lasso feature


























































Networks Core Network Filtered Network Extended Network All Features from the Data Level
All Features + Lasso
Figure 3.7: The AUPR values of 10 feature selection algorithms using SVM classifier. The
three panels correspond to three data levels. Within each panel, the AUPR values of the
10 algorithms are plotted. Each algorithm has three boxes of different colors denoting the
3 EMT networks. The blue and red dotted lines within each panel are the median AUPR
values of two comparative groups: 1) using all data level features and 2) Lasso feature
selection on all data level features.
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As also shown in our other experiments, random forest classifier gives comparable predic-
tions as SVM classifier, with lower or higher prediction performance than SVM in some
minority cases (certain combinations of networks and feature selection algorithms). Since
random forest classifier gives different results upon repetition because of its randomness,
our following discussions will be mainly based on the results from SVM classifier by default.
When the performance of these two classifiers are significantly different for the majority of
algorithms, we will discuss separately.
As shown in section 2.2.3 about evaluation metrics, accuracy measure is necessary
because a higher AUC value does not necessarily guarantee accurate predictions at a certain
cutoff. We have obtained the classification accuracy of each algorithm at different cutoffs.
Since we observed that most of the algorithms achieved highest prediction accuracy at
the cutoff of around 0.5 (as shown in Figure 7.2), we compared the algorithms’ average
prediction accuracy at 0.5 cutoff and presented it in Figure 3.9. We have observed the
following:
1. EMT network-based features achieved equivalent or higher prediction accuracy than
using all features from the corresponding data levels, with or without Lasso features
selection.
2. CNA data give lower prediction accuracy than the other two data levels for most of
the algorithms.
3. Larger network size does not always lead to better predictions. For the majority
combinations of algorithms and data levels, the prediction accuracy does not correlate
with network sizes.
3.3.3 Frequently Selected EMT Features
While it is difficult to select a single best feature selection algorithm, all evaluation metrics
show high variance from the results of 30 times 10-fold cross-validation. It can be observed
from both the density plots and box plots. This phenomenon has raised our concerns. It
could be attributed to the high heterogeneity of the samples. Depending on the division of
samples into training and testing sets, even very small variations can cause large difference
in the predictions on the testing set. We show an example below in Figure 3.10 and Figure
3.11. These two different cross-validation runs are from the same set of samples. The two
training sets have 89% of the samples in common. However, we observe the large difference
in prediction performance on the testing set. We have also performed clustering analysis
by firstly using t-SNE (t-distributed stochastic neighbor embedding) algorithm 1 to project
the samples into two dimensions and then applying hierarchical clustering on 2D. We have
performed this analysis for a set of ”good/bad pairs” of cross-validation runs but we have
not found a common explanation for this phenomenon. What we have observed is that it
occurs very often. This means that selecting biomarkers based on single cross-validation
runs or a certain division of samples into training and testing set is highly unreliable.
To improve the stability of EMT signatures, we proposed to use the frequently selec-
ted features (FSFs) from all 30 times 10-fold cross-validation. We selected 20 FSFs and
1t-SNE is a nonlinear dimensionality reduction technique that is particularly suitable for embedding


























































Networks Core Network Filtered Network Extended Network All Features from the Data Level
All Features + Lasso
Figure 3.8: The AUC values of 10 feature selection algorithms using random forest classifier.
The three panels correspond to three data levels. Within each panel, the AUC values of the
10 algorithms are plotted. Each algorithm has three boxes of different colors denoting the
3 EMT networks. The blue and red dotted lines within each panel are the median AUC
values of two comparative groups: 1) using all data level features and 2) Lasso feature
selection on all data level features.









































































































































































































































































































































































Comparisons All Features from the Data Level
All Features + Lasso
Figure 3.9: The prediction accuracy of the 10 feature selection algorithms at 0.5 cutoff
using SVM classifier. The three panels correspond to three data levels. Within each panel,
the average prediction accuracy of the 10 algorithms are plotted, which is grouped by EMT
networks. The blue and red dotted lines within each panel are the average accuracies of
two comparative groups: 1) using all data level features and 2) Lasso feature selection on










































































training_labels FALSE TRUE cl_hierarchical 1 2
testing_labels FALSE TRUE cl_hierarchical 1 2
Figure 3.10: An example of cross-validation test that gives good prediction performance.
The upper figure shows ROC curves on training and testing data. The lower figure shows
clustering analysis on training and testing data.







































































training_labels FALSE TRUE cl_hierarchical 1 2
testing_labels FALSE TRUE cl_hierarchical 1 2
Figure 3.11: An example of cross-validation test that gives unsatisfactory prediction per-
formance. The upper figure shows ROC curves on training and testing data. The lower
figure shows clustering analysis on training and testing data.
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performed 30 times 10-fold cross-validation to test their performance. The density plot of
AUC, AUPR, and accuracy values are shown Figure 3.12, with the comparison of individu-
ally selected features. Since the sample folds are kept the same for both groups, we used
paired t-test to compare their performance. The p-values are shown in each sub-figure.
The corresponding boxplot of AUC and AUPR values is given in Figure 3.13.
The results show that FSFs outperform individually selected features very significantly
(except Netrank algorithm). FSFs show much higher AUC, AUPR, and accuracy values
and lower variance. The average AUC values for t-test, Lasso, NetLasso, and addDA2 have
reached 0.773, 0.825, 0.796, and 0.833. This predictive performance is rather remarkable.
Recall that we only used less than 2.5% of the original dimensionality, namely EMT fea-
tures, for feature selection and prognosis prediction. This shows the predictive capability
of EMT features, which is consistent with biological findings that EMT process is highly
relevant to cancer prognosis. The results also suggest that using FSFs can effectively mit-
igate the effect of sample heterogeneity. We acknowledge that testing FSFs on the same
set of samples causes dependencies. But considering the significant performance gain, we
attribute most of the contributions to the stability of FSFs. In the next chapter we will
show that on independent samples the FSFs can also give significant sample stratifications.
3.3.4 The Effect of Adding Clinical Features
Next, we combined the FSFs with clinical features to make predictions. We obtained the
AUC values and average prediction accuracy and compared it with using only clinical
features. The boxplot of AUC values and the barplot of the average prediction accuracy
are shown in Figure 3.14 and Figure 3.15. Table 3.4 shows the average AUC and AUPR
values. Random forest classifier shows different AUC values than SVM classifier. The
boxplot of AUC values and the barplot of the average prediction accuracy are shown in
Figure 7.3 and Figure 7.4. The average AUC and AUPR values are shown in the Table
7.3. Note that the sample sizes for each data level are different from that of section 2.3.1
because we can only use the samples who have both the molecular data and the clinical
data. Due to the same reason, the performance of clinical features in the three panels is
also different as the sample sizes differ. In this way, the performance of clinical features
within each panel is comparable with other feature groups. From these results we have the
following observations:
1. Combining frequently selected EMT features with clinical features can significantly
outperform clinical features. Some combinations of data levels, networks and al-
gorithms achieved average AUC values of above 0.8. However, in some cases, the
combination of features leads to worse prediction performance than using only the
FSFs (as shown in Figure 3.13).
2. Lasso, NetLasso, and addDA2 algorithms give better performance than the other
feature selection algorithms using GE and DM data. Using CNA data, combining
features mostly does not significantly improve prediction performance.
3. It can be seen from both Figure 3.13 and Figure 3.14 that most of the contributions
come from FSFs, and not the clinical features for the top performing feature selection
algorithms.








































































Features Individually selected features Frequently selected features
Figure 3.12: The comparison of FSFs with individually selected features in terms of AUC,
AUPR, and accuracy values. We used DNA methylation data and extended EMT network
for feature selection and SVM classifier for classification. Gaussian kernel is used to estim-
ate the density functions based on results from 30 times stratified 10-fold cross-validation.
For each cross-validation iteration, individually selected features and FSFs are tested on
the same training and testing samples. The comparison between the two feature groups is





































Features Individually selected features Frequently selected features
Figure 3.13: The comparison of FSFs with individually selected features in terms of AUC
and AUPR values. We used DNA methylation data and extended EMT network for feature
selection and SVM classifier for classification. The boxplot is based on the results from 30
times stratified 10-fold cross-validation. The comparison between the two feature groups
is shown on five feature selection algorithms.
4. Comparing Figure 3.14 with Figure 7.3, random forest classifier significantly improved
the AUC values of some algorithms using GE data and DM data, especially for
addDA2 algorithm. Comparing Figure 3.15 with Figure 7.4, random forest algorithm
gave much better prediction accuracy for most of the algorithms using GE data and
DM data. It suggests that random forest classifier can do better with mixed features
- both numerical features and categorical features.
We further analyzed which variables in clinical features are relatively important. We
used a few methods to measure the feature importance, as given below:
1. The variable importance measure using random forest. It is based on the mean
decrease in Gini impurity after the splitting of a node. The Gini impurity index
is defined as G = ∑nci=1 pi(1 − pi), where nc is the number of classes in the target
variable and pi is the ratio of this class. The Gini decrease is calculated as I =
Gparent − Gsplit1 − Gsplit2. The Gini decrease of a feature is averaged over all splits
that are based on this feature in the forest. Since clinical variables are categorical
and with different number of levels, in which case random forests are biased to favor
features with more levels [231], we transformed the 8 clinical variables into 25 dummy
variables where each dummy variable corresponds to one level of the original variables.
For age variable, we binned it into three levels: young (30 to 50), middle (50 to 70),
and old (70 to 90). The dot chart of feature importance is given in Figure 3.16a.
2. Statistical measures including AUC values, Spearman correlation, and p-values of
univariate Cox model for each clinical variable (shown in Figure 3.16b)





























































Networks Core Network Filtered Network Extended Network Clinical Features
Figure 3.14: The average AUC values of FSFs combined with clinical features for three
data levels and three EMT networks using SVM classifier. The blue dotted lines show the















































































































































































































































































































































Figure 3.15: The average prediction accuracy at 0.5 cutoff of FSFs combined with clinical
features for three data levels and three EMT networks using SVM classifier. The blue
dotted lines are the median accuracy values of using only clinical features.
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Table 3.4: The average AUC and AUPR values of FSFs together with clinical features
using SVM classifier. For each algorithm, we evaluated its prediction performance using 3
data levels. On each data level, we used 3 different sizes of EMT networks.
Data Level Gene expression DNA Methylation CNA Metric
|V (G)| 74 123 455 74 123 455 70 117 445
clinical 0.695 0.682 0.756 AUC0.651 0.596 0.751 AUPR
t-test 0.701 0.735 0.762 0.724 0.766 0.770 0.755 0.806 0.756 AUC0.648 0.697 0.736 0.626 0.692 0.690 0.697 0.767 0.733 AUPR
Lasso 0.711 0.777 0.793 0.729 0.773 0.824 0.776 0.824 0.801 AUC0.648 0.761 0.777 0.633 0.700 0.756 0.704 0.780 0.753 AUPR
NetLasso 0.731 0.762 0.787 0.743 0.739 0.768 0.752 0.756 0.762 AUC0.690 0.738 0.761 0.644 0.672 0.689 0.684 0.703 0.730 AUPR
addDA2 0.684 0.733 0.772 0.648 0.717 0.794 0.752 0.724 0.749 AUC0.629 0.671 0.745 0.495 0.646 0.714 0.694 0.678 0.697 AUPR
Netrank 0.693 0.688 0.741 0.692 0.685 0.693 0.773 0.766 0.738 AUC0.638 0.648 0.712 0.563 0.604 0.581 0.708 0.714 0.690 AUPR
stSVM 0.669 0.689 0.660 0.648 0.630 0.656 0.722 0.721 0.755 AUC0.628 0.639 0.592 0.528 0.450 0.510 0.659 0.667 0.705 AUPR
Cox 0.705 0.706 0.701 0.647 0.694 0.662 0.734 0.791 0.756 AUC0.649 0.683 0.643 0.500 0.595 0.568 0.676 0.738 0.739 AUPR
RegCox 0.706 0.690 0.770 0.684 0.712 0.687 0.758 0.799 0.760 AUC0.642 0.655 0.717 0.589 0.608 0.574 0.687 0.752 0.714 AUPR
MSS 0.674 0.671 0.671 0.657 0.610 0.645 0.728 0.741 0.734 AUC0.621 0.631 0.655 0.501 0.370 0.496 0.683 0.707 0.699 AUPR



























0 1 2 3 4 5
MeanDecreaseGini
(a) Mean Gini decrease
Spearman’s rho AUC Cox p-value
pathology T -0.15 0.43 4.39e-3
pathology N -0.28 0.64 8.62e-5
pathology stage -0.33 0.68 3.57e-7
smoking history -0.058 0.47 7.41e-1
age -0.02 0.51 3.81e-1
gender -0.068 0.47 4.87e-1
radiation therapy -0.16 0.44 8.15e-4
molecular therapy -0.12 0.45 1.28e-1
(b) Statistical measures
|pathology_stage< 1.5



















Figure 3.16: Assessment of the importance of individual clinical features. We calculated
the relative importance of features using different methods: (a) the mean Gini decrease
over all trees in the random forest (b) the Spearman correlation, AUC value, and the p-
value of univariate Cox PH model, and (c) the recursive partitioning of samples based on
event rate.
3. Recursive partitioning for survival trees [242, 243]. The method can build either
classification or regression trees using a two-stage procedure. In the first stage the
tree is built based on a splitting criterion and in the second stage the tree is pruned
using cross-validation. Here we used event rate data to build a regression tree to
divide the samples into groups of different event rates. The result is shown in Figure
3.16c. At each leaf node, one can observe the number of events (death) and the
relative death rate compared to the overall rate. For example, for cancer in stage
1 with age <70, the relative death rate is 0.519. In contrast, for cancer in later
stages and with the smoking history (ranges from 1 to 5) ≥ 4, the relative death rate
increases to 2.772.
3.3.5 The Effect of Classification Thresholds
As mentioned in the Experiments section, we performed the same experimental procedure
using four different thresholds that are in the order of increasing discrepancy: 3 years,
<900 or >1200 days, <700 or >1400 days, <500 or >1500 days. DM data with core
EMT network were used for the testing. Figure 3.17 shows the AUC values of the 10
feature selection algorithms with four different thresholds using both SVM and random













































Thresholds 3 years <900, >1200 days <700, >1400 days <500, >1500 days
Figure 3.17: The AUC values of 10 feature selection algorithms using different thresholds
for good prognosis class and poor prognosis class. The data level is DNA methylation data.
The network is EMT core network.
forest classifiers. The corresponding AUPR values show similar trend and can be found in
the Figure 7.5. The average prediction accuracies with these four thresholds are shown in
Figure 3.18. We have observed the following:
1. Classification thresholds have an obvious effect on the AUC values and accuracy.
The more discrepant the threshold is, the higher is the AUC value and the prediction
accuracy. This apply to all feature selection algorithms. For all algorithms, the latter
two thresholds gave significantly higher AUC values and prediction accuracy than the
former two less discrepant thresholds.
2. The algorithms differ from each other in how sensitive they are to the effect of
thresholds. For example, addDA2, RegCox, and Survnet algorithms are more sens-
itive to the effect of thresholds, compared with t-test and MSS algorithms.
3.4 Analysis
3.4.1 Stability of Feature Selection Algorithms
It is shown that the results of 30 times 10-fold cross-validation have high variability. Al-
though the overlap of training instances among different training folds is around 78%, the
prediction performance on the testing set can vary greatly from one to another. Therefore,
























































Thresholds 3 years <900, >1200 days <700, >1400 days <500, >1500 days
Figure 3.18: The average prediction accuracy of 10 feature selection algorithms using
different thresholds for good prognosis class and poor prognosis class. The data level is
DNA methylation data. The network is EMT core network.
feature selection algorithms are to the variations in the training set. [122, 123] proposed
the notion of feature preference stability to quantify the sensitivity of feature selection
algorithms to differences in training sets drawn from the same distribution. The feature
preference can take different forms, e.g., a subset of selected features, a weighting-scoring,
or the ranking of features. Especially, the motivation of investigating the stability of fea-
ture selection algorithms is particularly strong in biomarker discovery because the data are
usually high-dimensional, and the selected molecular signatures are required to be stable -
high overlap of selected features given variations on the training set. The reason is that if
the selected features vary too much upon slight variations in the training data, then it is
difficult for domain experts to have confidence in the molecular signatures.
The measurements of the similarity for feature preferences are defined for feature se-
lection algorithms that provide weighting-scoring, ranking, or feature subsets [122, 123].
Let the feature vector f = (f1, f2, ..., fm), the similarity of feature preferences is calculated
accordingly for the three cases:
• A weighting vector: w = (w1, w2, ..., wm), w ∈ W ⊆ Rm. In this case, the similarity
between two weightings w,w′ is calculated using the Pearson’s correlation coefficient.
SW (w,w′) =
∑




• A ranking: r = (r1, r2, ..., rm), 1 ≤ ri ≤ m. In this case, the similarity between two
rankings r, r′ is calculated using Spearman’s rank correlation coefficient.
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• A subset of features: s = (s1, s2, ..., sm), si ∈ {0, 1}, with 0 indicating absence of a
feature and 1 presence. The similarity between two subsets s, s′ (bitmaps) is calcu-




i Xi ∨ Yi)
, where ∧,∨ are bitwise and, or operators.
As seen from the definitions, SS focuses on a given number of top ranked features while
SW and SR consider all features. In biomarker identification, SS is of greater interest
since we need to have small set of features as markers. Therefore, we use SS to measure
the feature preference similarity for each feature selection algorithm on each pair of cross-
validation tests. We set the subset size of 10 for the core network, 15 for the filtered network,
and 20 for the extended network . Since we applied 30 times 10-fold cross-validation, there
are 300(300 − 1)/2 pairs. Then we take the average similarity over all pairs as the final
stability score. We picked the network that gave the highest prediction performance to
evaluate the stability. We have also calculated the score for each comparative group. The
results are shown in Table 3.5.
In biomarker discovery it is desired to find a feature selection algorithm that has both
high stability and good prediction performance. Thus, we copied the average AUC values
of algorithms from Table 3.3 into Table 3.5 for a convenient comparison. We observed the
following:
1. EMT network-based feature selection achieved significantly higher stability than us-
ing all features plus Lasso from the corresponding data level, while having better
prediction performance. Especially when using all EMT features on DNA methyla-
tion data using core EMT network, the stability score is 1, while having AUC value
of 0.698. Table 3.5 shows that in many cases EMT feature selection achieved much
higher prediction performance than using all data level features while having higher
stability scores. Therefore, from the perspectives of both feature stability and pre-
diction performance, EMT network shows its value in biomarker selection.
2. The goodness of the 10 feature selection algorithms can be hard to distinguish, which
depends on the trade-off between AUC and stability score. stSVM and t-test feature
selection show higher stability than other algorithms. Note that both algorithms are
based on t-test while the former smoothed the t-statistic on a network. t-test feature
selection achieved higher AUC values than stSVM and around half of other feature
selection algorithms in each column of the table. Thus, if one takes into account both
stability and prediction performance, t-test is a good choice, although it usually does
not lead to the best AUC scores.
Because of the high-dimensionality of data, it is widely acknowledged that molecular
signatures produced by different studies usually differ widely and have few genes in common
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Table 3.5: The stability scores of feature selection algorithms. For each pair of cross-
validation tests we calculated the Tanimoto similarity and averaged the scores from all
pairs.
Data Gene expression DNA Methylation CNA Metric
|V (G)| 74 123 455 74 123 455 70 117 445
EMT 1 1 1 stability0.662 0.728 0.691 0.698 0.679 0.671 0.616 0.645 0.608 AUC
t-test 0.721 0.762 0.609 0.747 0.505 0.496 0.656 0.550 0.564 stability0.658 0.709 0.677 0.688 0.675 0.669 0.616 0.626 0.621 AUC
Lasso 0.299 0.443 0.238 0.539 0.359 0.347 0.315 0.336 0.211 stability0.616 0.703 0.620 0.697 0.666 0.667 0.615 0.619 0.617 AUC
NetLasso 0.618 0.562 0.324 0.692 0.408 0.198 0.546 0.380 0.396 stability0.659 0.718 0.686 0.700 0.678 0.677 0.619 0.635 0.621 AUC
addDA2 0.479 0.538 0.245 0.559 0.314 0.258 0.454 0.314 0.223 stability0.650 0.675 0.651 0.699 0.661 0.702 0.597 0.626 0.616 AUC
Netrank 0.577 0.652 0.402 0.728 0.582 0.600 0.626 0.474 0.565 stability0.656 0.691 0.668 0.695 0.685 0.693 0.615 0.619 0.610 AUC
stSVM 0.639 0.838 0.858 0.780 0.695 0.869 0.833 0.646 0.775 stability0.651 0.693 0.639 0.669 0.668 0.687 0.608 0.617 0.616 AUC
Cox 0.597 0.690 0.613 0.682 0.580 0.483 0.641 0.558 0.492 stability0.673 0.705 0.712 0.703 0.707 0.696 0.620 0.664 0.675 AUC
RegCox 0.473 0.505 0.424 0.518 0.413 0.281 0.455 0.425 0.316 stability0.648 0.698 0.729 0.696 0.717 0.666 0.645 0.669 0.653 AUC
MSS 0.179 0.304 0.062 0.404 0.095 0.055 0.276 0.162 0.075 stability0.662 0.694 0.659 0.674 0.654 0.640 0.608 0.627 0.625 AUC
Survnet 0.418 0.220 0.164 0.176 0.453 0.318 0.298 0.371 0.287 stability0.646 0.661 0.679 0.702 0.688 0.680 0.626 0.693 0.682 AUC
All features + Lasso 0.228 0.261 0.136 stability0.648 0.652 0.612 AUC
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[66, 67, 150, 171, 258]. This can already be observed using the same dataset with 10-fold
cross-validation. This lack of agreement raised doubts about the reliability of the identified
biomarkers. Using probably approximately correct (PAC) sorting algorithm, [67] shows
that to achieve a typical overlap of 50% between two sets of prognostic markers, one
would need the molecular profiles of several thousand patients, which is very challenging
in clinical settings. Here we propose that by using a prognosis relevant network (EMT),
one can increase the feature overlap significantly and meanwhile obtaining similar or even
better prediction performance.
3.4.2 Patterns in EMT Signatures
One thing that is of top interest is to analyze which features are selected in different data
levels and what do they indicate. We will first look at the network properties of the FSFs.
Then we investigate how these features relate to each other by using association rule mining
method.
Network Properties of FSFs
Cancer is nowadays acknowledged as a disease that involve dysregulation of multiple path-
ways that function in a complex GRN [80, 137]. Graph theory has been increasingly em-
ployed to better understand the network properties [168,191]. Here we use a few commonly
used centrality measures to characterize the FSFs at each data level. These measures are
introduced below:
• Degree centrality. It shows how many interactions is a node involved in. For a node
i, the degree centrality Cd(i) = deg(i). Nodes with high centrality are called hubs
since they are connected to many neighbors.
• Betweenness centrality. It gives higher rank to nodes that lie on a high proportion
of paths between other nodes in the network. These nodes are important for other
nodes to communicate with each other. For distinct nodes i, j, w ∈ V (G), let σij
be the total number of shortest paths between i and j and σij(w) be the number
of shortest paths from i to j that pass through w. The betweenness centrality is






In Table 3.6 and Table 3.7, we show the average Cd and Cb of the FSFs of feature
selection algorithms, grouped by data levels and network sizes. We used Wilcoxon signed-
rank test to test the differences between each pair of different data levels with the same
network size. The results of the test are given in Table 3.8. We observe that when the
network is small, there is hardly significant differences among the three data levels. When
the size of network increases, features selected from DM data have significantly higher Cd
and Cb than the other two data levels, while the difference between GE and CNA data
may or may not be significant.
We would like to further investigate why this pattern emerges. As the features are
selected according to their predictive capability of cancer prognosis, this suggests that the
important features on different data levels have different properties. To give an intuition
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Table 3.6: Average degree centrality of the FSFs of 10 feature selection algorithms.
GE74 DM74 CA70 GE123 DM123 CA117 GE455 DM455 CA445
t-test 2.10 2.15 2.35 3.30 6.15 4.90 9.35 15.15 9.95
Lasso 2.80 3.00 2.55 2.80 5.45 4.40 5.25 21.85 10.95
NetLasso 3.05 2.55 2.30 4.60 3.80 4.50 7.40 12.65 10.05
addDA2 3.91 3.91 2.38 5.52 7.00 5.46 24.50 18.26 14.79
Netrank 5.15 4.50 2.45 6.10 9.60 8.30 15.10 67.50 20.70
stSVM 2.40 4.35 2.80 6.30 9.55 7.70 45.10 52.90 15.95
Cox 3.50 2.00 3.65 2.55 5.75 3.45 6.70 19.00 13.75
RegCox 4.45 2.85 4.20 2.70 6.10 4.30 11.00 11.35 17.10
MSS 2.20 2.20 2.00 2.05 2.65 3.20 4.50 11.45 12.85
Survnet 3.42 3.38 2.29 4.53 7.71 5.00 17.58 23.79 11.72
ensemble 3.35 3.35 2.45 3.20 6.55 6.10 12.35 26.50 19.55
of the selected features, we visualized the FSFs of two algorithms - Lasso and addDA2 on
the EMT network, as shown in Figure 3.19. We observe that some nodes are selected for
more than one data levels and some are not. Important genes in one data level may not
be the important genes in other data levels. These two algorithms show clearly different
feature preference. addDA2 algorithm identified some important modules in which features
are selected on multiple data levels while features selected by Lasso are more separately
distributed. One can also observe that addDA2 algorithm selected less features that are
in the center of the network. We have performed feature visualization for all algorithms
on all three networks. However, when the network size grows, one can hardly identify the
patterns by eyes. It is hard even for small networks, to identify how these features interplay
in the context of cancer prognosis.
Although it is well-known that gene regulations take place in different levels and work
closely with each other in molecular biology, this interplay has not been revealed in cancer
prognosis prediction. Therefore, we propose the hypothesis that features from different
data levels play different and supplementary roles in cancer prognosis prediction. To test
this hypothesis, we need an approach that can make predictions while offering a model with
clear biological interpretations. We think association rule mining algorithm is suitable for
this purpose. It can give association rules for prognosis prediction and the rules can be
derived simultaneously from different data levels. In this way, one can check the biological
interpretation of the rules, e.g., how features from different data levels interact and how
this is associated with cancer prognosis. Additionally, one can use the derived rules to
make predictions to see how well these rules can stratify patients of different prognostic
outcome.
Association Rule Mining
Association rule mining is a machine learning method for discovering interesting relations
between features in a dataset. It consists of two steps: finding frequent itemsets and
representing them in the form of rules. The problem of association rule mining is originally
defined as the following [4]: Let I = {i1, i2, ..., in} be a set of n binary features called items.
Let D = {t1, t2, ..., tm} be a set of transactions called the database. A rule is defined in
74 Chapter 3 Single-omics Prognostic Signatures for Lung Adenocarcinoma












































































































































































































































































































Not selected Gene expression DNA methylation CNA
Figure 3.19: Visualization of the FSFs by Lasso and addDA2. Features selected from the
three data levels are visualized with different colors.
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Table 3.7: Average betweenness centrality of the FSFs of 10 feature selection algorithms.
GE74 DM74 CA70 GE123 DM123 CA117 GE455 DM455 CA445
t-test 76.94 41.09 48.31 70.26 311.22 200.32 228.04 504.66 334.72
Lasso 67.37 96.56 40.67 101.29 219.24 138.85 38.34 1180.07 243.55
NetLasso 59.53 87.78 20.78 202.22 160.59 142.33 140.74 424.31 504.14
addDA2 118.93 117.42 89.39 241.17 291.52 198.98 1152.11 783.38 743.91
Netrank 197.06 188.94 55.75 241.97 476.54 371.82 391.56 4816.10 1398.33
stSVM 78.33 170.34 82.97 231.83 448.63 282.70 2737.36 3273.28 960.79
Cox 125.55 52.20 140.78 61.37 219.61 108.57 103.73 930.45 393.60
RegCox 150.91 82.61 153.80 53.57 238.37 150.54 287.48 177.61 618.29
MSS 54.66 71.42 70.44 25.09 99.06 88.50 24.65 629.72 690.07
Survnet 153.94 113.28 95.79 195.83 321.77 186.74 782.45 1106.00 353.09
ensemble 107.74 116.46 60.90 92.99 249.79 245.22 305.96 1678.27 1119.17
Table 3.8: Results of Wilcoxon signed-rank test on the centrality measures of the FSFs
from different data levels. In the parenthesis after each p-value we give the comparative
relationship of the two groups.
Network size Data levels Degree Centrality Betweenness Centrality
74 GE vs. DM p=0.5286 p=0.7646
74 DM vs. CNA p=0.213 p=0.2783
70 GE vs. CNA p=0.05545 p=0.04199 (>)
123 GE vs. DM p=0.00293 (<) p=0.001953 (<)
123 DM vs. CNA p=0.009766 (>) p=0.0009766 (>)
117 GE vs. CNA p=0.008686 (<) p=0.04199 (<)
455 GE vs. DM p=0.009766 (<) p=0.01367 (<)
455 DM vs. CNA p=0.01855 (>) p=0.04199 (>)
445 GE vs. CNA p=0.5771 p=0.4648
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the form: X ⇒ Y , where X,Y ⊆ I. The itemsets X and Y are called left-hand-side (LHS)
and right-hand-side (RHS). In order to select interesting rules from the set of all possible
rules, constraints on various measures of significance and interest are applied. Let a rule
X ⇒ Y be identified on a set of transactions T . Commonly used constraints are given
below:
• Support. It indicates how frequently the itemset appears in T .
supp(X) = |{t ∈ T ;X ⊆ t}||T |
• Confidence. It indicates how often a rule has been found to be true.
conf(X ⇒ Y ) = supp(X ∪ Y )
supp(X)
• Lift. It indicates the degree to which X and Y depend on each other.
lift(X ⇒ Y ) = supp(X ∪ Y )
supp(X)× supp(Y )
To apply association rule learning, we first discretized the features using the mean.
Since we are trying to find molecular patterns for predicting prognosis, we set the RHS
of the rules to be the class labels of prognosis. Then we applied Apriori algorithm
[5] implemented in the arules R package [92] to discover rules, with the constraints of
confidence ≥ 0.8 and support ≥ 0.1. In principle, we can find association rules for each
combination of data levels, algorithms, and the size of networks. However, based on our
motivation, which is to investigate the association patterns among different data levels in
prognosis prediction, we will focus on the following questions:
1. Whether association rules agree with the underlying EMT gene regulations. For
example, whether the LHS of a rule gives a reasonable explanation of the prognosis
outcome.
2. Whether combining different data levels gives significantly more rules than using
the same number of features within a single data level. If this is true, it indicates
that combining data levels can potentially reveal more prognosis relevant molecular
interactions.
3. Whether the quality of rules, as measured by the metrics given above, is significantly
different among different combinations of data levels and feature selection algorithms.
We designed experiments fur the purpose of answering these questions. We identified
rules from the following combinations of data levels using the FSFs selected by each al-
gorithm. Table 3.9 shows the data combinations and the corresponding sample sizes. We
used the top 10 FSFs from each feature selection algorithm to identify rules. For a fair
comparison, we used in total 20 FSFs for each data combination. For single data levels,
we used top 20 features. For a combination of two data levels, we used 10 features from
3.4 Analysis 77
Table 3.9: Sample distribution of datasets containing combinations of data levels.
Data combinations Sample size Good prognosis Poor prognosis
Gene expression (GE) 183 84 99
DNA methylation (DM) 167 74 93
Copy number alteration (CNA) 149 73 76
GE + DM 165 73 92
GE + CNA 146 72 74
DM + CNA 135 66 69
GE + DM + CNA 133 65 68
each data level. For the combination of 3 data levels, we used 7 features from each data
level. Below we provide results attempting to answer the above questions.
Association rules provide interesting biological insights.
We have identified many rules for good and poor prognosis groups. Many of them agree
with the established findings in EMT literature, but some do not. Below we would like to
illustrate with three sets of examples. In the first two sets of examples the rules have good
biological interpretation and in the third set of examples the rules seem to be counter-
intuitive.
1. Rules from the core EMT network agree with the underlying gene regulations.
{LOXL2GE = high, TGFB1GE = high,miR.34aGE = low} ⇒ {prognosis = poor},
with support = 0.135, confidence = 1, lift = 2.046. This rule has a perfect confid-
ence for all samples that have these 3 items (features of gene expression). It has been
shown that LOXL2 can stabilize SNAI1. TGFB1 can phosphorylate SMAD2 and
SMAD3, which interact with SMAD4 and activates HMGA2, which then activates
SNAI1. When LOXL2 and TGFB1 gene expression are high, it not only induces
SNAI1 gene expression but also stabilizes SNAI1 protein. miR.34a has the role of
repressing SNAI1. Thus, when miR.34a has low gene expression, as indicated by
the rule, SNAI1 is less repressed. Therefore, these three conditions all lead to the
direction of the high expression of SNAI1, which is a key transcription factor to in-
duce EMT, thus leading to poor prognosis. In contrast, another rule which has the
opposite state of LOXL2 indicates good prognosis: {LOXL2GE = low,ETS1GE =
low, LOXL2DM = high} ⇒ prognosis = good, with support = 0.105, confidence =
1, lift = 1.956. In this condition, LOXL2 has high methylation status and low ex-
pression. It is highly liked to remain low gene expression and not able to stabilize
SNAI1. ETS1 gene can increase the expression of ZEB1 which induces EMT. In this
rule ETS1 has low expression so it does not contribute to inducing EMT. These two
opposite rules have both perfect confidence for a small group of samples and sound
biological interpretations.
2. Rules from the filtered EMT network give good biological interpretations across mul-
tiple data levels. Here we pick the top 20 rules, which all have confidence score of
1, as shown in Table 3.10. We observed that these rules consist of only 16 genes
and the associations of gene status with the prognosis outcome are consistent. For
example, the high expression of GATA6 gene always associates with poor prognosis
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and its low expression always associates with good prognosis. Another interesting
example is miR-34a gene. Its high methylation or low gene expression corresponds
to good prognosis, while its low methylation or high expression corresponds to poor
prognosis, as shown in rule 1, 7, 8, and 18. These consistent patterns suggest that
the rules are not random but are related to the underlying gene regulations in the
context of cancer prognosis. Although many molecules in the rules are not in the
core EMT network, upon literature review, we found out evidence for most of these
molecules. We list three examples below:
• High GATA6 gene expression is always associated with poor prognosis. GATA6
transcription factor can activate SNAI2 and down-regulates E-cadherin to in-
duce EMT. [28,139,225]. Thus, it is reasonable that a high expression of GATA6
contributes to poor prognosis.
• High expression of BIRC3 gene is always associated with poor prognosis. BIRC3
is shown to be a biomarker of mesenchymal phenotype in glioblastoma [265]. It
is also related to cell motility and invasion in breast cancer [166].
• High expression of BIRC5 gene is always associated with poor prognosis. BIRC5
gene encodes Survivin protein, which is expressed highly in most human tumors
[210] and it is required for tumor maintenance [9].
3. There are some items or rules that may be less apparent to explain or counter-
intuitive. We give three examples below.
• The low gene expression of CDH3 is always associated with good prognosis
while its high expression is associated with poor prognosis. CDH3 encodes P-
cadherin. It is a cell-cell adhesion molecule and plays an important role in
conserving the structural integrity of epithelial tissues. Meanwhile, it is known
as both a tumor suppressor and a tumor promoting molecule, depending on the
molecular context [260]. Therefore, the high expression of CDH3 is supposed to
be associated with good prognosis.
• The low DNA methylation of HMGA2 is always associated with good prognosis.
This is counter-intuitive as HMGA2 gene is known to promote cancer metastasis
by activating SNAI1 gene to repress E-cadherin [270, 304]. Thus, a low DNA
methylation level of HMGA2 is supposed to lead to poor prognosis.
• There are items in high confidence rules but their roles in cancer are not yet well
studied. For example, Table 3.10 shows that the high expression of FOXA3 is
always associated with poor prognosis and its low expression is always associated
with good prognosis. However, we did not find information about its role in
cancer.
One can see from the rules that there are multiple alternative molecular mechanisms
that are associated with prognosis. Since there are rules with high confidence and good
biological interpretations, one can suggest that instead of finding a model for all samples,
it could be more appropriate to use multiple rules for prognosis prediction. On the other
hand, there are potentially ”false positive” rules which also have a high confidence but do
not match the state-of-the-art biological insight. It would be interesting to differentiate the
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Table 3.10: Top 20 prognostic association rules extracted from the FSFs using filtered
EMT network. All the following rules have confidence scores of 1.
LHS prognosis supp lift
1 CDH3GE = low,miR.34aDM = high,HMGA2DM = low good 0.113 1.956
2 EGLN3GE = low,CDH3GE = low,HMGA2DM = low good 0.113 1.956
3 GFI1BGE = high,CDH3GE = low,HMGA2DM = low good 0.135 1.956
4 GATA6GE = low,E2F1GE = low,HMGA2DM = low good 0.120 1.956
5 GATA6GE = high,CDC20GE = low, FOXA3GE = high poor 0.150 2.046
6 GATA6GE = high,CDH3GE = high, FOXA3GE = high poor 0.135 2.046
7 GATA6GE = high,miR.34aDM = low, FOXA3GE = high poor 0.143 2.046
8 miR.34aGE = low,CCND1GE = high, FOXA3GE3 = low good 0.113 1.956
9 GATA6GE = low,miR.34aGE = low,CCND1GE = high good 0.105 1.956
10 BIRC3GE = low,CCND1GE = high, FOXA3GE = low good 0.113 1.956
11 LOXL2GE = high,miR.34aDM = low, FOXA3GE = high poor 0.158 2.046
12 BIRC3GE = low,miR.34aGE = low,CDH3GE = low
HMGA2DM = low
good 0.105 1.956
13 GFI1BGE = high,miR.34aGE = low,HMGA2DM = low
FOXA3GE = low
good 0.105 1.956
14 GFI1BGE = high,BIRC3GE = low,miR.34aGE = low
HMGA2DM = low
good 0.105 1.956
15 ITGA6GE = high,BIRC3GE = high,BIRC5GE = high
GATA6GE = high
poor 0.113 2.046
16 BIRC3GE = high,GATA6GE = high,E2F1GE = low
miR.34aDM = low
poor 0.105 2.046
17 BIRC3GE = high,GATA6GE = high,E2F1GE = low
GATA4GE = low
poor 0.135 2.046
18 BIRC5GE = high,GATA6GE = high,miR.34aGE = high
FOXA3GE = high
poor 0.128 2.046
19 EGLN3GE = high,BIRC5GE = high,GATA6GE = high
FOXA3GE = high
poor 0.113 2.046
20 BIRC5GE = high,GATA6GE = high,miR.192GE = low
FOXA3GE = high
poor 0.120 2.046
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true rules and false rules by the properties of items, either in the context of gene regulations
or network structures.
Combining multiple data levels improves the qualities of rules
We firstly measured the total number of rules inferred from the FSFs of different feature
selection algorithms. Especially, we have tested all different combinations of data levels. As
shown in Table 3.9, combining the data levels results in a smaller sample size, which tends
to have more rules. Therefore, we used only the samples that have all three data levels
for comparison. Here we have included the results of 8 algorithms, excluding algorithms
addDA2, stSVM, and Survnet. The reason is that these algorithms have an aberrant lower
number of rules compared with other algorithms, as shown in Table 7.4. In our opinion,
this is due to the network constraints of these algorithms. In addition, the quality of the
resulting rules is also lower and features from different data levels do not correlate well
with each other. Thus, to investigate the effect of combining different data levels, we did
not include these three algorithms.
We calculated the average length of rules, the average support, confidence, and lift of
rules using different combinations of data levels. The results are shown in Table 7.4. The
summary of rules based on 8 feature selection algorithms is shown in Figure 3.20. We
observe that combining different data levels gives significantly more rules. The rules have
significantly higher confidence and lift, while being shorter in length.
3.4.3 Survival Analysis Using EMT Signatures
In many state-of-the-art studies, selected signatures are evaluated using Kaplan-Meier sur-
vival curves and log-rank test to see whether these features can stratify patients into signi-
ficantly different survival groups. Having selected features using different EMT networks
and data levels, we would like to investigate whether these features can cluster patients into
groups with significantly different survival distributions. Therefore, we clustered samples
into 3 clusters using k-means algorithm with the FSFs of each feature selection algorithm.
We used top 20 FSFs for single features and top 10 for subnetwork features. We plot-
ted Kaplan-Meier survival curves for the 3 clusters and performed log-rank tests. To test
whether feature selection can improve sample stratification, we also performed clustering
using all features in the EMT networks and using all features in the data levels. To test
whether an ensemble feature selection can improve the clustering, we also used top 20
most FSFs across all 10 feature selection algorithms for comparison. Table 3.11 shows
the p-values of log-rank tests for each algorithm and comparative group, including the
combinations of data levels and networks.
We observe that compared with using all EMT features, feature selection in most of
the cases increased the quality of clustering for GE and DM data. EMT features can
significantly stratify the patients into different prognostic groups (p <0.05). Figure 3.21
shows two examples where good patient stratifications are obtained. The first (Figure
3.21a) is to use the FSFs (subnetworks) of addDA2 algorithm with extended EMT net-
work and DM data. Log-rank test gives a p-value of 4.06e-9. The 10 subnetworks are
[1] HSP90AA1, JAK1, MAP2K2, PIAS4, PIK3CA, STAT3; [2] AKT1, BCL2L2, CCNB1,
PRKDC, TRAF6; [3] GATA6, GRB2, LCK, miR-200a, MTOR, PIK3CA; [4] FLT4, JAK1,
LCK, PAK1, PIK3CA, SRC; [5] HSP90AA1, PAK1, PDGFRB, PIK3CA, SP1, STAT3; [6]







































































































Figure 3.20: The statistics of prognostic association rules using different combinations of
data levels. The top-left figure shows the number of rules given by each data combination.
The top right figure shows the average rule length. The bottom two figures show the
average confidence and lift of rules.
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Table 3.11: The p-values of log-rank tests based on k-means clustering for individual data
levels.
Data Gene Expression DNA Methylation Copy Number Alteration
|V (G)| 74 123 455 74 123 455 70 117 445
EMT 1.59e-1 3.88e-3 3.50e-2 9.76e-1 9.60e-1 3.45e-1 5.13e-1 9.75e-1 2.24e-1
t-test 2.97e-3 2.39e-5 5.56e-6 9.00e-2 4.19e-1 3.53e-2 4.80e-3 6.01e-4 1.43e-2
Lasso 1.60e-3 6.27e-4 4.88e-10 2.74e-1 8.40e-1 3.73e-2 4.46e-1 4.29e-1 8.06e-1
NetLasso 6.04e-2 2.41e-1 3.81e-1 3.58e-1 6.27e-1 4.24e-1 7.81e-1 9.27e-1 9.65e-1
addDA2 6.25e-5 5.63e-2 1.56e-6 9.11e-1 1.08e-3 4.06e-9 8.48e-3 8.69e-4 4.46e-5
Netrank 2.79e-4 1.14e-3 5.18e-8 7.08e-1 9.11e-1 5.59e-2 6.58e-3 5.85e-3 3.64e-3
stSVM 8.84e-2 3.86e-2 3.81e-2 3.79e-1 6.79e-1 3.48e-1 6.89e-2 5.30e-1 9.25e-1
Cox 9.19e-7 8.65e-8 8.22e-4 7.24e-2 1.77e-1 9.85e-4 4.24e-2 9.42e-2 1.36e-5
RegCox 4.19e-4 1.29e-4 2.68e-9 4.20e-1 1.29e-1 1.86e-2 1.40e-2 8.80e-2 3.36e-3
MSS 2.45e-3 3.80e-5 3.15e-4 2.45e-2 9.66e-2 2.52e-1 2.48e-1 1.86e-1 2.10e-1
Survnet 6.93e-4 2.89e-2 9.20e-6 3.19e-1 9.17e-1 5.50e-3 2.29e-1 5.52e-3 1.52e-2
ensemble 1.65e-4 2.00e-5 1.50e-10 5.62e-1 6.11e-1 7.63e-2 1.91e-1 7.66e-2 1.77e-2
All data level features 3.46e-2 3.91e-1 3.83e-1
FGFR1, GRB2, PIK3CA, RAC2, SP1; [9] AKT1, BCL2L2, GLI2, RAC3; and [10] AKT1,
BCL2L2, CCNB1, HIC1, RAC2, RAC3. The second example (Figure 3.21b) is to use
the FSFs of Lasso algorithm with extended EMT network and GE data. Log-rank test
gives a p-value of 4.88e-10. These 20 genes are ITGA6, EGLN3, ZNF2, YES1, CDC42,
ABL1, ZNF146, PIK3CG, PPP1R13B, PTGS2, GLI2, WNT3A, SHC1, RELA, EPAS1,
HIST1H1A, IGF1R, KAT2B, BIRC3, and LOXL2. Note that both feature selection al-
gorithms selected features based on only labeled data, which contain 183 (GE) and 167
(DM) samples. Here we use these features to cluster all 497 (GE) and 447 (DM) samples.
Although many samples were not exposed to the algorithms during feature selection, the
FSFs can very well cluster these unseen samples. Last but not least, we observe that
using all features from the data levels does not give satisfactory clustering results, which
highlights the importance of feature selection.
3.5 Discussion
3.5.1 Advantages of EMT Features
We constructed EMT GRN from the review of EMT research articles. In this way we
captured the central genes in EMT gene regulations. It is shown in Figure 3.4 and 3.5 that
the features selected from EMT networks always obtained significantly better prediction
performance than the features selected from random networks, no matter which feature
selection algorithm was employed. This shows that feature selection based on biological
knowledge makes a real difference. Given that the major challenge in biomarker discovery is
to differentiate between the true signatures and statistically equivalent random signatures,
our proposed approach of using phenotype relevant network-based feature selection can
increase the robustness of molecular signatures.












































Strata + + +cl_kmeans=1 cl_kmeans=2 cl_kmeans=3
77 38 14 3 3
206 132 40 18 11
















































Strata + + +cl_kmeans=1 cl_kmeans=2 cl_kmeans=3
151 102 52 30 22
215 152 64 34 18










(b) GE data using FSFs of Lasso algorithm
Figure 3.21: Kaplan-Meier survival curves of 3 patient clusters and log-rank tests using
individual data levels.
GRN, which has at most 2.5 % of the original dimensionality. However, our experiments
show that selecting features based on EMT networks can significantly outperform the fea-
tures selected from the original data (Figure 3.6, 3.7, 3.8, and 3.9), which corresponds to
19,290 GE features, 20,074 DM features, and 21,456 CNA features. Consistently, EMT-
based features can stratify all stage samples and early stage samples into significantly
different prognostic groups while using all data level features cannot (Table 3.11). Addi-
tionally, EMT-based features have much better biological interpretations, as shown from
the prognostic association rules derived from the FSFs. These performance gains suggest
that using biological knowledge to shrink the feature space to phenotype relevant features
is an effective method to mitigate the curse of dimensionality. The Wolpert’s famous ”no
free lunch” machine learning theorems [275], which state that no learner can beat random
guessing over all possible functions to be learned, also support our conclusions. Without
certain level of domain knowledge, data alone are not enough for a machine learning model
to have good generalization [61].
We meanwhile compared the performance of three EMT networks: core network,
filtered network, and extended network. In most of the cases, the extended EMT network
gives the best performance. This observation is consistent with state-of-the-art studies,
where it is shown that the central transcription factors may not change their expressions
as much as the genes they regulate. Thus, the central network may not show obvious
difference among patients that belong to different prognostic groups. Attention needs to
be paid on this point because it can let us utilize biological knowledge to a better extent.
For example, one can first identify the central GRN and extend it to involve down-stream
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genes using biological databases that describe PPIs, TF-gene interactions, etc.
3.5.2 Considerations among Multiple Evaluation Metrics
Having evaluated the feature selection algorithms using different metrics, we observe that
these metrics can give different conclusions if we base our conclusions only on statistical
tests. For example, in Figure 3.6 one can perform statistical tests between each pair of
boxes. If the same statistical tests are applied again on the results in Figure 3.9, one
cannot hold the same conclusions, let alone when different classifiers are employed with
different parameters. The same phenomenon is observed when we use other evaluation
metrics. [34] performed prognosis prediction in breast cancer employing five predictive
models. They found that different metrics of evaluating survival prediction models gave
different conclusions. They also showed that the performance of binary classifiers is highly
dependent on how the two risk groups are defined. A slight change of the threshold can
lead to very different prediction results. This agrees with our results of experimenting
with different prognostic thresholds. Taking these factors into account, we see that it
is not reliable to evaluate prognostic feature selection algorithms using a single metric,
as the conclusions can change upon the variations of evaluation metrics, classifiers and
parameters. Most of the state-of-the-art studies use ≤ 2 evaluation metrics. As the metrics
can be different among studies and these metrics do not guarantee to agree with each
other, the best biomarker found in one study may not be good for the other studies. In
our opinion, this contributes to the very low overlap among the biomarkers reported in
different studies. Therefore, we advocate to employ a few different metrics when evaluating
feature selection algorithms.
When we draw conclusions based on several evaluation metrics, addDA2 algorithm is
one of the best performing algorithms. Especially, the FSFs of addDA2 perform very well
in stratifying samples into distinct survival groups. Lasso algorithm has also achieved
consistent good performance. t-test feature selection has a very good stability while per-
forming better than several other algorithms. It is hard to rank the other feature selection
algorithms as their performance measured by different evaluation metrics is not consistent.
What we find more interesting is the comparison of different data levels. The comparisons
among 3 data levels: GE, DM and CNA are consistent regardless of evaluation metrics.
EMT GE and DM features are more predictive than CNA features.
3.5.3 Comparisons to State-of-the-art Studies
As shown in Chapter 1, we have reviewed studies that aim to identify molecular signatures
from omics data for cancer prognosis prediction. In the following we relate our results to
theirs to either support our findings or to share some new insights.
Random Features Can Significantly Predict Prognosis
[258] conducted a study to identify signatures for breast cancer outcome prediction. They
found out that most random gene expression signatures are significantly associated with
breast cancer outcome. Upon comparison of 47 published breast cancer outcome signa-
tures to random gene signatures, 28 of them (60%) were not significantly better outcome
predictors than random signatures of identical size and 11 (23%) were worse. They showed
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that in breast cancer any set of 100 or more genes selected at random has a 90% chance
to be significantly associated with clinical outcome. Our experiments show similar results.
One can observe in Figure 3.4 and Figure 3.5 that at least half of the feature sets selected
from random networks (consisting of random chosen features) are significantly predictive,
in terms of AUC value, AUPR value, and accuracy. What’s more, this holds true for both
GE data and DM data, and for different network sizes. This demonstrates that statistical
significance is not enough for the conclusion that a good molecular signature has been
discovered. One needs to deal with the underlying irrelevant features that could be hidden
in the signature.
Another study [8] also agrees with our conclusions on using random networks. They
evaluated the prognosis prediction performance of features selected from 3 different net-
works - PPI network in [228,229], co-expression network, and a random network by shuﬄing
the nodes in a PPI network. Their results show that features selected from the random net-
work give similar prediction AUC values as features selected from the PPI network. Several
other studies [66,97,229] on breast cancer prognosis prediction using gene expression data
have drawn consistent conclusions. Briefly, [97] did not detect any feature selection method
to be significantly better than random features using paired ANOVA test. [66] showed that
random signatures can reach a baseline AUC value comparable to that of feature selection
algorithms.
EMT Features Achieved Competitive Prediction Performance
We related the prediction performance of EMT features to that achieved in state-of-the-
art studies of prognosis prediction. [297] carried out a comprehensive study to evaluate
the features selected from different omics data types in their prognosis prediction per-
formance. Four cancer types from TCGA are included: kidney renal clear cell carcinoma
(KIRC), glioblastoma multiforme (GBM), ovarian serous cystadenocarcinoma (OV), and
lung squamous cell carcinoma (LUSC). The omics data types under comparison are: (a)
mRNA expression, (b) miRNA expression, (c) DNA methylation, (d) CNA, and (e) protein
expression. What’s more, they investigated the effect of classifiers (8 classifiers including
SVM), feature selection algorithms, and the number of features on the classification per-
formance by calculating the average AUC values of 10-fold cross-validation. They tuned
the parameters of classifiers and picked the one that gave the highest AUC values. Using
SVM classifier, they achieved average AUC values of 0.658, 0.531, 0.628, and 0.696 with
data types a, b, d, and e for LUSC, and the values of 0.626, 0.625, 0.619, 0.615, and 0.625
with data types a, b, c, d, and e for OV. In our experiment, we used the default paramet-
ers of RBF kernel. Our results in Table 3.3 show higher average AUC values. Although
the AUC values are not directly comparable because the cancer type differs, we can at
least conclude that EMT-based feature selection is competitive. Since [297] investigated
different factors that can potentially influence the prediction performance, they concluded
that the effect of machine learning algorithms is moderate compared with the effect of
data types. This is consistent with our findings, where the performance difference between
SVM and random forest classifiers is much smaller than the difference among data types.
[163] selected features using four data types (mRNA, miRNA, DM, and CNA), as
well as integrated data (a concatenation of individual data types with features that meet
certain criterion) to predict prognosis in OV with L1 regularized Cox PH model [188] .
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With the selected features from integrated data, they clustered the holdout test data into
three clusters. The results of log-rank tests using either individual data types or integrated
data did not show satisfactory separation of patients in terms of overall survival (p >0.05).
The integrated data did not lead to a significantly better results. As the concatenated
data have even higher dimensionality, the potential to find more important signatures may
be out-weighted by the increased noise. The CoxReg algorithm [224] we employed has the
same optimization function, except that a different method - cyclical coordinate descent is
used to find the optimal model parameters. Using EMT networks, CoxReg algorithm can
stratify patients into significantly different survival groups.
FSFs Boosted the Prediction Performance of EMT Features
This has been shown in Figure 3.12 and Figure 3.13. It suggests that using FSFs can better
cope with the heterogeneity and noise of individual cross-validation tests and obtain more
robust molecular signatures. We have observed from Figure 3.10 and Figure 3.11 that
feature sets can fit the training sets very well but have very different performance on the
testing set. In other words, it is hard to know whether a set of features will perform well
on the testing set based on its performance on the training set. By using FSFs, we have
a much better chance to select the true signals and avoid overfitting. This idea has been
used in algorithm MSS [150], where the author also found out that the features selected
from individual cross-validation folds are highly unstable. However, probably due to the
high dimensionality, the performance gain of using FSFs in [150] was not as satisfactory
as shown in our study, where only phenotype relevant features are employed for feature
selection.
Clinical Features Alone Can Only Give Moderate Prediction Performance
As shown in Figure 3.14 and Figure 3.15, clinical features alone without molecular features
give inferior performance than the combination of clinical features with molecular features.
This agrees with several other studies [34, 218, 297, 303]. These studies, however, have
not tried to understand how much clinical features and molecular features contribute to
the prediction improvement. Our results in Figure 3.14 (second panel on DM data with
extended EMT network) and Figure 3.13 can be compared in parallel to shed light on this
question. We observe that the performance gain is mainly from the FSFs. For t-test and
NetLasso algorithms adding clinical features to FSFs has even decreased the performance.
It meanwhile suggests that combining clinical features directly with molecular features may
not be a good implementation, as the variables come in different scales and types.
While state-of-the-art studies usually assess clinical features as a whole, we have in-
stead analyzed the variable importance of clinical features using different methods - mean
Gini decrease, Spearman correlation coefficient, AUC value, univariate Cox PH model,
and survival trees, as shown in Figure 3.16. In univariate analysis, we found out that
pathological stage and pathology N are the two most important variables. What we found
more useful is to build a survival tree like Figure 3.16c that can better utilize all clinical
variables to assess the risks of patients and assist therapy choice. For example, on the node
split of radiation therapy, it is shown that for the patients whose size and/or extension of
the primary tumor ≤ T2, radiation therapy leads to increased death rate.
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3.5.4 Single Features vs. Composite Features - Our Insights
Multiple studies have shown that composite features (e.g., subnetworks) are superior to
single genes as biomarkers. However, it is still under debate whether the integration of
network connectivity information can improve the prediction performance of the selected
features [48, 228, 229]. We have shown in our experiments that composite features do not
necessarily outperform single gene features. t-test feature selection can outperform more
complicated network-based feature selection methods, as shown in Figure 3.6, Figure 3.7,
Table 3.3, and Figure 3.9. Our results are consistent with the results in a few recent
studies [97,215]. [97] compared 32 feature selection methods on 4 gene expression datasets
for breast cancer prognosis prediction. They found out that feature selection algorithms
significantly influence the prediction accuracy. Overall, t-test feature selection gives the
highest average AUC values.
A few studies including [8] conclude that network-based prognosis prediction methods
mainly contribute to the robustness of features, rather than the prediction performance. [8]
found out that the frequently used average operator is a poor choice to summarize genes
into meta-genes. They proposed the Direction Aware Average (DA2) operator, which
takes into account the directions of genes before taking the average. We have adopted
this operator to improve the original algorithm [40] and yields the addDA2 algorithm.
In our experiments, this algorithm often gave superior prediction performance than other
feature selection algorithms. It shows that the operators used for generating meta-genes are
important. [8] employed both PPI network and random network to test the performance
of network-based feature selection algorithms. Their results show that the contribution of
biological networks to the prediction performance is negligible. They accredit this to the
existence of a large number of genes that are correlated with the target labels. As we have
discussed before, it is very hard to differentiate the marker genes and irrelevant genes when
they have similar statistical relevance with the target labels. We agree that using a global
biological network does not help much on mitigating this issue. However, we show that
using EMT networks, which cover <2.5% of the original dimensionality, addDA2 algorithm
can select robust features that give superior prediction performance according to several
evaluation metrics.
The potential of EMT molecules in prognosis prediction has also been studied before.
[38] studied whether individual EMT molecules in primary tumor can be used as biomarkers
for prognosis prediction in LUAD. They analyzed the correlation of the expression values
of a few proteins, e.g., E-cadherin, vimentin, and fibronectin, with the survival data. They
found some associations between these variables and pathological stages. However, survival
analysis showed that none of these molecules are significantly associated with prognosis.
[301] assessed whether the protein expression of EMT markers E-cadherin, Twist, and
Vimentin could be predictive of patient survival in bladder cancer. Their analysis showed
that none of these molecules were significantly predictive of the overall survival. We think
that there could be two potential reasons why these biological meaningful markers did
not do well in predictions. The first one is that these studies did not consider different
variables simultaneously. The conclusions were made based on univariate analysis. Since
the molecules usually regulate each other, it is reasonable to expect that a set of variables
can jointly lead to a more predictive model. The second reason we think is that there could
exist patient subgroups. This is supported by our observations on prognostic association
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rules, as shown in Table 3.10. We found many rules of high confidence with moderate
support, which suggests that there may exist patient subgroups that have different disease
mechanisms.
We would also like to address the wide application of Lasso algorithm. It is often
employed to select features before building predictive models. What’s more, the selected
features were sometimes considered as the representatives of the corresponding omics data
type for comparing the predictive capability among multiple data types [297, 303]. [303]
applied Lasso feature selection and used the selected features to make prognosis predictions
on four cancer types using four omics data types. It is shown that for all combinations of
data types and cancer types, the average AUC values are between 0.5 and 0.7. 80% of the
AUC values are below 0.6. This very much agrees with our results, as shown in Figure
3.6 and Figure 3.8, where the red dashed lines correspond to the average AUC values of
Lasso algorithm applied on all data level features. These results illustrate that it is hard
to select the true signals by applying Lasso directly on high-dimensional omics datasets.
Therefore, by performing Lasso feature selection we cannot obtain a reliable estimation of
the predictive potential of certain types of omics data. In contrast, applying Lasso feature
selection on all data level features rarely outperforms EMT features. [8] also showed that
using features selected by Lasso does not give a good estimate of the prediction performance
that could be achieved if features were selected with other principles.
Last but not least, we have analyzed the patterns of the FSFs on different data levels.
We found out that they have significantly different network properties. Besides, features
from different data levels often appear in the same prognostic association rules and together
they can give sound biological interpretations. Therefore, we want to further investigate
whether features from different data levels can complement each other and further improve
prognosis prediction performance. This will be introduced in Chapter 4.
Chapter 4
Multi-omics Prognostic Signatures for Lung
Adenocarcinoma
The molecular portrait of a tumor manifests at multiple omic levels. We have learned
from the last chapter that EMT features are very useful in prognosis prediction. We have
evaluated EMT-based features on three data levels - gene expression (GE), DNA methyl-
ation (DM), and Copy Number Alteration (CNA), alternatively. In addition to observing
their difference in prediction performance, we discovered that the network properties of the
frequently selected features (FSFs) from these data levels are significantly different. This
inspires us to explore whether the features from different data levels are complementary to
each other. We therefore investigate whether more accurate predictions can be obtained if
features from different data levels are used simultaneously.
In this chapter we will identify and test multi-omics EMT signatures. The most
straightforward approach is to combine the FSFs from individual omics levels. Besides,
we propose a multiplex-based integrative feature selection approach to directly select fea-
tures spanning multiple omics data levels. We show that both approaches have achieved
significantly better prognosis predictions than using single-omics features. Last but not
least, we have tested the EMT signatures, both single-omics and multi-omics ones, on
real-world clinical datasets. Using EMT features we are able to separate the patients into
significantly different prognostic groups. Further, multi-omics signatures can often achieve
superior performance than single-omics signatures.
4.1 Multi-omics Signatures from Single-omics Signatures
4.1.1 Survival Analysis on All Stage Samples
Having stratified the samples successfully using the FSFs from single data levels, we would
like to know whether combining features from different data levels can better stratify the
samples than using single data levels. We employed both k-means and spectral clustering
algorithms to test this hypothesis. Note that for different data level combinations, we try
to use the same number of features for clustering. For example, with GE data level, we
used top 20 FSFs from each feature selection algorithm. When we use the combination of
GE and DM data levels, we picked top 10 FSFs from each data level and combined them.
When three data levels are combined, we picked top 7 FSFs from each data level. For
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Table 4.1: The p-values of log-rank tests based on the clustering of k-means algorithm
for different data level combinations using extended EMT network. We highlighted all
p-values that are lower than 10e-5.
GE DM CNA GE+DM GE+CNA DM+CNA GE+DM+CNA
t-test 7.87e-06 1.12e-01 3.62e-03 7.55e-06 8.75e-04 1.90e-03 8.25e-06
Lasso 4.58e-06 5.56e-02 5.54e-01 1.66e-04 2.28e-07 8.71e-01 1.18e-04
NetLasso 2.71e-01 6.45e-01 7.58e-02 2.96e-02 1.53e-02 4.83e-01 4.34e-01
addDA2 5.20e-10 5.17e-09 1.24e-04 8.99e-18 3.75e-05 1.11e-09 1.35e-07
Netrank 1.13e-07 1.79e-01 2.19e-02 2.50e-07 6.97e-06 7.31e-02 3.28e-06
stSVM 4.14e-02 3.39e-01 8.91e-01 8.86e-01 6.37e-02 5.85e-01 6.83e-01
Cox 2.55e-09 2.91e-03 5.30e-07 3.12e-04 1.70e-06 1.13e-04 6.11e-06
RegCox 1.78e-07 8.52e-03 2.67e-01 2.36e-09 1.52e-10 1.81e-07 2.52e-07
MSS 1.48e-03 5.95e-01 2.78e-01 6.29e-05 2.28e-04 2.59e-01 1.63e-03
Survnet 7.36e-05 6.25e-03 5.19e-03 2.59e-06 1.54e-03 3.77e-05 2.19e-05
Ensemble 2.32e-09 4.72e-02 6.05e-03 1.20e-04 1.62e-05 1.01e-01 1.18e-04
allemt 1.39e-02 4.30e-01 1.07e-01 7.64e-01 1.45e-02 2.07e-01 5.34e-01
subnetwork-based algorithms addDA2 and Survnet, we used top 10 subnetworks for single
data levels, top 7 subnetworks when combining two data levels, and top 5 subnetworks
when combining 3 data levels. We experimented with 439 samples which have all three
data levels available. We applied k-means algorithm to divide the samples into 3 clusters
and performed survival analysis on the clusters. We used extended EMT network because it
is shown in the previous section to give better sample stratifications. The results of log-rank
tests are shown in Table 4.1, where the columns show different data level combinations and
the rows correspond to feature selection algorithms. We have also included the comparative
group allemt. It stands for using all EMT features without feature selection.
We observe that the p-values of log-rank test are the same or remarkably lower after
combining features from different data levels. This is also observed when we applied
spectral clustering algorithm. The results are given in Table 7.5. Note that no matter
whether we used features from single data level or combinations, feature selection shows
its importance in clustering performance. When no feature selection is performed, as
shown in the row named allemt, the clustering performance is very poor compared with a
clustering with selected features.
addDA2 algorithm gives very good clustering performance when combining features
from GE and DM data levels. Using top 10 features from GE and DM data separately,
the p-values of log-rank tests are 5.20e-10 and 5.19e-7 respectively. When using 7 top
subnetwork features from both data levels altogether, it achieved a much lower p-value
of 8.99e-18. The survival curves of using individual data levels, compared with those of
using combined data levels are shown in Figure 4.1. The top 10 subnetwork features
from DM data can be found in Chapter 3. The top 10 subnetwork features from GE
data are [1] DNMT1, miR-215, RAF1, RB1, TP53; [2] GFI1B, GLI2, MAP2K1, MAPK1,
SMAD3; [3] BCL2L11, BIRC5, MED1, miR-101-1, PRKDC, PTGS2, TP53; [4] FOS,
miR-192, RXRB, SMAD3, TGFB2; [5] CEBPB, KLF4, LCK, NFKB1, PRKCA, RXRB;
[6] CDKN1B, IGF1R, KAT2B, LOXL2, miR-192, STK3; [7] KLF4, KRT18, TGIF2; [8]
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APPL1, CSNK2A1, HDAC1, MAP3K7, SMAD3; [9] BTRC, GFI1B, GLI2, MAP2K1,
ZNF2; and [10] IGF1R, LOXL2, miR-192, NFYA, ZEB2.
We are also interested to know whether the patient clusters in the three sub-figures of
Figure 4.1 are consistent. Thus, we counted the number of common samples in these three
clusters. This is done in two steps. First, we found the matching patient clusters in Figure
4.1a, 4.1b, and 4.1c by picking the matchings that have the highest sample overlap. Since
there are 3 clusters in each sub-figure, we found 3 groups, each containing the matched 3
clusters. Then we plotted a Venn diagram for each group. R package VennDiagram [33]
was used for the visualization. In Figure 4.2 we show the cluster matchings across these
three sub-figures and the Venn diagrams. We observe that within each group, the three
clusters have large fraction of common samples, especially in Group 2 and Group 3.
4.1.2 Survival Analysis on Early Stage Samples
We also tested the EMT signatures on early stage patients by selecting the samples with
pathologic stages either I or II. We obtained 125 patients in early stage which have all three
data levels. 80 patients belong to stage I and 45 patients belong to stage II. We performed
the same clustering approach as above using different combinations of FSFs from individual
data levels. The results of log-rank tests are given in Table 4.2. We noticed that the p-
values are less significant than the values in Table 4.1. This is as expected because it is much
harder to differentiate the prognosis of early stage patients. Even though it is a hard task,
EMT-based features can separate the patients into significantly different prognosis groups.
Consistent with our previous results, Lasso and addDA2 algorithms obtained lower p-values
than the other feature selection algorithms. Combining features from multiple data levels
achieved equivalent or significantly better sample stratifications than using features from
single data levels. In Figure 4.3 we visualized the Kaplan-Meier survival curves of the
patient clusters obtained using the FSFs of addDA2 algorithm. Figure 4.3a and Figure
4.3b show the results of using GE features and DM features separately. Figure 4.3c shows
the results of using both GE and DM features.
Next, we would like to visualize how these features are related to each other. We
extracted these 14 subnetworks from the extended EMT network. The top 7 subnetworks
from GE data have 32 unique genes. The top 7 subnetworks from DM data have 27 unique
genes. In total, there are 53 unique genes. They are connected within the extended EMT
network. The visualization is given in Figure 4.4. The nodes in gray correspond to GE data
and nodes in tomato correspond to DM data. Figure 4.4a highlights all nodes and edges.
Figure 4.4b , 4.4c , and 4.4d highlight the edges and the associated nodes that belong to
different gene regulatory networks. We observe that with PPIs, features from GE data level
were more frequently selected, while with TF-gene and gene-miRNA regulations features
from DM data level were more frequently selected.
4.1.3 The Application of Integrative Clustering Algorithms
As introduced in Chapter 1, clustering algorithms that can integrate multiple omics data
have been proposed. This is achieved by, for example, integrating multiple similarity
networks or using joint latent variables. Representative algorithms are SNF [264] and
iCluster [219]. Here we would like to employ both algorithms on EMT FSFs from multiple
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Strata + + +cl_kmeans=1 cl_kmeans=2 cl_kmeans=3
63 31 7 1 1
196 118 44 21 13










(c) GE and DM features
Figure 4.1: Kaplan-Meier survival curves of 3 patient clusters using k-means algorithm
based on the subnetwork features selected by addDA2 algorithm. Clustering using (a) top
10 subnetwork features selected from GE data, (b) top 10 subnetwork features selected
from DM data, and (c) top 7 subnetwork features from GE data + top 7 subnetwork
features from DM data.
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GE DM GE+DM
Group1 181 203 196
Group3 183 159 180
Group3 75 77 63
(a) Matching clusters
(b) Group 1
(c) Group 2 (d) Group 3
Figure 4.2: The Venn diagrams of the matching patient clusters in Figure 4.1a, 4.1b, and
4.1c. (a) The matching clusters in three patient prognostic groups. (b) Venn diagram
of prognostic Group 1. (c) Venn diagram of prognostic Group 2. (d) Venn diagram of
prognostic Group 3.
Table 4.2: The p-values of log-rank tests on early stage patients for different data level
combinations using extended EMT network. We highlighted all p-values that are lower
than 10e-3.
GE DM CNA GE+DM GE+CNA DM+CNA GE+DM+CNA
t-test 6.28e-3 9.38e-2 1.93e-1 4.78e-4 8.40e-3 1.55e-1 2.47e-1
Lasso 1.82e-04 1.20e-03 1.01e-01 2.35e-01 1.67e-06 2.51e-03 4.94e-03
NetLasso 7.95e-3 8.56e-1 2.46e-1 2.29e-1 1.01e-1 9.69e-1 9.31e-1
addDA2 2.53e-04 1.98e-05 1.63e-03 6.88e-08 3.52e-02 1.03e-05 8.51e-04
Netrank 9.31e-06 5.39e-01 4.08e-03 3.52e-03 5.35e-04 7.54e-03 8.57e-04
stSVM 3.17e-2 2.99e-1 2.86e-1 4.00e-1 2.16e-2 1.32e-1 8.57e-1
Cox 4.40e-4 2.15e-1 2.42e-2 1.85e-2 3.30e-2 1.10e-2 6.43e-4
RegCox 8.52e-04 3.36e-01 2.33e-02 8.58e-03 2.18e-05 2.03e-03 3.90e-02
MSS 6.51e-2 6.51e-1 2.43e-1 2.34e-2 3.10e-2 9.91e-1 5.91e-2
Survnet 4.16e-3 3.05e-1 6.24e-2 6.78e-2 8.66e-2 2.27e-2 8.08e-3
Ensemble 4.03e-4 1.54e-1 4.54e-2 5.06e-3 4.01e-4 5.79e-4 7.95e-4
allemt 2.59e-1 9.45e-1 7.04e-3 6.31e-1 1.38e-2 4.16e-1 9.73e-1
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(c) GE and DM features
Figure 4.3: Kaplan-Meier survival curves of 3 early stage patient clusters using k-means
algorithm based on the subnetwork features selected by addDA2 algorithm. Clustering
using (a) top 10 subnetwork features selected from GE data, (b) top 10 subnetwork fea-
tures selected from DM data, and (c) top 7 subnetwork features from GE data + top 7
subnetwork features from DM data.













































































































































































































Figure 4.4: Visualization of the top 14 selected subnetworks using addDA2 algorithm.
These 14 subnetworks consist of 7 subnetworks from GE data (nodes in gray) and 7 sub-
networks from DM data (nodes in tomato). If a node is involved in both data levels, we
show both colors on the node. In total there are 53 nodes. A subgraph was extracted from
the extended EMT network that included these nodes and the edges among them. The
subgraph is connected. Subgraph (a) shows all nodes and highlighted all edges. Subgraph
(b), (c), and (d) highlighted the edges that belong to protein-protein interactions, TF-gene
regulations, and gene-miRNA regulations.
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data levels to cluster samples. The aim is to investigate whether these algorithms can
further improve patient stratification into different prognostic groups. In the following we
briefly introduce the two algorithms.
Introduction of Algorithms
The main idea of [264] is to construct a sample similarity network for each omic data
type (mRNA expression, DNA methylation, and miRNA expression) and then fuse these
networks into a single similarity network. Suppose we have n samples and m features.
Let G = (V,E) represent a sample similarity network. The vertices V correspond to the
samples. W is an n× n matrix of edge weights. W (i, j) indicates the similarity between
sample xi and xj . The weight of an edge is calculated as:






where µ is a hyperparameter and εi,j is used for scaling. A full and sparse kernel P is
defined on the vertex set V. It is a normalized weight matrix as follows:
P (i, j) =

W (i, j)
2∑k 6=iW (i, k) , j 6= i
1/2, j = i
Let Ni represent a set of xi’s neighbors including xi in G. The local similarity matrix







It is assumed that local similarities are more reliable than remote ones. This approach
assigns similarities to non-neighbors through graph diffusion - start from P as the initial
state and use S as kernel matrix. Suppose there are two omics data types and corresponding
kernel matrices and similarity matrices P (1), P (2), S(1), S(1). P (1) and P (2) are updated
in each iteration t: 
P
(1)
t+1 = S(1) × P (2)t × (S(1))T
P
(2)
t+1 = S(2) × P (1)t × (S(2))T





2 . When there are more than
two data types (m > 2), the kernel matrices are updated as the following:
P (v) = S(v) ×
(∑
k 6=v P (k)
m− 1
)
× (S(v))T , v = 1, 2, ...,m
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Spectral clustering is applied on the final kernel matrix P (c) to determine patient
clusters. In [264] the method has been applied on four cancer types to divide the samples
into 3 to 5 clusters. Log-rank tests are performed to evaluate the clusters. It shows that
individual data types are mostly not able to stratify samples into significantly different
prognostic groups while the proposed method can lead to significant stratifications.
The second algorithm we employed is iCluster [219]. It integrates multiple omics data
simultaneously to cluster samples by employing the joint latent variable model. Let X
denote the data matrix of dimension p×n with rows being genes and columns being samples.
Z = (z1, z2, ...,zK−1)′ is the cluster indicator matrix of dimension (K − 1)× n. K is the
number of clusters. W is the coefficient matrix of dimension p×(K−1). ε = (ε1, ε2, ..., εp)′
is a set of independent error terms. A Gaussian latent variable model of the eigengene k-
means clustering is written as:
X = WZ + ε
The basic concept of iCluster is to jointly estimate Z from multiple omics data: X1 of
dimension p1 × n for CNA data, X2 of dimension p2 × n for DM data, X3 of dimension
p3 × n for GE data. The form of the integrative model is:
X1 = W1Z + ε1
X2 = W2Z + ε2
...
Xm = WmZ + εm
Z is the latent component that connects the m omics data types measured on the same
set of samples. It is estimated using expectation maximization algorithm to decide the
cluster memberships of samples.
Results and Analysis
We used EMT FSFs as the input to SNF and iCluster algorithms. Each algorithm takes
as input the combinations of the FSFs from individual data levels and divides the samples
into 3 clusters. Log-rank tests are performed on the resulting clusters. Table 4.3 shows the
results of using SNF algorithm. Table 4.4 shows the results of using iCluster algorithm.
Compared with the results of using k-means algorithms in Table 4.1 for all stage samples
and in Table 4.2 for early stage samples, we have observed the following:
• Although more sophisticated, these two algorithms give inferior performance than
k-means algorithm, while SNF performed better than iCluster. In the original art-
icle [264] both SNF and iCluster algorithms were applied on multiple cancer types.
Although the results of integrative clustering were shown to be better than using
single data levels, the p-values they obtained from log-rank tests (the lowest p-value
was 2.0e-4) are much less significant than our results, not to mention that much more
features were used in these studies. Even for clustering early stage samples, we have
obtained good sample stratifications. This further demonstrates the advantages of
using phenotype relevant biological networks for feature selection.
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Table 4.3: The p-values of log-rank tests based on SNF clustering using different data level
combinations with extended EMT network. We highlighted all p-values that are lower
than 10e-5.
GE DM CNA GE+DM GE+CNA DM+CNA GE+DM+CNA
t-test 2.71e-05 6.33e-02 3.32e-01 6.81e-03 5.61e-06 2.22e-03 1.72e-03
Lasso 7.95e-04 9.79e-02 5.05e-01 4.39e-03 8.30e-08 1.87e-03 8.73e-03
NetLasso 7.09e-02 5.91e-01 2.51e-01 2.70e-01 2.38e-02 9.23e-02 7.39e-02
addDA2 7.19e-07 8.27e-10 8.50e-04 9.60e-12 1.36e-03 7.41e-02 5.25e-09
Netrank 2.05e-03 3.45e-01 3.17e-01 1.61e-06 1.09e-03 1.76e-03 2.07e-05
stSVM 9.83e-02 4.11e-01 5.76e-01 5.49e-01 5.58e-01 7.25e-01 6.61e-01
Cox 7.50e-05 9.18e-04 1.50e-01 3.33e-03 3.53e-03 4.47e-03 8.89e-04
RegCox 2.01e-03 6.60e-01 1.76e-01 2.39e-08 4.34e-02 6.70e-06 1.28e-08
MSS 9.45e-04 6.22e-02 3.47e-01 1.04e-02 1.63e-02 2.48e-01 6.00e-04
Survnet 9.44e-05 5.75e-02 3.14e-02 2.71e-03 4.95e-05 6.96e-05 9.74e-05
Ensemble 1.14e-03 4.10e-03 6.14e-02 1.20e-03 1.05e-02 5.73e-04 2.51e-04
allemt 1.94e-02 7.26e-01 2.70e-01 1.91e-01 3.41e-01 7.15e-01 5.92e-01
Table 4.4: The p-values of log-rank tests based on iCluster clustering using different data
level combinations with extended EMT network. We highlighted all p-values that are lower
than 10e-5.
GE DM CNA GE+DM GE+CNA DM+CNA GE+DM+CNA
t-test 1.32e-02 3.16e-01 7.70e-02 1.24e-01 4.92e-04 6.65e-04 2.79e-01
Lasso 2.16e-01 8.66e-01 7.33e-01 1.26e-03 4.74e-05 1.64e-01 2.00e-04
NetLasso 4.23e-01 8.34e-01 7.63e-01 6.22e-01 3.75e-02 3.49e-01 4.62e-03
addDA2 1.69e-02 1.57e-02 4.23e-03 2.36e-01 3.48e-03 2.75e-02 2.74e-01
Netrank 2.41e-02 2.66e-01 4.33e-02 2.47e-02 5.04e-03 7.67e-02 7.71e-04
stSVM 2.77e-08 7.28e-01 1.33e-01 2.12e-01 7.46e-02 6.51e-01 9.37e-01
Cox 9.48e-04 6.85e-04 6.13e-01 4.01e-03 5.17e-04 3.07e-04 2.57e-02
RegCox 9.51e-01 2.61e-01 2.72e-02 2.22e-03 6.12e-06 3.57e-03 2.96e-08
MSS 3.76e-02 2.30e-01 1.33e-01 4.24e-03 5.75e-01 9.48e-01 2.06e-01
Survnet 1.25e-03 2.60e-01 6.94e-02 7.15e-01 2.71e-02 5.93e-02 4.51e-02
Ensemble 9.75e-03 8.77e-01 7.73e-02 2.50e-05 2.10e-03 1.10e-03 1.09e-03
allemt 7.15e-01 9.65e-01 2.68e-01 1.29e-01 7.58e-02 5.54e-01 1.70e-01
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• In terms of feature selection algorithms, we have observed consistent conclusions that
addDA2 algorithm, Lasso, t-test, Netrank algorithms give better clustering results
than the other algorithms. It indicates that feature selection algorithms are more
stable than the choice of clustering algorithms.
• We have observed consistent conclusions with SNF algorithm that integrated mo-
lecular signatures from more than one data levels can better divide the samples into
different prognostic groups.
4.2 A Novel Integrative Feature Selection Approach
Although individual omic data levels have been investigated for biomarker identification,
intrinsically integrative data analysis methods are still lacking. The benefit of identifying
molecular signatures across multiple data levels simultaneously remains to be revealed. In
this section we will explore this direction. Since we have three omics data levels, one can
imagine having three identical EMT networks mapped with values. These three layers of
networks can be laid on top of each other to form a vertical network - a multiplex, with
the correspondence of genes on each layer. One can also imagine that each network node
is not only mapped with one value, but a vector of values from different data levels. Then
the network becomes a network of vectors. Following different network constructions, one
can formulate the task differently, e.g., identifying molecular signatures on a multiplex, or
identifying signatures by combining vectors of values.
4.2.1 The Construction of Multiplex Networks
We will focus on the formulation of multiplex for two main reasons. The first is that
it offers a natural extension of the feature selection methods used in the last chapter,
which take the input of a network and a data matrix to be mapped on the network.
The second reason is that multiplex is a suitable structure for representing hierarchies
of networks. This is desired because biological systems are often composed of multiple
layers of regulations [173, 280]. The regulations happen both within layers and across
layers [75, 130]. Multiplex network has been recently applied on multiple omics data of
yeast (transcriptomic and fluxomic layers) to better infer similarity of growth conditions.
Recent reviews [18, 110] included studies that use multiple omic data sequentially or
simultaneously for different analysis in bioinformatics. However, most of the studies focus
on gene privatization, studying the intrinsic relations between different data sources, and
sample clustering. Finding features for prognostic prediction using multiple data sources
simultaneously has not been investigated. Based on the EMT networks, which are shown
to be predictive and of reasonable sizes, we aim to identify molecular signatures using
multiplex-based feature selection.
We extend the algorithms in the previous chapter to incorporate multiple data levels.
For algorithms that do not use network information, we apply them on concatenated fea-
tures of multiple levels. For methods that use network information, we form a multiplex
and apply those algorithms. While concatenation is rather straightforward, we would like
to elaborate on how to build the multiplex. An interesting question is how to decide edges
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Figure 4.5: An illustration of multiplex construction based on Pearson correlation coeffi-
cients using GE and DM data.
that connect vertical layers. Although it has been long acknowledged that DNA methyl-
ation patterns and copy number alterations affect gene expression, we have not found
previous work that try to identify molecular signatures using a multi-layered molecular
network structure. Existing studies have, as introduced previously, simultaneously con-
sidered different layers of patient similarity networks to more accurately cluster samples
into subtypes [129,264]. Here we use two unsupervised methods for constructing the inter-
layer edges.
• Pearson correlation coefficient (PCC). We calculated the correlations between GE
and DM, and between GE and CNA for each gene. Edges are added when the
absolute value of correlation exceeds a threshold. Assuming that certain levels of
correlation indicate the effects of DM and CNA on gene expression, adding edges
between them reflects this influence. An illustration is provided in Figure 4.5.
• CNAmet scores proposed by [158]. They employed signal-to-noise ratio [98] to relate
CNA and DM data to GE data for the same gene. The method first dichotomizes
DM and CNA data Mcn,Mme ∈ {0, 1}m×p, where m is the number of samples and p




, σidm,1 > 0, σidm,0 > 0,
where µidm,1 is the average expression of gene i when its DM level is high and σidm,1
is the standard deviation of gene i expression when its DM level is high. Likewise,
the scores for CNA W icna can be calculated. Then for each gene i permutation tests
are performed on W idm and W icna by randomly permuting the labeling vectors and
recalculating the scores. The p-values of the permutation tests are used to assess the
influence of DM and CNA status on gene expression.
4.2 A Novel Integrative Feature Selection Approach 101
Table 4.5: The numbers of between-layer and within-layer edges using multiplex network
for all three EMT networks using GE and DM data.
Edge type Between-layer # edges Within-layer
# edgesScoring method PCC Permutation test all edgesThreshold abs > 0.2 abs > 0.1 p<0.01 p<0.05 none
|V (G)| = 74
(core network) 34 51 24 34 74 113
|V (G)| = 123
(filtered network) 65 95 46 62 123 253
|V (G)| = 455
(extended network) 198 318 141 215 455 2620
Table 4.6: The number of samples after combining different data levels. For each data
level combination, we kept the samples that have data for all involved data levels. Within
one data level combination, the number of samples is the same for different network sizes.
Data level
combinations
Classification Survival analysisgood prognosis poor prognosis
GE+DM 73 92 442
GE+CNA 72 74 494
DM+CNA 66 69 444
GE+DM+CNA 65 68 439
4.2.2 Experiments
We would like to evaluate the features selected from a multiplex that is mapped with
different levels of omics data. For network-based feature selection algorithms, we used
the above two methods to construct a multiplex. Certainly, the number of inter-layer
edges depends on the threshold on Pearson correlation and CNAmet scores. We calculated
both scores and used different thresholds for determining the inter-layer edges. We first
constructed the multiplex using GE and DM data. The thresholds for determining the
edges, and the resulting numbers of between-layer edges are given in Table 4.5. Besides,
we would like to compare the prediction performance of multi-level molecular signatures
with that of single-level signatures. Note that the results obtained from the last chapter are
not directly comparable because here we can only use the samples that have the information
of all the involved data levels. Therefore, we experimented on single data levels in parallel
to enable paired comparisons. The sample sizes for classification and survival analysis are
given in Table 4.6.
4.2.3 Results
We have obtained the AUC, AUPR, accuracy for both concatenation-based algorithms
and multiplex-based algorithms. The test was performed using 30 times 10-fold cross
validation. For network-based feature selection algorithms, this procedure was performed
on each different settings of between-layer connectivity. Eventually, for each combination
of network and feature selection algorithm we picked the network connectivity that gave
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then highest average AUC value. To enable an objective comparison, the data folds were
kept the same for comparative groups. For example, concatenation-based feature selection
using GE and DM data was tested using the same cross-validation folds as individual GE
and DM data levels. Multiplex-based feature selection was tested using the same cross-
validation folds as network-based feature selection algorithms on individual data levels.
Since we have observed from Chapter 3 the importance of using FSFs and clinical features,
here we also tested the combination of FSFs with clinical features.
Concatenation-based algorithms
Figure 4.6 shows the average AUC values with GE data, DM data, and concatenated
data. Figure 4.7 shows the average AUC values of all three individual data levels and
concatenated data. Both figures have two sides. On the left side we used only molecular
features and on the right side we combined clinical features with FSFs. In each side
there are three panels, corresponding to the three EMT network sizes. The results for the
concatenation of GE and CNA features are given in Figure 7.6.
We have observed the following from Figure 4.6 and Figure 4.7:
• Without using FSFs, the concatenation of data levels mostly did not give better
performance. Comparatively, DM data have better performance with the core EMT
network. FSFs are shown to be much more robust and have achieved much better
prediction performance, as also observed in Chapter 3.
• When combining FSFs with clinical features, Lasso feature selection algorithm has
achieved significantly better prediction performance with concatenated data in both
figures. t-test feature selection has achieved better performance when concatenating
GE data with DM data using filtered and extended EMT features.
Multiplex-based algorithms
Figure 4.8 shows the average AUC values with GE network, DM network, and the multi-
plex. Figure 4.9 shows the average AUC values with all three individual networks and the
multiplex. Both figures have two sides. On the left side we used only molecular features
and on the right side we combined clinical features with FSFs. In each side there are three
panels, corresponding to the three EMT networks. The results for the multiplex combining
GE and CNA features are given in Figure 7.7.
We have observed from Figure 4.8 and Figure 4.9 that in most of the cases, selecting
molecular features from multiplex did not give significant performance gain. However,
when combining FSFs with clinical features, multiplex-based feature selection has shown
significant performance gain. For example, with addDA2 algorithm, using FSFs from the
multiplex combining GE and DM data increased the average AUC value from 0.656 to
0.777. With FSFs from the multiplex of GE, DM and CNA data, the prediction per-
formance is remarkable. The highest average AUC value (0.881) is achieved by addDA2
algorithm with extended EMT network.
Last, we compared concatenation-based feature selection and multiplex-based feature
selection. We would like to address the following two observations:

























































































































































































































































































































Groups GE DM Concatenation
Figure 4.6: The average AUC values of concatenation-based feature selection using GE
and DM data. The left side shows the performance of molecular features. The right side
shows the performance of FSFs combined with clinical features. On each side we show the
results of using 3 EMT networks.



















































































































































































































































































































































































































Groups GE DM CNA Concatenation
Figure 4.7: The average AUC values of concatenation-based feature selection using GE,
DM, and CNA data. The left side shows the performance of molecular features. The right
side shows the performance of FSFs combined with clinical features. On each side we show
the results of using 3 EMT networks.







































































































































































































































































































































Groups GE DM Multiplex
Figure 4.8: The average AUC values of multiplex-based feature selection using GE and
DM data. The left side shows the performance of molecular features. The right side shows
the performance of FSFs combined with clinical features. On each side we show the results
of using 3 EMT networks.

































































































































































































































































































































































































































Groups GE DM CNA Multiplex
Figure 4.9: The average AUC values of multiplex-based feature selection using GE, DM,
and CNA data. The left side shows the performance of molecular features. The right side
shows the performance of FSFs combined with clinical features. On each side we show the
results of using 3 EMT networks.
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• While data concatenation did not show significant performance gain in most of the
cases, using FSFs of multiplex-based feature selection has significant improvements
in prediction performance.
• With network-based feature selection algorithms, the performance of FSFs together
with clinical features increases as the size of network increases. With none network
feature selection algorithms this is not apparent.
The second observation attracts our attention. It seems that with the increase of
network size, the FSFs become more and more robust. This agrees with our experimental
results where FSF boosted the prediction performance, especially when we use the extended
EMT network. Therefore, we are curious to look closer at the FSFs with respect to the
network sizes and the usage of multiplex network structures.
4.2.4 Multi-omics Feature Compositions
Since we mostly observed performance gain with FSFs, in this part we would like to un-
derstand two questions. The first one is that why the FSFs from concatenation improved
the performance with some algorithms but not some other algorithms. The second one is
why the FSFs from multiplex give better performance than the FSFs from single layer net-
works. Since the samples and cross-validation folds are kept the same in each experiment,
we attribute the reasons to the differences in the features. Specifically, we will compare
the features selected on individual data levels with that of joint selections to find out the
potential reasons.
On FSFs from concatenated data
First, we analyzed FSFs selected on concatenated data. While individual sets of molecular
features are not beneficial for the prediction, FSFs can give significantly better predictions.
Even though clinical features are included to add more information, we know that the main
contribution comes from the FSFs. This is supported by Figure 3.12 in chapter 3, where
FSFs remarkably increased the AUC values. We think that whether concatenation-based
feature selection improves the performance may be associated with the feature composition
- the ratio of GE and DM features. It may be also relevant to the overlap between features
selected on concatenated data and features selected on individual data levels.
To test our hypotheses, we calculated the feature ratios of the FSFs of the four none
network-based feature selection algorithms on three EMT network sizes as well as the
feature overlap. The results are given Table 4.7 for the concatenation of GE and DM data
and Table 4.8 for the concatenation of all three data levels. We also list the average AUC
values in the tables for a convenient comparison. We would like to address the following
findings:
• Except for Cox and MSS algorithms with filtered EMT network, a higher ratio
between non-GE features and GE features always associates with a better predic-
tion performance in both tables. This suggests that algorithms that can select more
balanced features across omics data levels can benefit more from data concatenation.
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Table 4.7: The ratios between DM and GE features and the average AUC values for
concatenation-based feature selection.
Algorithms |V (G)| = 74 |V (G)| = 123 |V (G)| = 455Ratio AUC Overlap Ratio AUC Overlap Ratio AUC Overlap
t-test 0.45 0.704 0.95 0.15 0.789 0.95 0.3 0.794 1
Lasso 0.70 0.779 0.85 0.50 0.803 0.9 0.4 0.844 1
Cox 0.4 0.698 1 0.05 0.691 1 0.15 0.684 1
MSS 0.05 0.639 0.55 0.20 0.686 0.7 0.00 0.647 0.45
Table 4.8: The ratios between non-GE and GE features and the average AUC values for
concatenation-based feature selection.
Algorithms |V (G)| = 74 |V (G)| = 123 |V (G)| = 455Ratio AUC Overlap Ratio AUC Overlap Ratio AUC Overlap
t-test 0.5 0.772 1 0.35 0.825 0.9 0.3 0.801 1
Lasso 0.75 0.815 1 0.5 0.849 0.8 0.45 0.873 0.95
Cox 0.5 0.790 1 0.05 0.766 0.95 0.15 0.752 1
MSS 0.05 0.715 0.5 0.05 0.751 0.75 0.05 0.745 0.5
• We have not observed associations between feature overlap and AUC values. How-
ever, we find that when the size of network increases the feature overlap either be-
comes higher (Table 4.7) or remains on the same level (Table 4.8, except for MSS
algorithm where the feature overlap is much worse than the other algorithms). This is
very interesting because with a larger network size, the signatures from concatenated
feature selection become more consistent with individual data levels. It indicates
that the important features become more apparent to identify. But we think if the
scope further increases, e.g., to the whole PPI network, this may not hold true. Since
we used a phenotype relevant network, the extension from the core EMT network to
the extended network added more useful information than noise.
On FSFs from multiplex
In this part we look at the FSFs of multiplex. There are two types of feature selection
algorithms in Figure 4.8 and Figure 4.9. One type selects single features based on network
connectivity - NetLasso, netrank, and RegCox. The other type selects subnetworks as
features - addDA2 and Survnet. We have shown that the FSFs of these algorithms in most
cases gave significantly better predictions, especially for NetLasso and addDA2 algorithms.
We would like to find clues in the features.
Recall that in Chapter 3, we have found that the network properties of features se-
lected at different data levels are significantly different. We have also used association
rule approach to show that combining features from multiple data levels can provide in-
teresting biological insights and improve the quality of rules. What is different now is
that the features are not combined from different omics data levels, but directly selected
from a multiplex. Therefore, first it is interesting to see how much the features selected
from the two scenarios overlap. It is straightforward for single features. For subnetwork
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Table 4.9: The overlap of FSFs on multiplex with FSFs on individual networks. The
multiplex is composed of GE and DM layers.
Algorithms |V (G)| = 74 |V (G)| = 123 |V (G)| = 455GE DM GE DM GE DM
NetLasso 0.3 0.45 0.35 0.25 0.25 0.25
addDA2 0.3 0.33 0.36 0.25 0.24 0.49
Netrank 0.5 0.4 0.65 0.2 0.55 0.25
RegCox 0.6 0.4 0.65 0.35 0.75 0.20
Survnet 0.63 0.16 0.42 0.0 0.53 0.00
addDA2(net) 3 3 4 2 2 4
Survnet(net) 9 2 3 0 1 0
Table 4.10: The overlap of FSFs on multiplex with FSFs on individual networks. The
multiplex is composed of GE, DM, and CNA layers.
Algorithms |V (G)| = 74 |V (G)| = 123 |V (G)| = 455GE DM CNA GE DM CNA GE DM CNA
NetLasso 0.15 0.25 0.15 0.25 0.25 0.05 0.20 0.25 0
addDA2 0.14 0.45 0 0.27 0.18 0 0.11 0.38 0
Netrank 0.60 0.15 0.10 0.50 0.20 0.05 0.50 0.25 0
RegCox 0.60 0.2 0.2 0.55 0.25 0.20 0.70 0.20 0
Survnet 0.44 0.17 0.11 0.57 0 0.04 0.47 0 0
addDA2(net) 1 4 0 3 2 0 0 0 0
Survnet(net) 5 0 0 6 0 0 1 0 0
features, we calculated both the molecular level overlap and the proportion of multiplex
subnetworks that contain FSFs (subnetworks) of individual data levels. Table 4.9 shows
the feature overlap using the multiplex of GE and DM networks. Table 4.10 shows the
feature overlap using the multiplex of GE, DM and CNA networks. We observe that the
feature overlap in general is smaller than using concatenation-based feature selection. The
total feature overlap tends to decrease with the increase of network size. We have not
observed associations between feature ratios of non-GE features and GE features and the
prediction performance (results not shown).
Then we want to know whether multiplex-based features are superior, e.g., can provide
better association rules for prognosis prediction. Following the experimental setting in
Chapter 3 we derived association rules and evaluated the confidence of top ranked rules.
The results are given in Figure 4.10. We observed that multiplex-based features give
equivalent or higher rule confidence in most of the cases. With the increase of network
size, we observed that multiplex-based rules have always increasing average confidence.
The same does not hold true for the features from single-layered networks. This shows
the advantage of integrating information on a multiplex, where the FSFs show higher
importance. We would like to draw the attention that due to the high sensitivity of feature
selection algorithms to the sample folds, individually selected features with multiplex did
not show clear advantages, which can be seen on the left sides of Figure 4.8 and 4.9.
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Figure 4.10: The average confidence of prognostic association rules derived from the FSFs
on single-layered networks and multiplex. The top 30 rules are taken for evaluation.
However, with FSFs, multiplex always shows superiority over single-layered networks.
4.3 EMT-based Prognosis Prediction on Real-world Clinical
Datasets
In this part we tested EMT-based molecular signatures identified in Chapter 3 and Chapter
4 on an independent cohort of LUAD samples. Out testing is novel because the independent
data have both GE and DM profiles for the same group of samples. The data were provided
by our collaborating partner in Oslo University Hospital (OUH) from their study [21].
The data include 164 samples for DNA methylation data. A subset of these samples
(n=121) has mRNA expression data available. The mRNA expression analysis was assessed
using gene expression microarrays from Agilent technologies (SurePrint G3 human GE,
8 x 60 K). The mRNA expression data were log2 transformed and normalized between
arrays by using the 75th percentile method in Genespring GX analysis Software v.12.1
(Agilent technology). The DNA methylation data were generated using Illumina Infinium
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Table 4.11: Fitting univariate Cox PH models with probes and gene aggregates for mi-
croarray data. We listed below the number of probes/genes with p <0.01 or p <0.05 out
of all probes or genes that belong to the EMT network.
Microarray data p <0.05 p<0.01
Probe level 72/671 20/671
Aggregate by mean 53/455 14/455
Aggregate by median 51/455 16/455
HumanMethylation450BeadChips. Detailed experimental procedures and the processing
of raw data to level 3 data are provided in [21].
The patient follow-up time ranges between 2 and 99 months with the median of 44
months. The outcome (event) is defined as the occurrence of relapse, distant metastasis
or death. The time to progression was calculated from the date of surgery to the date of
event. We evaluated individual level EMT features, combined GE and DM features, and
multiplex features on this dataset using hierarchical clustering and survival analysis. The
reason why we use hierarchical clustering was that the original article [21] used the same
approach and thus we can relate our analysis directly to theirs. In the following we will
introduce data pre-processing steps and then give the test results and analysis.
4.3.1 Data Pre-processing
We need to summarize the probe level microarray and DNA methylation data to gene
level data. Since there can be multiple ways to do so, we used the p-value of univariate
Cox PH model (using the follow up data) to decide which processing method to adopt.
For microarray data there are in some cases more than one probes for one gene, either
referring to transcript variants or being repetitions. We tried taking the mean or the
median of duplicated probes. The results are shown in Table 4.11. As both options give
similar outcome and median is more often used than mean aggregation, we adopted the
median aggregation.
With DNA methylation data we tried three ways to take the aggregates: averaging all
probes per gene, averaging the probes at the promoter region (TSS200 and TSS1500) per
gene, and taking the probe that has the lowest Pearson correlation coefficient with the
corresponding gene (using the median processing above). The results are shown in Table
4.12. Based on the results, we choose to average all probes per gene. This is also the data
pre-processing method that is adopted for TCGA DNA methylation data in our previous
experiments.
4.3.2 Results
We extract EMT signatures from the test data and conducted survival analysis. Note that
we took the features directly as selected using TCGA data and applied on the test data
without any training or using additional information. We would like to present the results
in two parts: using single-omics features and using multi-omics features.
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Table 4.12: Fitting univariate Cox PH models with probes and gene aggregates for DNA
methylation data. We listed below the number of probes/genes with p <0.01 or p <0.05
out of all probes or genes that belong to the EMT network.
DNA methylation data p <0.05 p<0.01
Probe level 342/11434 171/11434
Average all probes 89/455 33/455
Average promoter region probes 43/455 8/455
Least correlated probe 34/455 6/455
Using single-omics features
We tested the EMT features selected from TCGA RNA-Seq and miRNA data on the test
(microarray) data. Since miRNA measurements are not available in the test data, we
removed miRNA features from the signatures before the testing. If a subnetwork feature
contains miRNA features, we removed the miRNAs from the subnetwork. Using EMT
features in the testing set, we applied hierarchical clustering to divide the samples into
2 or 3 clusters and performed survival analysis. Table 4.13 shows the results of log-rank
tests, on both 2 sample clusters and 3 sample clusters. With the same approach we used















Table 4.13: The p-values of log-rank tests using EMT gene expression features on independent data. The samples are divided into
either 2 clusters (upper table) or 3 clusters (lower table). We highlighted all p-values that are lower than 0.01.
Network t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 4.55e-01 4.53e-01 2.53e-01 1.11e-01 8.11e-01 9.28e-02 1.83e-01 8.20e-01 7.00e-01 7.83e-02 5.50e-01 3.85e-01
123 nodes 3.36e-01 2.60e-01 9.54e-02 3.47e-01 8.17e-01 9.45e-01 1.33e-01 7.36e-02 1.85e-01 2.58e-01 2.55e-01 1.79e-02
455 nodes 2.04e-01 9.98e-01 1.21e-01 1.05e-01 3.25e-01 5.81e-01 4.68e-02 5.55e-01 2.04e-01 4.31e-02 2.01e-03 3.39e-01
Network t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 6.41e-01 4.59e-01 4.34e-01 4.93e-03 9.07e-01 2.39e-01 1.95e-01 9.37e-01 9.19e-01 1.50e-01 6.50e-01 2.35e-01
123 nodes 7.23e-02 2.48e-01 2.35e-01 6.43e-01 1.48e-02 2.42e-01 1.10e-01 1.85e-01 3.02e-02 1.84e-01 1.63e-01 5.81e-02
455 nodes 4.23e-01 8.33e-01 8.39e-02 9.00e-02 5.88e-01 6.53e-01 2.88e-02 6.87e-01 3.82e-01 6.41e-02 6.14e-03 5.19e-01
Table 4.14: The p-values of log-rank tests using EMT DNA methylation features on independent data. The samples are divided
into either 2 clusters (upper table) or 3 clusters (lower table). We highlighted all p-values that are lower than 0.01.
Network t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 4.34e-01 8.00e-02 8.05e-01 3.38e-01 2.48e-01 2.21e-01 6.09e-01 2.33e-01 4.69e-01 7.23e-01 2.20e-04 5.17e-02
123 nodes 3.38e-01 8.92e-01 5.05e-01 4.51e-03 2.28e-01 1.01e-01 2.54e-02 2.54e-02 6.23e-01 1.11e-02 1.01e-01 2.29e-01
455 nodes 5.81e-03 1.05e-01 8.84e-03 5.24e-03 4.38e-01 6.29e-03 1.60e-03 2.39e-02 1.10e-01 7.28e-02 1.22e-01 7.11e-03
Network t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 6.76e-01 2.16e-01 4.92e-01 5.21e-01 3.52e-01 1.67e-01 1.02e-01 1.45e-01 7.59e-01 9.10e-01 1.08e-03 8.42e-02
123 nodes 5.89e-01 1.93e-01 6.48e-01 1.63e-02 1.28e-01 7.07e-03 8.21e-02 6.59e-02 7.07e-01 3.78e-04 2.60e-01 4.83e-01
455 nodes 1.58e-02 1.64e-01 2.85e-02 8.44e-03 3.62e-01 2.26e-02 6.73e-03 4.48e-02 8.82e-02 4.01e-02 2.75e-01 2.55e-02
114 Chapter 4 Multi-omics Prognostic Signatures for Lung Adenocarcinoma
Using multi-omics features
Based on the good sample stratification results of using combined features on TCGA data,
we have performed the same testing on OUH data. We combined EMT signatures from
GE data and DM data for each feature selection algorithm as the new feature set. For
single gene features, we combine the top 10 features from GE data with the top 10 features
from DM data, and compare it with using 20 features from GE data or using 20 features
from DM data. With subnetwork features, we combine the top 7 subnetwork features from
GE data with the top 7 subnetwork features from DM data, and compare it with using
10 subnetwork features from GE data or using 10 subnetwork features from DM data.
The reason why we do not use 5 but 7 subnetwork features is to account for the overlap
of subnetwork features. Using EMT features in the testing set, we applied hierarchical
clustering to divide the samples into 2 or 3 clusters and performed survival analysis. Table
4.15 shows the results of clustering samples into 2 clusters. Table 4.17 shows the results of
clustering samples into 3 clusters. We have also tested multiplex features on the test data.
The results are given in Table 4.16 for separating samples into 2 clusters and Table 4.18














Table 4.15: The p-values of log-rank tests using combined EMT gene expression and DNA methylation features on independent
data. The samples are divided into 2 clusters. We highlighted all p-values that are lower than 0.01.
Core EMT network
Data t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 4.55e-01 4.53e-01 2.53e-01 1.11e-01 8.11e-01 9.28e-02 1.83e-01 8.20e-01 7.00e-01 7.83e-02 5.03e-01 1.23e-01
DM 1.60e-01 6.79e-01 9.25e-01 3.05e-01 3.37e-01 1.71e-01 9.20e-01 8.07e-02 4.43e-01 4.26e-01 1.96e-02 7.09e-01
GE+DM 3.37e-01 7.08e-01 1.79e-01 4.90e-03 5.67e-02 5.07e-01 1.49e-02 1.74e-01 3.94e-01 9.33e-01 2.71e-02 7.65e-01
Filtered EMT network
Data t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 3.36e-01 2.60e-01 9.54e-02 3.47e-01 8.17e-01 9.45e-01 1.33e-01 7.36e-02 1.85e-01 2.58e-01 4.19e-03 4.88e-01
DM 3.37e-01 3.37e-01 5.03e-01 6.61e-01 2.23e-01 6.06e-02 8.96e-01 2.56e-02 4.41e-01 3.77e-02 3.37e-01 2.78e-01
GE+DM 4.30e-01 4.47e-02 5.03e-01 2.23e-01 2.23e-01 6.77e-05 5.87e-01 5.87e-01 2.77e-01 1.52e-01 2.00e-03 5.36e-01
Extended EMT network
Data t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 2.04e-01 9.98e-01 1.21e-01 1.05e-01 3.25e-01 5.81e-01 4.68e-02 5.55e-01 2.04e-01 4.31e-02 3.73e-02 1.07e-01
DM 4.62e-01 2.48e-01 5.25e-01 3.58e-01 4.83e-01 1.99e-01 1.55e-01 3.21e-01 1.49e-01 7.23e-02 1.91e-02 4.66e-01
GE+DM 2.78e-03 6.58e-01 1.87e-01 3.49e-02 9.64e-02 6.22e-01 2.46e-01 1.50e-02 2.34e-02 7.58e-02 5.46e-02 7.87e-01
Table 4.16: The p-values of log-rank tests using concatenation/multiplex EMT features to separate samples into 2 clusters. We
highlighted all p-values that are lower than 0.01.
t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 1.79e-02 6.55e-01 2.75e-01 4.76e-02 1.52e-02 1.52e-02 2.26e-01 1.33e-01 9.54e-02 6.81e-02 3.82e-04 6.45e-01
123 nodes 1.23e-01 2.49e-01 1.28e-01 9.54e-02 1.30e-04 4.28e-02 2.25e-02 8.96e-01 2.28e-02 6.04e-02 3.81e-01 1.44e-01















Table 4.17: The p-values of log-rank tests using combined EMT gene expression and DNA methylation features on independent
data. The samples are divided into 3 clusters. We highlighted all p-values that are lower than 0.01.
Core EMT network
t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 6.41e-01 4.59e-01 4.34e-01 4.93e-03 9.07e-01 2.39e-01 1.95e-01 9.37e-01 9.19e-01 1.50e-01 6.05e-01 2.80e-01
DM 2.84e-01 8.62e-01 5.07e-01 5.08e-01 1.56e-01 3.31e-01 8.27e-01 2.01e-01 3.80e-01 6.36e-01 6.18e-02 4.35e-01
GE+DM 9.45e-02 7.20e-01 2.64e-01 1.78e-02 1.53e-01 6.65e-01 4.32e-03 3.29e-01 1.23e-01 9.90e-01 6.21e-02 3.61e-01
Filtered EMT network
t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 7.23e-02 2.48e-01 2.35e-01 6.43e-01 1.48e-02 2.42e-01 1.10e-01 1.85e-01 3.02e-02 1.84e-01 1.51e-02 2.19e-01
DM 6.27e-01 2.66e-01 7.95e-01 6.14e-01 1.87e-01 1.21e-01 1.97e-01 2.67e-02 5.96e-01 1.15e-01 4.95e-01 4.32e-01
GE+DM 6.14e-01 7.98e-02 6.08e-01 2.61e-01 1.84e-01 2.83e-04 4.19e-01 6.76e-01 5.27e-01 2.70e-01 7.72e-03 3.28e-01
Extended EMT network
t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
GE 4.23e-01 8.33e-01 8.39e-02 9.00e-02 5.88e-01 6.53e-01 2.88e-02 6.87e-01 3.82e-01 6.41e-02 9.99e-02 1.78e-01
DM 5.93e-01 3.88e-01 6.74e-01 2.36e-01 7.77e-01 3.54e-01 3.63e-01 3.96e-01 2.99e-01 1.94e-01 6.36e-02 7.67e-01
GE+DM 5.84e-03 5.80e-01 1.13e-01 1.08e-01 6.24e-03 3.38e-03 1.14e-01 1.73e-02 7.49e-02 1.18e-01 1.53e-01 4.26e-01
Table 4.18: The p-values of log-rank tests using concatenation/multiplex EMT features to separate samples into 3 clusters. We
highlighted all p-values that are lower than 0.01.
t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet ensemble all
74 nodes 3.99e-02 7.18e-01 4.63e-02 9.86e-02 1.74e-02 3.01e-02 2.40e-01 2.35e-01 1.34e-01 6.19e-02 1.04e-03 3.51e-01
123 nodes 2.02e-02 1.85e-04 2.60e-01 5.20e-02 6.16e-04 1.04e-01 3.54e-02 6.11e-01 4.35e-02 2.46e-03 3.24e-02 1.98e-01
455 nodes 2.42e-01 1.80e-01 5.10e-02 7.40e-03 2.00e-04 1.88e-02 1.52e-01 9.94e-02 1.22e-03 3.07e-02 9.37e-02 4.26e-01
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From the test results above we have a few interesting findings:
• Some sets of EMT features selected from TCGA data are able to significantly stratify
samples in OUH data. Examples are shown in Figure 4.11. EMT DM features in
general show better performance than EMT GE features. This may be due to the
platform difference in transcriptomics profiling between TCGA data and the testing
data. It could also because of the absence of miRNA information in the testing data.
• With some feature selection algorithms, combining features from the two data levels
can lead to significantly improved clustering results. Examples are shown in Figure
4.12 and Figure 4.13. Since the sample size of the test data is much smaller than
TCGA data, it is harder to obtain a significant sample stratification. Nevertheless,
the p-values we obtained in several cases are even lower than the results obtained in
the original study. This shows that EMT features have biological significance and
can give robust prognosis predictions.
• Multiplex-based feature selection shows slightly better sample stratifications than
combining features from individual data levels.
4.4 Discussion
4.4.1 Advantages of Integrative EMT Signatures
In this chapter we fist improved the prediction performance remarkably by combining EMT
features selected from individual data levels. This has been shown on all stage samples
and also on early stage samples. Although it is generally hard to predict the prognosis
of early stage patients, EMT features achieved significant sample stratifications. We have
also tested two integrative clustering algorithms - SNF [264] and iCluster [219], to see
whether they can further improve sample clustering. However, although the resulting
sample clusters show significantly different clinical outcome, the stratification is no better
than using k-means clustering. As we already show that EMT features are capable of
clustering patients into different outcome groups, the inferior results could be due to the
algorithms themselves. [264] assumes that local similarities on the patient similarity net-
work are more important than remote similarities. [219] models the relationships among
multiple omics data using latent variable model assuming that there is a single cluster
assignment for the samples across all omics levels. These assumptions may not agree with
the data. The exact causes of this inferior performance need to be further investigated.
Note that in the original articles, these two algorithms use all the dimensions of several
omics data types without feature selection. This causes much irrelevant information to
influence the sample clustering. Nevertheless, using multiple omics data types improved
sample stratification. However, in both articles it is shown by log-rank tests that the
significance level was rather low (on the scale of 10e-4 for 3 sample clusters) compared
with our results, although the data they employed contain all the EMT features that
we used. This highlights the importance of extracting phenotype relevant features for
subsequent analysis.
We have also proposed a multiplex-based feature selection approach that extends
network-based feature selection algorithms to incorporate multiple network layers. To
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(a) EMT GE features
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(b) EMT DM features
Figure 4.11: Survival analysis on independent data using EMT single-level signatures. The
samples are divided into two clusters with hierarchical clustering using (a) top 20 FSFs
by ensemble algorithm with TCGA GE data, (b) top 10 FSFs (subnetworks) by addDA2
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(a) EMT GE features
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(b) EMT DM features
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(c) Combined EMT GE and DM features
Figure 4.12: Survival analysis on independent data using EMT single- and multi-level
signatures. The samples are divided into two clusters with hierarchical clustering using (a)
top 20 FSFs by t-test with TCGA GE data, (b) top 20 FSFs by t-test with TCGA DM
data, and (c) top 10 FSFs by t-test on TCGA GE data + top 10 FSFs by t-test on TCGA
DM data.
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(b) EMT DM features
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(c) Combined EMT GE and DM features
Figure 4.13: Survival analysis on independent data using EMT single- and multi-level
signatures. The samples are divided into three clusters with hierarchical clustering using
(a) top 20 FSFs by Netrank algorithm with TCGA GE data, (b) top 20 FSFs by Netrank
algorithm with TCGA DM data, and (c) top 10 FSFs by Netrank algorithm on TCGA GE
data + top 10 FSFs by Netrank algorithm on TCGA DM data.
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our knowledge, this is the first time when multiplex is employed in feature selection. We
have tested two methods - Pearson correlation and CNAmet [158] for determining between-
layer connections. Thanks to the construction of EMT networks which keeps important
genes and meanwhile reduces the dimensionality, we are able to perform 30 times strat-
ified 10-fold cross validation to evaluate the selected features. We have shown that due
to the limits of sample size and heterogeneity, the overall performance still suffers from
large variance. However, the FSFs from multiplex show significantly improved perform-
ance compared with the FSFs from single-level networks. This finding also agrees with
our experiments in Chapter 3 where FSFs significantly improved the average prediction
performance.
4.4.2 The Importance of Relevant Network-based Feature Selection
As we have shown, without feature selection it is difficult to stratify samples into different
prognostic groups. However, selecting features using the whole dimensionality of the data is
difficult, which often results in features that generalize poorly on independent data. By first
constructing phenotype relevant networks and extracting these features from the original
data, we can reduce the computational cost, decrease the randomness of selected features,
and improve the predictive performance and biological interpretation of the molecular
signatures. We successfully demonstrated that EMT network-based feature selection and
data integration can provide advantages in selecting cancer prognostic signatures. We show
that it is a good strategy to first use domain knowledge to extract relevant features and
networks from the original data and then select molecular signatures in the low-dimensional
space.
A similar idea to our strategy has been very implicitly and not systematically utilized
in several recent studies, mainly as a remedy or trial-and-error approach to avoid dealing
with many features. For example, [127] aims to predict clinical outcomes in ovarian car-
cinoma. They applied feature screening on each omics data type and then transformed the
selected features into a pathway-based dataset using biological knowledge-base. Feature
screening was applied again on this pathway dataset to select features, which were used
for subsequent analysis. [107] aimed to select features for predicting distant metastases in
lung cancer. They did not use all features as input but selected 4314 transcripts annotated
as EMT-related according to the Ingenuity Knowledge Base. From these transcripts they
selected 474 top-ranked transcripts according to their p-values of t-test between the two
classes. On these 474 features an optimization approach was applied to select molecular
signatures. In [299], where the algorithm RegCox was proposed, only a list of 2647 genes
that were previously known to be related to cancer were used to identify features for can-
cer prognosis. In [35], where network-constrained support vector machine was evaluated,
only 584 genes and 2280 interactions were used from all the features. These genes were
either breast cancer related [76] or involved in estrogen signaling pathways according to
Ingenuity Pathway Analysis. By giving these examples we show that recent studies tend
to first shrink the scope of features by using biological database resources before selecting
molecular signatures.
However, these studies follow their own methods to trim the search space. There is no
consensus on how to do this systematically. This introduces much arbitrariness because the
gene pre-selection can be highly dependent on the dataset. Therefore, it may not improve
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the robustness of the molecular signatures. Within our knowledge, our study is the first one
to systematically construct a phenotype relevant network to identify molecular signatures.
Based on the successful use case of EMT network-based feature selection in lung cancer
prognosis prediction, we propose to construct an intelligent decision support system for a
wide range of medical applications, as will be introduced in Chapter 6.
Chapter 5
Strategies for Handling Large Biological Data
In the previous chapters we have shown that integrative omics data analysis can signi-
ficantly improve prognosis prediction. With the goal of individualized medicine, similar
analysis can be performed on each individual patient to assist decision makings in medical
treatments. Thanks to the decreasing cost of obtaining molecular profiles, medical treat-
ments are becoming more and more individualized. As a result, this requires a powerful
data infrastructure to support the storing and querying of large amount of omics data. So
far this has not raised enough concerns because individual studies typically take several
hundred samples which does not necessitate a data infrastructure. However, in the long
term, we think it is necessary to investigate what could be a suitable data infrastructure to
handle large amounts of omics data. Here we take proteomics data as an example because
of their large size and complexity. In the following we will introduce proteomics data,
relational and non-relational databases (NoSQL); and then we compare these database
systems in their performance of storing and querying proteomics data.
5.1 Proteomics and Mass Spectrometry
In this section we will introduce the complexity of proteomics data, the analysis of proteo-
mics using mass spectrometry (MS) technologies, and its potentials in biomarker discovery.
5.1.1 The Complexity of Proteomics Data
Proteomics is the large-scale experimental analysis of gene and cellular functions at the
protein level. While the genome of an organism is more or less constant, protein expression
varies in different cell types and different cellular conditions. Protein expression levels
can hardly be predicted by genomic and transcriptomic analysis except in some cellular
machines such as ribosome and cell adhesion complexes. For example, research has shown
that there are only modest correlations between mRNA expression and protein abundance
[58, 132, 206]. Multiple regulatory mechanisms can contribute to this phenomenon. For
example, some gene transcripts are not translated to produce proteins [11]. Many mRNAs
give rise to more than one proteins through alternative splicing. A mRNA produced
in abundance may be degraded rapidly or translated inefficiently, resulting in a small
amount of protein. Under distinct conditions such as cell cycle, cellular differentiation, or
carcinogenesis, a cell can produce different sets of proteins.
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Figure 5.1: Post-translational modifications dramatically increase the diversity of pro-
teome. While there are by estimation 19,000-20,000 human protein-coding genes [70],
human proteome is estimated to encompass over 1 million proteins due to alternative spli-
cing, single amino acid polymorphisms, and PTMs [197]. Figure source: Thermo Fisher
Scientific.
The complexity does not end here. Besides translational regulations, various post-
translational modifications (PTMs) are critical to protein functions. One of the most well-
studied modification is phosphorylation. A phosphate is added to a particular amino acid
mediated by kinases. It causes a protein to interact or bind other proteins that recognize the
phosphorylated domain. This is necessary for many signal transduction pathways. Other
PTMs includes ubiquitination, acetylation, etc. These PTMs can happen to some proteins
in time-dependent combinations. Proteins are subject to degradation with different half-
life times, by complex and temporally controlled mechanisms such as ubiquitin-mediated
proteolysis [79, 82]. Figure 5.1 illustrates the complexity of proteomics analysis that is
scaled up by PTMs.
Proteome therefore carries rich biological information that is not accessible by genom-
ics or transcriptomics. Meanwhile, it is also more complex due to its molecular complex-
ity and dynamic nature. Various techniques have been developed to measure proteome.
Polyacrylamide gel electrophoresis (PAGE) technique resolves proteins by molecular mass.
Isoelectric focusing (IEF) technique resolves proteins by isoelectric points. 2D PAGE sep-
arates proteins by both of these two properties in two dimensions [184]. Cell imaging
by light and electron microscopy has been used to mark proteins, e.g., imaging specific
proteins in live cells after binding fluorescently labeled antibodies to these proteins [248].
Protein microarray is developed based on DNA microarray to measure protein interac-
tions and activities [94]. However, due to the complexity of cellular proteome and the low
abundance of many proteins, these technologies are not sensitive enough.
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5.1.2 MS and MS/MS Technologies for Protein Characterization
MS has been developed to offer sensitive protein characterization. Proteins or peptides are
ionized and their mass-to-charge ratios (m/z) are measured by mass analyzer. The num-
ber of ions at each m/z value is detected by ion detector. The m/z values are compared
with protein database to identify the peptides and proteins. Nowadays MS has becoming
a powerful and the most commonly used techniques for protein quantification [162]. The
performance of mass spectrometers in terms of sensitivity, speed, mass accuracy, and res-
olution has been improved rapidly [13]. MS-based proteomics can deliver three different
types of experimental results [45]. One is to quantify the amount of proteins in a sample,
which is analogous to transcriptomics. Another usage is for analyzing the presence and
sites of PTM for >200 PTMs [165] although some low molecular weight PTMs are hard
to be detected robustly [186]. Thirdly, MS is used for studying protein interactions [17].
Here we focus on the first experimental type - proteome profiling. The widely employed
technique is the coupling of liquid chromatography (LC) with high-resolution tandem mass
spectrometry (MS/MS) to identify and quantify peptides [45]. We are going to explain the
basic steps of a LC-MS/MS experiment below. An illustration is provided in Figure 5.2.
1. Sample fractionation. Proteins are separated from samples by biochemical fractiona-
tion or affinity selection. Gel electrophoresis can be used to define the sub-proteome
to be analyzed.
2. Trypsin digestion. Proteins are digested to peptides because MS of whole proteins
is less sensitive than peptide MS and the mass of the intact protein by itself is
insufficient for identification.
3. Peptide chromatography coupled with ionization. High-pressure liquid chromato-
graphy (HPLC) is used to separate the peptides in very fine capillaries and elute the
peptides into an electrospray ion source (ESI) for ionization.
4. m/z determination. The ionized peptides enter the mass spectrometer and their m/z
values are measured at this time point (MS1). In the mass analyzer, peptide ions
are exposed to electrostatic and/or magnetic fields and their motions in such field
can be written as a function of their m/z values. Different mass analyzers have been
devised based on different technical ways to measure this ratio. For example, there
are time-of-flight (TOF), quadrupole, ion traps, Orbitraps, and Fourier transform
ion cyclotron resonance (FT-ICR) mass analyzers. Ion trap mass analyzer is often
chosen for LC-MS with ESI ionization. The peaks for MS1 can be selected for se-
quencing. Inside the mass spectrometer peptides of particular m/z value are selected
and fragmented using techniques such as collision induced dissociation (CID). The
m/z values of the fragments are recorded in tandem mass spectrum (MS2).
5. Peptide mass fingerprinting (PMF). The peptide m/z values in MS1 and MS2 are
searched against a database of known protein sequences. These proteins are digested
in silico and the masses of produced peptides are computed. The searching process
finds matches between the observed peptide masses and the ones in the database.
While it is likely to find multiple peptides for a single m/z value, it becomes more
reliable to find the peptide matches that exist in the same protein [115,164].
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Figure 5.2: An illustration of a typical LC-MS/MS procedure. It combines the physical
separation capabilities of HPLC with the mass analysis capabilities of MS.
5.1.3 The Potential of Proteomics in Biomarker Discovery
Numerous studies have demonstrated that molecular aberrations at different molecular
levels can induce cancer [103, 290]. Let us take the example of the tumor suppressor gene
TP53. Its somatic mutations [185] and PTMs [22] both play important roles in tumori-
genesis. One can thus only partially capture its influence in cancer using genomic data
alone. This simple example is in line with the key question in cancer research, which is to
understand how the information flow from genome to proteome is altered in tumors [7,156].
Therefore, integrating proteomics with transcriptomics and genomics becomes indispens-
able to unravel this information flow. It has the potential to more accurately identify
the disease driver molecules including their PTM status, which is necessary for biomarker
translation [221]. However, compared with other types of genomic data, proteomic data
have been rarely used to model, predict phenotypes, or discover biomarkers. There could
be a few reasons or difficulties. First, the use of microarrays to measure mRNA expression
and genomic profiling using NGS technologies are more ubiquitous than proteomic tech-
nologies [7]. Second, there are difficulties in mapping peptides to proteins and identifying
coding genes of the proteins [273]. Third, data are generated and processed using different
platforms with varying performance. This causes difficulties in the alignment of multiple
datasets after data processing and feature detection [233]. Last but not least, the challenge
of ’big data’: it is nontrivial to effectively store and manage large amount of proteomics
data using traditional databases. [273] developed the ProteomicsDB in-memory database
for storing and analyzing MS data. Using a random-access memory (RAM) of 2TB, the
data can be stored in memory all the time for processing. However, such computational
infrastructure may not be feasible to build for every application.
TCGA has used reverse phase protein arrays to measure abundances of cancer-related
proteins [151]. However, only a small fraction of the proteome was measured. This cannot
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provide a global profile, as that provided by transcriptomes such as RNA-Seq data. This
could be one reason that biomarker discovery studies that use TCGA data usually did not
consider protein expression profile. For this reason and also due to the limited number
of samples, we could not conveniently include protein features in our experiments in the
previous chapters, e.g., to map protein data on the EMT networks. In contrast, MS can
provide good proteome coverage to support integrative studies. With MS-based proteom-
ics, researchers started to compare transcriptomes with proteomes and investigated their
relationships [177,262]. A new area of research Proteogenomics has emerged. Several pro-
teogenomic applications have been launched to study alternative splicing, discover novel
protein coding regions, etc [180].
5.2 The Big Data Challenge
As mentioned above, a few challenges remain before a seamless integration of proteomics
data with genomics and transcriptomics data. Here we address the last challenge - the
big data challenge. Our scope here is to find the suitable data infrastructure to efficiently
store and query MS data.
MS data are eligible for the name ”big data” which is characterized by the large volume,
velocity and variety [141]. Traditional relational databases become unsuitable for the big
data challenge in bioinformatics as they follow rigid table schema and lack scalability for
data aggregation. NoSQL databases emerge in recent years to provide alternative, flex-
ible and more scalable data stores. For example, there are key-value databases such as
DynamoDB, column-oriented databases such as HBase and Cassandra, document-based
databases such as CouchDB and MongoDB, and graph databases such as Allegro Graph
and Neo4j [238]. Relational databases guarantee ACID properties (atomicity, consistency,
isolation and durability) while NoSQL databases guarantee BASE properties (basically
available, soft state, and eventual consistency) instead [178]. NoSQL databases are charac-
terized with the ability to store large volume of data and support flexible data models. The
storage of data is not restricted by fixed table schema as relational databases. Therefore,
NoSQL databases can have an advantage in the applications where ACID is not essential,
but scalability and flexibility are more important [12]. Biological data are commonly stored
as flat files or in relational databases. Once the data are stored, most of the operations
on the data are queries and not to modify the data. For example, many MS data are
produced and stored. Later they need to be queried over and over again to be analyzed
for biomarker identification and protein identification. Therefore, an ideal database should
have low latencies in storing and querying data, while maintaining the consistency. Since
relational model is not necessary for MS data, it is therefore interesting to investigate
whether NoSQL techniques can provide benefits.
There have been a number of qualitative or conceptual studies to compare relational
and NoSQL databases [178,238,239]. Databases are compared in terms of their data mod-
els, query models, consistency models, scalability, and maturity, etc. They show that each
data store has its own data structures. NoSQL data stores are designed to manage large
volumes of unstructured data. However, relational databases cannot be replaced because
of their unique features such as the support of transactions, reliability (ACID), and the
maturity of technology. There have also been a few quantitative studies to compare differ-
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ent data stores. They deployed certain data stores in concrete problems. [147] performed
experiments to store and query clinical data with XML database. The results showed that
XML database can store more flexible clinical data, but it has higher query latencies than
NoSQL databases. [259] compared the usefulness of MySQL and graph database Neo4J on
storing and querying graph data. The results show that Neo4J is much faster than MySQL
for traversal queries because Neo4J has a built-in traversal framework. As Neo4J uses Lu-
cene for query which treats data as text, MySQL has better query speed than Neo4J on
integer databases. However, when the data are stored as text, MySQL and Neo4J have
comparable performance and Neo4J has better scalability. [99] used Neo4J graph database
to store STRING human protein interactions data. They pointed out that depending on
the types of queries, graph database may not be the best choice for graph data.
Note that the suitability of data stores, especially NoSQL data stores, not only depend
on their own features, but also depend on the individual problems and use cases. There-
fore, we are going to conduct quantitative studies to compare the performance of different
databases on proteomics mass spectrometry data. Since MS data do not have graph data
structure, graph databases are not included in the study. We compared the latencies of one
relational database (MySQL), three NoSQL databases and the flat file system on storing
and querying MS and MS/MS data, as well as the disk or memory usage. The four data
stores are the representatives from four main database categories. In addition, both in
memory and disk-based configurations are considered, as listed below:
• Relational database (MySQL, both disk-based and in memory configurations)
• Document-oriented database (MongoDB, disk-based)
• Column-oriented database (HBase, disk-based)
• Key-value database (Redis, in memory)
5.3 Methods
5.3.1 Data for Testing the Databases
MS data
We used both MS and MS/MS data for testing these databases. The MS data are from [42],
where they analyzed the proteome of blood samples for testicular germ cell cancer and
thyroid disease detection. The MS data are produced using MALDI-TOF techniques.
Matrix-assisted laser desorption/ionization (MALDI) is an ionization technique that uses
a laser energy absorbing matrix to create ions from large molecules with minimal frag-
mentation. Time-of-flight (TOF) is a type of mass analyzer that measures the m/z values
based on the time it takes for the ions to reach the detector. The data have been processed
and are in the form of text files in the dat format. The dat format presents the data in
a simple table with two columns for m/z values and intensity values. Each text file has
42,381 pairs of m/z and intensity values. The m/z values for each sample range between
1000 and 10,000 Da. The m/z values among different samples are aligned by finding the
masterpeaks as proposed in [42]. The average size of one MS sample is about 440KB.
Figure 5.3 provides an illustration of one MS sample.
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Figure 5.3: An illustration of the data structures of a MS sample and a MS/MS sample.
MS/MS data
The MS/MS data were taken from the study [71], where they analyzed the proteome of
paired malignant and non-malignant tissue samples from 38 early stage LUAD patients
using LC-MS/MS approach. LC separation was performed using a Waters Nano Acquity
UHPLC. Mass spectra were collected on an Orbitrap Q Exactive Plus mass spectrometer
(Thermo Fisher Scientific). It separates precursor ions ”in time” using ion traps and
performs MS2 analysis on the separated ion populations in high resolution. The precursor
isolation is achieved by applying a quadrupole to the precursor ions which allows only a
certain ion population (within the chosen mass window) to remain stable in the trap. The
m/z values are measured by Orbitrap ion trap mass analyzer. We converted the raw files
to MS1 format using ProteoWizard msConvert [126]. Different MS2 spectra are marked
with different retention time (elution time from LC), base peak intensity (BPI), base peak
mass (BPM), and TIC (total ion current). Each MS2 spectrum contains 283 pairs of m/z
and intensity values. The m/z values range from 346.5157 to 1616.158 Da. The average
size of one MS/MS sample is about 2GB. Figure 5.3 provides an illustration of the data
for one MS/MS sample.
5.3.2 Databases and Data Models
Each database has its unique features. When we store MS data in them the data models
are different. In some cases, there are alternative ways to store the same data. We decide
to choose the data model based on the distinguishing feature of a database while taking
into account its constraints. For example, MongoDB is document-oriented, so we store
each sample file in one document. HBase is column-oriented thus we store each sample file
in one column. We deployed the standalone mode of all databases. In the following we
use an example of student data including basic student information to show the schemas
of different databases. Then we explain how MS and MS/MS data are stored in these
databases.
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MySQL
MySQL is the most widely used open-source relational database management system (RD-
BMS). It uses tables to store data. A table has rows for records and columns for the fields.
When the table is created each field is assigned a data type such as CHAR(30) (can hold up
to 30 characters), DATE, FLOAT, etc. MySQL supports a number of data types: numeric
types, date and time, character and byte types, and spatial types. Queries in tables are
done using SELECT statement. It can be combined with Where, AND & OR, Order By,
and Group By clauses to specify query conditions and the output aggregates. SQL tables
can be linked in queries using for example JOIN, and UNION clauses. FOREIGN KEY
constraints can be added to the columns of a table that point to the columns of other
tables, which makes sure that only valid data can be inserted into the foreign key columns.
An SQL table needs to be created with a rigid schema - at least the data types and the
primary key, before data can be inserted. The inserted data cannot violate the data types
and constraints.
MySQL supports several storage engines, which are software modules that a database
management system can employ to handle CRUD (create, read, update and delete) oper-
ations. InnoDB is the default engine and is most widely used. Memory storage engine is
a fast one because it creates tables in memory. It does not support transactions. Since
choosing the right storage engine is important for database performance, we included both
InnoDB and Memory engines for testing.
The student data can be stored in a relational table as shown in Figure 5.4a. To
store MS samples, we create a table with three columns: sample number, m/z value and
intensity value, as shown in Figure 5.4b. An index is built on the sample number column
to accelerate the search for multiple samples. As a table can contain a maximum of 1017
columns we could not store the data row-wise. As the VARCHAR data type can hold
maximum 65,535 bytes, it is not convenient either to store a sample as a string. Thus, to
store MS/MS data, we need two tables for one sample - one table for storing the spectra
and one table for storing the metadata, including the retention time, BPI, BPM, and
TIC. Since the two tables are related, the common schema design is to add a foreign key
constraint to ensure data integrity. We built a foreign key on the spectrum ID column
of the spectra table, which points to the primary key of the metadata table. The table
schemas are shown in Figure 5.4c. To accelerate inserting data, we use the bulk load
operation to insert one MS sample, or one MS/MS spectrum at a time.
MongoDB
MongoDB is a document-oriented NoSQL database. It does not have fixed table structures.
A record in MongoDB is a document, which is a data structure composed of field and value
pairs. Every document has an id field as a primary key. MongoDB stores documents in
collections, and collections in databases. Collections can be considered as an analog to
tables in relational databases. Documents are stored as BSON (binary representation of
JSON document) objects. The values can include strings, arrays, and other documents.
This offers flexibility in data storage. For example, to store embedded data structure in
relational database, one has to break the data into multiple cross-referenced tables. While
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2 Bob 34 art 6









































1 0.001869566 1352.308 632.8213 20239.16
2 0.008350816 44570.84 391.2832 173710.4
... ... ... ... ...
m 125.0028 296452.7 365.104 4141702
(c) MS/MS tables
Figure 5.4: MySQL data models. (a) student data are stored in an SQL table where each
field corresponds to one attribute and is assigned a data type. The student ID is the
primary key. (b) MS data are stored in one SQL table in three columns. (c) One MS/MS
sample is stored in two tables, one for spectra and one for metadata.
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sample document (field-value pairs)
1 name:Ana, age:24, subject:math, year:3
2 name:Bob, age:34, subject:art, year:6
3 name:Tom, age:25, subject: medicine, year:5
(a) Student collection
sample document (field-value pairs)
1 1000 02:29, 1000 12:21, ..., 9999 68:5
2 1000 02:26, 1000 33:8, ..., 9999 68:30
... ...
n 1000 02:4, 1000 12:38, ..., 9999 68:7
(b) MS data collection
id document (metadata pairs and m/z - intensity value pairs)
... sample:1, rtime:0.001869566, bpi:1352.308, bpm:632.8213, tic:20239.16, 346 5157:692.9346, ... 1616 158:1181.356
... sample:1, rtime:0.008350816, bpi:44570.84, bpm: 391.2832, tic:173710.4, 346 5157:0, ...
... ...
... sample:m, rtime:125.0028, bpi:296452.7,bpm:365.104, tic:4141702, ..... 1616 158, 1181.356
(c) MS/MS data collection
Figure 5.5: MongoDB data models. (a) student data are stored in a collection with the
student ID as the primary key. (b) MS data are stored in a collection with sample ID as
the primary key. (c) MS/MS data are stored in a collection with automatic ID and an
index on the retention time field.
have to be defined upon creation, collections do not need to be defined. Documents with
different structures can be stored in the same collection.
In addition to being able to store data flexibly, complex queries and aggregations can
be performed on the data. In queries, the dot notation is used to access the elements of
an array or the fields of embedded documents. Query selectors are used to specify the
conditions on a field. The selectors cover different categories such as comparison, logical
operators, bitwise operators, etc. Conditions can be specified on multiple fields to have a
compound query. In terms of aggregations, MongoDB is able to process documents and
return computed results. It can group values from multiple documents and perform a
variety of operations such as map-reduce function, single purpose aggregation operations
(e.g., count(), distinct()), etc.
The student data can be stored in a collection as shown in Figure 5.5a. We store the MS
sample files in one collection with one document for one sample. The key of the document
is the sample number. Within each document, the field-value pairs are the m/z value-peak
value pairs in the sample files. Since the field value of a field-value pair in MongoDB is a
string and cannot contain dot, we could not store the m/z values as float values. We use
strings with dots replaced by underscores, as shown in Figure 5.5b. For MS/MS data, we
stored each spectrum as a document with the first a few fields storing sampleId, retention
time, BPI, BPM, and TIC. Different from storing MS data, we used the automatically
generated id field. To accelerate spectrum query, we built an index on the retention time
field. The data schema is shown in Figure 5.5c.
HBase
HBase is a column-based NoSQL database modeled after Google’s Bigtable. It stores data
in wide tables. A table in HBase does not have fixed column schema. Only the column
families (CF) need to be declared at the schema definition time. A table is a collection
of rows. A row is a collection of CFs. A column family is a collection of columns. Each
column is identified by a collection of column qualifier-value pairs. A row key, a CF, a
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Figure 5.6: An illustration of Memstore usage in HBase read/write paths.
column qualifier and a timestamp can exactly specify a cell in a HBase table. The names
of CFs and column qualifiers are copied on each row. The student data can be stored as
in Figure 5.7a.
It is suggested in the HBase manual that the number of column families should be kept
low (not more than two or three) to have a good performance. In many cases having one
column family is the best schema design. This is due to the write and read paths in HBase.
Figure 5.6 shows how HBase handles write requests. The RegionServer (RS) serves data
for read and write. It directs the requests to a specific region. HBase tables are divided
horizontally by the row key range into Regions. Each region stores a set of rows. The rows
are separated in multiple column families. There is one MemStore for each column family.
The main reason for using Memstore is to sort the data by the row key before writing it
to the distributed file systems.
When we write data to HBase tables, the data are firstly written into MemStore. When
the size of data exceeds certain thresholds the data in MemStore are flushed into HFiles.
The Memstore flush creates one HFile per CF and all CFs are flushed together. This
means that when there are multiple CFs and the data from one CF exceed the MemStore
threshold, the other CFs in this region are flushed as well (in the default setting). Thus
N (the number of CFs) HFiles are created per flush which causes needless i/o operations.
In addition, to handle the many HFiles created by frequent flushes, HBase periodically
compacts multiple small HFiles into a big one. Thus, having multiple CFs also increases
the compaction cost. In our experiment, to avoid unnecessary i/o operations, we will define
one CF. HBase is deployed in standalone mode. It uses local file system instead of hadoop
distributed file system (HDFS).
In contrast to the design of CFs, HBase does not have a limit regarding the number
of columns in a CF. All mutations on a row in HBase are atomic - it either completes
entirely or not at all. This applies when mutations occur to multiple CFs of a row. When
a row is updated, it is locked by the RS until the update is finished. HBase can scale
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Row key personal data[column family 1]
study
[column family 2]
ID [column qualifier: value] pairs [column qualifier: value] pairs
1 name: Ana age:24 subject: math year:3
2 name: Bob age:34 subject: art year:6
3 name: Tom age:25 subject: medicine year:5
(a) Student table
Row key MS[column family]
Sample ID m/z : intensity[column qualifier: value] m/z: intensity ... m/z: intensity
1 1000.02:29 1000.12:21 ... 9999.68:5
2 1000.02:26 1000.33:8 ... 9999.68:30
...
n 1000.02:4 1000.12:38 ... 9999.68:7
(b) MS table
Row key MS/MS[column family]
sampleID RTime BPI: value[column qualifier: value] BPM: value TIC: value m/z: intensity ...
1 0.001869566 BPI:1352.308 BPM:632.8213 TIC:20239.16 346.5157:692.9346 ...
1 0.008350816 BPI:44570.84 BPM: 391.2832 TIC: 173710.4 346.5157:0 ...
...
m 125.0028 BPI:296452.7 BPM: 365.104 TIC: 4141702 ... ...
(c) MS/MS table
Figure 5.7: HBase data models. (a) student data are stored in two CFs based on data
categories with student ID as the row key. (b) MS data are stored in one CF with the
sample ID as the row key. (c) MS/MS data are stored with sampleID RTime as the row
key. The spectra and other metadata are stored in one CF.
to handle very large tables with billions of rows and millions of columns. To store MS
data, we define the sample number as the row key and the m/z value-intensity value pairs
as the column qualifier-value pairs, as shown in Figure 5.7b. To store MS/MS data, we
take advantage of the HBase row keys, which are sorted to provide fast random find and
contiguous scanning of rows, e.g., prefix-based row key scans. We store the sample ID and
retention time information in the row keys and the other meta-data in columns. The table
schema is illustrated in Figure 5.7c.
Redis
Redis is an in-memory NoSQL database. It can be used as a database, cache, or message
broker. By using in-memory configurations, it can provide high read and write speed.
Depending on the use case, the dataset in memory can be dumped to disk manually or at
certain intervals. Data are stored in the form of key-value pairs. Keys are associated with
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key hash
1 (name,Ana) (age,24) (subject,math) (year,3)
2 (name,Bob) (age,34) (subject,art) (year,6)
3 (name,Tom) (age,25) (subject, medicine) (year,5)
(a) Student hash
Key hash
1 (1000.02,29) (1000.12,21) ... (9999.68,5)
2 (1000.02,26) (1000.33,8) ... (9999.68,30)
... ...
n (1000.02,4) (1000.12,38) ... (9999.68,7)
(b) MS data stored in hash
Key string
1 1000.02 2 1000.12 21 ... 9999.68 5
2 1000.02 26 1000.33 8 ... 9999.68 30
... ...
n 1000.02 4 1000.12 38 ... 9999.68 7
(c) MS data stored in string
Key (rtime sample) Hash
0.001869566 1 (bpi,1352.308) (bpm,632.8213) (tic,20239.16) (346.5157, 692.9346) ... (1616.158,1181.356)
0.008350816 1 (bpi,44570.84) (bpm,391.2832) (tic,173710.4) (346.5157, 0) ...
... ...
125.0028 m (bpi,296452.7) (bpm,365.104) (tic, 4141702) ... (1616.158,1181.356)
(d) MS/MS data stored in hash
Key (rtime sample) string
0.001869566 1 bpi 1352.308 bpm 632.8213 tic 20239.16 346.5157 692.9346 ... 1616.158 1181.356
0.008350816 1 bpi 44570.84 bpm 391.2832 tic 173710.4 346.5157 0, ...
... ...
125.0028 m bpi 296452.7 bpm 365.104 tic 4141702 ... 1616.158 1181.356
(e) MS/MS data stored in string
Figure 5.8: Redis data models. (a) student data are stored using hash with student ID as
the key. (b) MS data are stored using hash with the sample ID as the key. (c) MS data
are stored using string with sample ID as the key. (d) MS/MS data are stored using hash
with retention time and smaple ID as the key. (e) MS/MS data are stored using string
with retention time and sample ID as the key.
string values. Keys are binary safe, which allows any binary sequence to be used as a key,
ranging from a string to an image file. The values allow different data structure such as
strings, hashes, lists, sets, sorted sets, bitmaps, etc. The student table can be stored using
hashes (field-value pairs) as shown in Figure 5.8a.
We found that both hash and string data structures can be adapted to store MS data.
Thus, we used both of them and compared their performance. With hash data structure
we use field-value pairs to store the m/z value-intensity value pairs, as shown in Figure
5.8b. With string data structure, we append all lines of the MS sample file to a string,
as shown in Figure 5.8c. The key of a hash or a string is the sample ID. List and sorted
set are not suitable in our use case. List is implemented as linked list in Redis. This data
structure is efficient for inserting data but requires sequential scanning to retrieve data.
Sorted set can only keep unique intensity values, which does not apply to the data.
5.3.3 Experiments
We performed experiments to compare the latencies of MySQL, MongoDB, HBase, Redis,
and flat file system on storing and querying MS and MS/MS data, as well as the disk
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or memory usage. Java clients and JDBC (Java database connectivity) API (application
programming interface) were used to uniformly access the databases and local file systems.
To evaluate the suitability of these databases for building a proteomics data infrastructure,
we selected a few commonly needed operations when working with MS and MS/MS data
to serve as proxy applications. We used a powerful local workstation for the experiment.
The workstation is equipped with 12 Intel Xeon (R) CPUs running at 3.50GHz, 64GB
RAM and 2 TB SATA hard-disk drive (Model: MegaRAID SAS 9341-8i). The operating
system is Ubuntu 16.04.
We have 3 use cases for MS data:
1. Store new data: insert n MS samples. n ranges from 500 to 150,000. The total size
of files on disk ranges from 200MB to 64.3GB (close to the size of the main memory).
We choose the sequence of n to be n = (500, 2500, 5000, 10000, 20000, 30000, 40000,
50000, 60000, 70000, 80000, 90000, 100000, 110000, 120000, 130000, 140000, 150000),
in total 18 measurements.
2. m/z range query: select all m/z - intensity value pairs from all samples where m/z
values are within a certain range. Here we use the range from 1500 to 1800 Da.
3. Sample query: select all spectra of m samples from all samples by sample IDs. We
generate the sample IDs randomly and the number of IDs is 10% of the total samples.
For example, if we stored n samples in a database, n/10 sample IDs are generated
randomly for the query.
We have 3 use cases for MS/MS data:
1. Store new data: insert n MS/MS samples. n ranges from 1 to 32. The total size of
files on disk ranges from 2GB to 64GB. We choose the sequence of n to be n = (1,
2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32), in total 18 measurements.
2. Retention time query (RTime query): select all spectra from each sample where the
retention time falls into a certain range. Here we choose the time window to be
between 20 and 22 seconds.
3. RTime and m/z range query: select all m/z-intensity value pairs from each sample
where the retention time falls into a certain range and the m/z values are within a
certain range. Here we choose the retention time window to be between 20 and 25
seconds, and the m/z value range to be between 400 and 500 Da.
5.4 Results and Analysis
5.4.1 Storing and Querying MS Data
Figure 5.9 shows the latencies of storing MS data and the consumed space on disk or in
memory. We observe the following:
• HBase and MySQL are slowest in storing data. It is mainly because they are disked
based systems. Comparatively, in memory databases are very fast to store data.
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Figure 5.9: The latencies of storing MS data and the disk or memory usage.
MongoDB is also a disk-based database, but it is much faster than MySQL and
HBase. We think this is due to the fact that MongoDB uses documents to store
samples rather than tables. This not only accelerates the write operations but also
saves storage space.
• HBase consumes the most disk space. It is because in each row (which stores one MS
sample), the names of the column qualifiers and the CF need to be stored. Within
each cell, a timestamp is also stored. This makes HBase more demanding on disk
space. MongoDB uses the least space among disk-based databases.
• Redis database gives very different performance when using string data structure and
when using hash data structure. Storing data with Hash is much more expensive than
with Strings. The latter can store the data in memory using nearly the same space
as the size of disk-based files.
Figure 5.10 shows the query latencies of the two use cases: m/z range query and sample
query. We observe that in m/z value query, MySQL and HBase are slower than using flat
files. MongoDB shows significantly lower latencies compared with flat files. It is even faster
than MySQL with MEMORY storage engine. Redis is the fastest. Hash data structure
leads to much lower latencies than string data structure because it is faster to filter the
m/z value range based on hash keys. When the data in Redis reach the size of memory,
the latencies increase dramatically. On sample queries, MySQL is extremely expensive
compared with the other databases, which are able to store one sample in one record:
a HBase row, a MongoDB document, or a Redis hash or string. Excluding MySQL, we
observe that MongoDB has lower latencies than HBase, Redis hash, and MySQL with
MEMORY engine.
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Figure 5.10: The latencies of m/z value range query and sample query on MS data.
5.4.2 Storing and Querying MS/MS Data
Figure 5.11 shows the latencies of storing MS/MS data and the consumed space on disk
or in memory. It also gives the query latencies of two use cases: RTime query, RTime and
m/z range query. We observe the following:
• Consistent with the observations on MS data, MongoDB achieved top performance
among disk-based databases. It has low latencies in storing data. The memory
consumption is efficient - on average 1.47 times the size of flat files. It shows much
lower query latencies than the majority of other databases, even including MySQL
with MEMORY engine and Redis with hash data structure. MongoDB shows good
potentials for handling data that are in the structure of key-value pairs.
• MySQL database still shows very high latencies in storing and querying data. In
both queries, especially the RTime and m/z range query where MySQL has to per-
form JOIN operations on tables, the latencies increase rapidly to a different scale
compared with the other databases. It shows that querying MS/MS data is not a
good application of relational databases.
• Some of the curves follow a linear trend but the shape has some variations, especially
for MongoDB. We accredit it to the memory allocation of the operating system when
we run consecutive testings, where we delete the current data and store data of the
next (larger) size. As it is certain that storing and querying more samples requires
longer time, we believe the results would look more regular if the testings on different
data sizes were performed separately.
Above all, there are significant performance differences among the databases. Since
all storage systems show a nearly linear dependency between the latencies and data sizes,
we calculate the average latencies of storing or querying one MS or MS/MS sample, and
the average disk or memory consumption of storing one MS or one MS/MS sample. The
results are given in Table 5.1 and Table 5.2.
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Figure 5.11: The performance of databases on MS/MS data. Upper figures: the latencies
of storing MS/MS data and the disk or memory usage. Lower figures: The latencies of
RTime query, and RTime and m/z range query.
Table 5.1: The average storing and querying latencies, and the disk or memory consump-
tions of the databases per MS sample.









37.22 235.2 160.4 20.87 21.60 0.84 - mean
2.76 37.34 25.01 0.61 0.93 0.16 - sd
Range query latency
(millisecond)
2.82 13.80 18.33 5.19 0.31 1.70 7.97 mean
0.65 4.50 2.13 0.08 0.19 0.13 0.26 sd
Sample query latency
(millisecond)
1.70 3.01 55.80 0.79 2.28 0.054 0.040 mean
0.69 0.89 42.31 0.27 1.16 0.014 0.039 sd
Size (KB) 647.8 3727 1361 1669 2722 448.2 440.8 mean0 1456.52 35.30 0.11 1.94 0.30 0 sd
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Table 5.2: The average storing and querying latencies, and the disk or memory consump-
tions of the databases per MS/MS sample.









338.1 574.7 904.7 106.43 101.25 4.91 - mean
95.80 98.06 10.45 31.26 65.95 2.88 - sd
RTime query
(second)
1.80 5.00 16.27 1.91 3.10 0.10 0.10 mean
0.41 1.12 0.98 0.79 1.57 0.036 1.43e-2 sd
RTime and m/z
range query (second)
1.54 7.97 55.08 3.63 2.89 0.83 0.151 mean
0.34 0.20 6.58 1.44 2.17 0.11 2.34e-2 sd
Size (GB) 2.24 8.03 6.39 4.73 7.55 1.84 1.65 mean3.10e-5 0.76 0.16 0 0.097 6.49e-4 0 sd
5.5 Discussion
Compared with our previous study [217] where only 7000 MS samples (around 3GB) were
used for testing due to the technical limitations, in this study we experimented with 150,000
MS samples (around 63GB) and 32 MS/MS samples (around 53GB). As a result, we are
able to compare the performance of the databases more objectively. Having looked at
the individual performance above, we would like to address some common ground for all
database systems involved.
Better memory utilization results in lower latencies. As expected, the two in
memory databases (Redis and MySQL with MEMORY engine) have lower write latencies
compared with disk-based databases. On querying data, MongoDB gives comparable per-
formance as in memory databases. This is because MongoDB uses memory-mapped files
which first utilizes all available memory before using the hard-disk. This contributes to its
good performance in queries.
Accessing data from disk and from memory are intrinsically different 1. Accessing data
from disk is done through the serial ATA interface. It has a theoretical bandwidth of
4,800 MB/s. The theoretical bandwidth of memory is much higher. It is calculated as the
product of base DRAM clock frequency, the number of data transfers per clock, memory
bus width, and the number of memory interfaces, which is 2133 million clocks per second
× 2 × 64 bits per line × 2 = 68.26GB/s. Thus, accessing data from disk is about 27 times
slower than accessing data from the main memory. Besides, the latencies of seeking to the
correct location on a disk takes about 4 milliseconds. This makes random access on disk
much slower than in the memory.
Flat file storage can achieve comparable query latencies. Although querying
from flat files involves disk reads, it achieves optimistic query latencies compared with
certain databases. It has achieved the lowest latency on sample query of MS data and
RTime query of MS/MS data. This shows that databases may not be necessary for some use
cases. Nowadays, technical improvements such as operating system dependent page caching
and hardware-based caching mechanisms can reduce the latencies of disk read, especially
when the reads are sequential. In querying MS and MS/MS data, many operations are
sequential because researchers are usually interested in a range of m/z values. Additionally,
performing queries in individual sample files avoids the overhead of loading large volume
1The following data is based on the configurations of our workstation.
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Table 5.3: Conditions in which the databases may be considered
If you have ...
Unstructured or flexible data that require complex queries MongoDB
Very large data volume applications HBase
Data that require a relational model and ACID transactional properties MySQL
Data that do not require complex queries and can fit in the memory Redis
Data that only require limited operations Flat files
of data to the memory, which can cause page faults and disk swaps if the data do not fit
in the memory.
Range queries are more expensive. Our experiments show that querying data
ranges is usually much more expensive than querying the entire records. This occurs
because sequential access is usually faster than random access. Databases often implement
range queries as first returning all data fulfilling the lower bound and then filtering on
the upper bound. This can increase the query latencies. For example, on MS data range
query always has higher latencies than sample query except MySQL (InnoDB) and Redis
(hash). For MySQL, it is because the database engine has to query the entire table for
sample query. Regarding Redis, its hash data structure is especially designed to retrieve
key ranges which makes range query faster. On MS/MS data, RTime and m/z range query
always requires longer time than RTime query except Redis (hash) and MongoDB. This
is because in MongoDB we built an index on the RTime field so that the time to find the
correct documents is significantly reduced. Within each document it only needs to pick
the sequential key-value pairs within the required m/z value range. This can explain the
results observed with MongoDB.
The trade-off between ACID compliance and other desired properties. MySQL
and HBase have higher write and query latencies than other databases. At the same time,
they are the most reliable because they guarantee higher level of data consistency. MySQL
provides ACID properties. HBase can provide ACID properties within the same row.
These inevitably require more disk writing. In comparison, MongoDB does not guarantee
ACID properties. It trades off ACID compliance for higher availability which contributes
to better speed. NoSQL databases relax the ACID compliance for other desired properties
such as availability, horizontal scalability, etc [179, 213]. Our experimental results show
that this is necessary to efficiently manage MS and MS/MS data.
The suitability of a database depends on the use case. We have shown that
the combinations of databases and data models give different performance, depending on
individual use cases. Nevertheless, we would like to give our general use experience in
Table 5.3. Overall, we would recommend MongoDB as the default choice when storing
data in the structure of key-value pairs.
5.6 Conclusion
As introduced in the beginning of this chapter, system-level investigations of cellular and
molecular interactions produce large amounts of data. MS and MS/MS proteomics data
are among these data types. Efficient database systems can assist data management and
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analysis. We have used an experimental approach to compare the performance of a rela-
tional database (MySQL) and three NoSQL databases (MongoDB, HBase, and Redis) on
their latencies of storing and querying MS and MS/MS data with representative use cases.
We also performed the same queries on a flat file system for comparison. To the best of
our knowledge, this study was the first quantitative comparison among relational database,
NoSQL databases, and flat file system in storing and querying both MS and MS/MS data,
which can provide reference for researchers who would like to build a bioinformatics data
infrastructure.
Our results show that NoSQL databases with suitable data models can achieve lower
write and query latencies as well as less disk or memory consumption than relational
databases. Overall, MongoDB achieved good performance compared with other disk-based
databases. Depending on the use cases, flat file system can achieve comparable query
performance as with using databases. Last but not least, the suitability of databases and
data models need to be considered based on the application requirements. In the future,
we would like to extend our study by comparing the performance of the databases in
distributed mode, e.g., HBase with Hadoop and HDFS, MongoDB with sharding technique,
to provide references for bioinformatics data centers.
Chapter 6
Summary
Given the high dimensionality of omics data, feature selection has become a prerequisite
for building predictive models. In this thesis, we have covered comprehensively, from the
understanding state-of-the-art feature selection methods, to the proposal and evaluation of
phenotype relevant network-based feature selection (PRNFS) framework, and to the bench-
mark of large data applications. We have achieved data integration in cancer prognosis
prediction based on epithelial mesenchymal transition (EMT) gene regulations, which have
been demonstrated as highly relevant to the metastasis and prognosis of epithelial cancers.
The results have shown the good predictive performance of this approach. In the follow-
ing we will summarize our contributions, identify the limitations and propose to build an
intelligent decision support system (IDSS) to support a wide variety of predictive tasks in
personalized medicine.
6.1 Contributions
Our contributions are manifold. The major ones are summarized below:
1. A comprehensive literature review. We have reviewed the development of feature
selection algorithms in cancer prognosis prediction, from using one type of omics
data without network, to the integration of single omics data with network, and to
the integrative analysis of multiple omics data. In each of the three categories we
have discussed the advantages and disadvantages of several underlying methodologies.
Based on our review and several other studies where feature selection algorithms are
objectively evaluated, we identified the research gaps.
2. The proposal of RRNFS framework. Motivated by the research gaps, we proposed the
novel RRNFS framework to selected robust features from omics data for phenotype
predictions. We demonstrated the benefits of this approach with the application of
prognosis prediction in lung adenocarcinoma, where we constructed EMT networks
and selected molecular signatures from them. We have shown that even the dimen-
sionality was reduced to less than 2.5 % of the original data, remarkable prediction
performance was obtained.
3. The identification of EMT single-omics signatures. We mapped multiple types of om-
ics data alternatively on EMT networks to identify molecular signatures and com-
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pared their predictive performance. Further, we analyzed the frequently selected
features (FSFs) from different data levels. We found out that the network properties
of FSFs from individual data levels are significantly different. We derived prognostic
association rules from the FSFs of different omics data and analyzed their biological
interpretations. We showed that combining FSFs from different omics data gave rules
of higher qualities.
4. The identification of EMT multi-omics signatures. We obtained multi-omics signa-
tures first by combining single-omics signatures. We showed that combined features
can separate all-stage samples and early-stage samples into more significantly dif-
ferent groups. Then we proposed an integrative feature selection approach using
multiplex network. We can directly select multi-omics signatures with this multi-
layered network structure, where each layer was mapped with one type of omics
data. We showed that the FSFs from multiplex network gave more optimistic pre-
diction performance than any single-omics FSFs. To our knowledge, we for the first
time employed multiplex for feature selection in cancer prognosis prediction.
5. The evaluation of EMT signatures on independent patient cohorts. To test the
utilities of EMT-based feature selection, we tested both single-omics and multi-omics
EMT signatures on a real-world clinical dataset consisting of both gene expression and
DNA methylation data for a cohort of patients. Employing EMT signatures, we were
able to stratify the samples into significantly different prognostic groups. Further,
multi-omics signatures gave superior performance over single-omics signatures.
6. The benchmark of database systems for handling large biological data. An integrative
omics data analysis requires efficient database systems. We chose proteomics data as
an example due to its complexity and large volume. Both SQL and NoSQL databases
were tested in terms of their latencies of storing and querying MS and MS/MS data,
as well as the disk or memory consumption.
We have shown in both Chapter 3 and Chapter 4 that the selection of molecular signa-
tures is sensitive to small changes in the training set, even though only the EMT features
were employed. By using the FSFs, we have obtained remarkable improvements in pre-
diction performance. As introduced in Chapter 1, methods for integrating multiple omics
data have been developed in recent years for different predictive purposes. In this ongoing
endeavor, one has to inevitably deal with even higher dimensionality of data. Thus, feature
selection becomes indispensable to avoid overfitting and improve the robustness of the sig-
natures. Our study shows convincingly that biological knowledge-based feature selection,
both on individual data level and on multiple data levels, can improve the predictability
of the models significantly. This is in line with the current research frontier where the
utilities of knowledge-driven predictive models are being acknowledged.
6.2 Limitations
Much of the limitations of our study come from the data. The curse of dimensionality makes
it hard to find the molecular signatures. Additionally, the heterogeneity of samples makes
it more difficult to differentiate signals and noise. For the same reason, some variations in
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omics data are probably caused by other reasons unrelated to the phenotype of interest,
e.g., whether the patient has other diseases. However, due to the limitation of the sample
size and clinical data, this effect cannot be separated. As for most of the cancer omics
measurements, the molecular data are generated at the time of diagnosis or surgery. The
data are static and cannot capture the changes of molecular profiles in a later disease stage.
With static data, it is not known how the disease develops and affects the prognosis. For
example, we know that EMT is a gene regulatory process that can be found in different
status. Studies show that the master regulators in each status can be different [214, 236].
When using static EMT data, the profile of how EMT evolves remains unknown.
The second limitation or challenge in our opinion is the complexity of molecular in-
teraction networks. Given a large network such as PPI, it is hard to know which parts
of it are important for the phenotype of interest. If we take the entire network, the ir-
relevant information can overwhelm the signals. Additionally, it is often hard to map the
expression or modifications of the functional molecules - usually proteins, to the network
nodes, because the data may not be available. Many post-translational modifications are
still technically difficult to measure [162].
6.3 Outlook - an Intelligent Decision Support System
Although recent studies have proposed new methods for omics data integration, the po-
tential clinical utility of integrating these data levels remains largely unknown. This is
related to the randomness of results from different studies, which could be caused by
the curse of dimensionality. Based on the good prediction performance of our proposed
RRNFS framework that integrates multiple omics data, we propose to build an intelligent
decision support system (IDSS) for not only prognosis prediction, but also for a variety of
other phenotypes. A schematic view is given in Figure 6.1. Its major components are the
data management system (DMS), model management system (MMS), knowledge manage-
ment system (KMS), and user interface. They goal is to integrate multiple levels of omics
data with biologically relevant features from each level, which can be identified with the
assistance of domain knowledge. These phenotype relevant features will be used for fea-
ture selection and building predictive models. The models can be refined iteratively with
increased sample size, updated domain knowledge, and new feature selection algorithms.
Building such an IDSS requires large amount of digital patient data, a rich variety
of biological knowledge-base [138], and efficient computational infrastructures. All these
requirements can nowadays be satisfied. To realize personalized medicine for complex
diseases, which necessitates timely decision makings in diagnosis, prognosis, and treatment,
a centralized IDSS is desirable. It can potentially:
• Improve the quality of decisions. IDSS can select phenotype relevant features and
evaluate multiple predictive models to support its decision making. With the addition
of more patient data, the MSS iteratively refines the models to give robust predictions.
• Facilitate data integration. While it is hard for individuals to process large amount
of biological knowledge and employ a wide variety of models, this system can offer
these options at one place.
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Figure 6.1: A schematic view of an IDSS for personalized medical decision making.
• Improve the communication of experts. IDSS can provide user interfaces to stake-
holders at different locations. They can jointly contribute to the knowledge-base and
predictive models.
• Reduce cost. Compared with building one intelligent system at every research insti-
tute and hospital, this system can benefit many medical centers. By improving the
quality of decisions, unnecessary medical treatments could be avoided.
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Figure 7.1: Extended EMT Network. We extended the EMT core network to incorporate
the molecules that interact with or being regulated by the genes and miRNAs in the core
network. We referred to three databases: STRING protein-protein interactions, ENCODE
transcription factor - gene regulations, and miRTarBase miRNA-gene regulations.
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Figure 7.2: The accuracies at different cutoffs of each feature selection algorithm for each
combination of data levels and networks using SVM classifier.





























































Networks Core Network Filtered Network Extended Network Clinical Features
Figure 7.3: The average AUC values of FSFs combined with clinical features for three data
levels and three EMT networks using random forest classifier. The blue dotted lines show















































































































































































































































































































































Figure 7.4: The average prediction accuracy at 0.5 cutoff of FSFs combined with clinical
features for three data levels and three EMT networks using random forest classifier. The
blue dotted lines are the median accuracy values of using only clinical features.













































Thresholds 3 years <900, >1200 days <700, >1400 days <500, >1500 days
Figure 7.5: The AUPR values of 10 feature selection algorithms using different thresholds
for good prognosis class and poor prognosis class. The data level is DNA methylation data.


























































































































































































































































































































Groups GE CNA Concatenation
Figure 7.6: The average AUC values of concatenation-based feature selection using GE
and CNA data. The left side shows the performance of molecular features. The right side
shows the performance of FSFs combined with clinical features. On each side we show the
results of using 3 EMT networks.







































































































































































































































































































































Groups GE CNA Multiplex
Figure 7.7: The average AUC values of multiplex-based feature selection using GE and
CNA data. The left side shows the performance of molecular features. The right side
shows the performance of FSFs combined with clinical features. On each side we show the
results of using 3 EMT networks.
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Table 7.1: Gene regulatory interactions in the core EMT network.
SNAI1 represses CDH1 miR-141 represses ZEB1 TGFβ1 increases DAB2
SNAI2 represses CDH1 miR-429 represses ZEB1 CK1 phosphorylates SNAI1
ZEB1 represses CDH1 miR-200a represses ZEB2 GSK3β phosphorylates SNAI1
ZEB2 represses CDH1 miR-200b represses ZEB2 βTRCP1 degrades SNAI1
TCF3 represses CDH1 miR-200c represses ZEB2 TNFa stabilizes SNAI1
SNAI1 induces CDH2 miR-141 represses ZEB2 MDM2 degrades SNAI1
SNAI2 induces CDH2 miR-429 represses ZEB2 MDM2 degrades SNAI2
ZEB1 induces CDH2 miR-205 represses ZEB1 FBXL14 degrades SNAI1
SNAI1 induces FN1 miR-205 represses ZEB2 FBXL14 degrades SNAI2
SNAI1 represses MUC1 miR130b represses ZEB1 PPA1 degrades SNAI1
ZEB1 represses MUC1 ZEB1 represses miR-141 PPA1 degrades SNAI2
SNAI1 induces LEF1 ZEB1 represses miR-200c PPA1 degrades TWIST1
SNAI1 induces ZEB1 ZEB1 represses miR-200a PPA1 degrades ZEB2
SNAI2 induces VIM ZEB1 represses miR-200b PPA2 degrades SNAI1
HRAS induces VIM ZEB1 represses miR-429 PPA2 degrades SNAI2
SOS interacts HRAS ZEB2 represses miR-141 PPA2 degrades TWIST1
SOS interacts KRAS ZEB2 represses miR-200c PPA2 degrades ZEB2
KRAS interacts RAF1 ZEB2 represses miR-200a PAK1 stabilizes SNAI1
HRAS interacts RAF1 ZEB2 represses miR-200b LOXL2 stabilizes SNAI1
RAF1 interacts MEK1 ZEB2 represses miR-429 LATS2 stabilizes SNAI1
RAF1 interacts MEK2 SNAI1 represses miR-34a PRKD1 nucleus exports SNAI1
MEK1 interacts ERK2 SNAI1 represses miR-34b β-catenin activates LEF1
MEK2 interacts ERK2 SNAI1 represses miR-34c TGFβ1 phosphorylates SMAD2
ERK2 induces ZEB1 miR128-1 represses BMI1 TGFβ1 phosphorylates SMAD3
ERK2 induces ZEB2 miR128-2 represses BMI1 SMAD2 interacts SMAD4
ERK2 induces SNAI1 miR-200c target BMI1 SMAD3 interacts SMAD4
ERK2 induces SNAI2 miR-203 target BMI1 SMAD3 activates HMGA2
ERK2 interacts EGR1 MIR101-1 represses EZH2 SMAD4 activates HMGA2
EGR1 induces SNAI1 SNAI1 represses ESRP1 HMGA2 induces SNAI1
SNAI1 represses cytokeratin 18 ZEB1 represses ESRP1 SMAD3 interacts ETS1
SNAI1 represses claudin 3 ZEB2 represses ESRP1 ETS1 increases ZEB1
SNAI1 represses claudin 4 SNAI1 represses ESRP2 SMAD2 inhibits ID2
SNAI1 represses occludin ZEB1 represses ESRP2 SMAD3 inhibits ID2
ZEB2 represses claudin 4 ZEB2 represses ESRP2 ID2 inhibits TCF3
ZEB2 represses P cadherin SNAI1 interacts DNMT1 TCF3 increases SNAI1
p53 induces miR-34a DNMT1 represses CDH1 miR-200b inhibits JAG1
p53 induces miR-34b SNAI1 interacts HDAC1 miR-200b inhibits JAG2
p53 induces miR-34c HDAC1 represses CDH1 JAG1 activates NOTCH
miR-34a represses SNAI1 SNAI1 interacts HDAC2 JAG2 activates NOTCH
miR-34b represses SNAI1 HDAC2 represses CDH1 NOTCH increases SNAI1
miR-34c represses SNAI1 ZEB1 interacts SIRT NOTCH increases SNAI2
p53 induces miR-200a SIRT represses CDH1 NOTCH increases LOXL2
p53 induces miR-200b ZEB1 interacts BRG1 EGF activates JAK
p53 induces miR-200c BRG1 represses CDH1 EGF activates PI3K
p53 induces miR-141 TWIST1 interacts EZH2 PI3K activates AKT2
p53 induces miR-429 EZH2 represses CDH1 AKT2 increases SNAI1
p53 induces miR-192 TWIST1 interacts BMI1 AKT2 increases SNAI2
p53 induces miR-215 BMI1 represses CDH1 JAK phosphorylates STAT3
miR-192 represses ZEB2 YB1 increases SNAI1 STAT3 increases TWIST1
miR-215 represses ZEB2 YB1 increases ZEB2 AKT2 inhibits GSK3β
miR-200a represses ZEB1 YB1 increases LEF1 GSK3β phosphorylates β-catenin
miR-200b represses ZEB1 YB1 increases TWIST1 wnt1 inhibits GSK3β
miR-200c represses ZEB1 TGFβ1 increases ILEI
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Table 7.2: The average AUC and AUPR values of the 10 feature selection algorithms using
random forest classifier. For each algorithm, we evaluated its prediction performance using
3 data levels. Within each data level, we used 3 different sizes of EMT networks.
Data Level Gene expression DNA Methylation CNA Metric
|V (G)| 74 123 455 74 123 455 70 117 445
EMT 0.631 0.709 0.700 0.634 0.643 0.655 0.621 0.626 0.617 AUC0.590 0.687 0.672 0.586 0.599 0.629 0.595 0.615 0.590 AUPR
t-test 0.630 0.714 0.704 0.635 0.647 0.655 0.621 0.637 0.606 AUC0.583 0.696 0.677 0.587 0.590 0.617 0.597 0.618 0.551 AUPR
Lasso 0.617 0.688 0.639 0.640 0.633 0.649 0.625 0.612 0.614 AUC0.562 0.662 0.597 0.591 0.584 0.621 0.577 0.567 0.543 AUPR
NetLasso 0.628 0.697 0.695 0.634 0.642 0.660 0.627 0.631 0.616 AUC0.579 0.675 0.680 0.589 0.594 0.636 0.591 0.598 0.572 AUPR
addDA2 0.640 0.685 0.665 0.655 0.655 0.704 0.609 0.631 0.614 AUC0.583 0.637 0.630 0.611 0.606 0.676 0.547 0.612 0.584 AUPR
Netrank 0.640 0.697 0.700 0.637 0.639 0.644 0.632 0.623 0.615 AUC0.586 0.679 0.660 0.592 0.581 0.599 0.596 0.601 0.570 AUPR
stSVM 0.630 0.674 0.642 0.627 0.644 0.638 0.623 0.606 0.615 AUC0.595 0.646 0.596 0.567 0.570 0.579 0.593 0.588 0.570 AUPR
Cox 0.648 0.694 0.704 0.653 0.677 0.697 0.626 0.642 0.646 AUC0.607 0.659 0.655 0.605 0.628 0.653 0.599 0.601 0.626 AUPR
RegCox 0.667 0.694 0.721 0.668 0.679 0.661 0.636 0.636 0.635 AUC0.631 0.661 0.690 0.610 0.633 0.589 0.603 0.602 0.596 AUPR
MSS 0.634 0.685 0.656 0.633 0.634 0.631 0.615 0.626 0.619 AUC0.598 0.667 0.619 0.580 0.576 0.581 0.585 0.588 0.580 AUPR
Survnet 0.667 0.679 0.663 0.711 0.683 0.659 0.631 0.677 0.670 AUC0.652 0.661 0.632 0.681 0.649 0.618 0.596 0.652 0.633 AUPR
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Table 7.3: The average AUC and AUPR values of FSFs together with clinical features using
random forest classifier. For each algorithm, we evaluated its prediction performance using
3 data levels. On each data level, we used 3 different sizes of EMT networks.
Data Level Gene expression DNA Methylation CNA Metric
|V (G)| 74 123 455 74 123 455 70 117 445
clinical 0.710 0.696 0.771 AUC0.641 0.612 0.750 AUPR
t-test 0.706 0.741 0.782 0.759 0.769 0.750 0.761 0.789 0.745 AUC0.677 0.717 0.763 0.671 0.705 0.680 0.724 0.746 0.691 AUPR
Lasso 0.733 0.802 0.812 0.749 0.756 0.803 0.781 0.800 0.788 AUC0.700 0.779 0.798 0.683 0.697 0.743 0.727 0.757 0.744 AUPR
NetLasso 0.740 0.764 0.771 0.742 0.745 0.755 0.783 0.765 0.779 AUC0.713 0.725 0.732 0.666 0.675 0.699 0.746 0.722 0.754 AUPR
addDA2 0.686 0.773 0.858 0.689 0.813 0.854 0.732 0.771 0.791 AUC0.627 0.727 0.853 0.573 0.776 0.799 0.713 0.729 0.770 AUPR
Netrank 0.700 0.716 0.773 0.710 0.712 0.700 0.753 0.760 0.725 AUC0.653 0.694 0.755 0.599 0.629 0.600 0.719 0.703 0.688 AUPR
stSVM 0.685 0.704 0.699 0.700 0.680 0.729 0.728 0.748 0.752 AUC0.652 0.698 0.661 0.611 0.583 0.633 0.656 0.710 0.714 AUPR
Cox 0.720 0.717 0.717 0.701 0.737 0.721 0.725 0.772 0.733 AUC0.682 0.672 0.653 0.588 0.668 0.673 0.678 0.720 0.713 AUPR
RegCox 0.728 0.725 0.791 0.733 0.735 0.727 0.750 0.781 0.737 AUC0.679 0.668 0.746 0.662 0.657 0.635 0.706 0.743 0.693 AUPR
MSS 0.717 0.687 0.695 0.709 0.678 0.659 0.739 0.744 0.769 AUC0.682 0.648 0.650 0.642 0.565 0.549 0.700 0.727 0.751 AUPR












x Table 7.4: The summary of association rules inferred from the FSFs of 10 feature selection algorithms and the ensemble algorithm.We have counted the total number of rules with confidence ≥ 0.8 and support ≥ 0.1, and measured their average confidence, lift,
and length.
Data levels t-test Lasso NetLasso addDA2 Netrank stSVM Cox RegCox MSS Survnet Ensemble Metric
GE
343 179 95 38 231 105 209 81 162 212 212 #rules
0.93 0.91 0.85 0.84 0.92 0.89 0.88 0.86 0.89 0.9 0.92 confidence
1.85 1.8 1.69 1.66 1.84 1.79 1.78 1.72 1.77 1.78 1.79 lift
3.78 3.49 4.21 3.24 3.75 3.98 4.02 3.48 3.87 3.97 3.53 length
DM
219 86 58 9 364 158 359 139 41 2 157 #rules
0.9 0.86 0.84 0.85 0.94 0.89 0.95 0.9 0.84 0.83 0.91 confidence
1.79 1.7 1.69 1.71 1.85 1.76 1.92 1.81 1.7 1.66 1.8 lift
3.87 3.52 3.57 3.56 3.82 4.26 3.94 3.57 3.63 4.00 3.53 length
CNA
204 58 64 48 183 37 60 77 22 34 109 #rules
0.9 0.84 0.87 0.85 0.89 0.84 0.84 0.86 0.83 0.85 0.87 confidence
1.77 1.7 1.71 1.67 1.75 1.65 1.67 1.7 1.66 1.69 1.71 lift
3.29 3.97 3.25 3.02 3.31 3.19 3.43 3.64 3.27 3.47 3.46 length
GE+DM
184 217 86 57 247 29 181 215 243 31 229 #rules
0.91 0.92 0.87 0.87 0.91 0.84 0.91 0.91 0.89 0.84 0.91 confidence
1.8 1.83 1.74 1.77 1.8 1.68 1.85 1.81 1.82 1.67 1.82 lift
3.73 3.54 3.66 3.61 3.68 3.52 3.59 3.42 4.30 3.45 3.65 length
GE+CNA
334 284 68 92 362 9 204 139 73 48 303 #rules
0.94 0.93 0.86 0.87 0.94 0.82 0.89 0.89 0.85 0.83 0.9 confidence
1.84 1.89 1.73 1.73 1.84 1.65 1.76 1.78 1.7 1.65 1.79 lift
3.70 3.69 3.37 3.49 3.65 3.22 3.50 3.53 3.86 3.69 3.61 length
DM+CNA
351 198 62 32 298 22 267 212 61 51 218 #rules
0.94 0.89 0.84 0.85 0.92 0.85 0.93 0.92 0.85 0.85 0.92 confidence
1.84 1.76 1.68 1.7 1.8 1.67 1.84 1.82 1.72 1.68 1.82 lift
3.56 3.43 3.16 3.28 3.47 3.32 3.53 3.51 3.75 3.10 3.44 length
GE+DM
+CNA
382 427 167 84 318 31 188 363 250 32 524 #rules
0.95 0.95 0.89 0.86 0.95 0.85 0.9 0.94 0.91 0.83 0.95 confidence
1.87 1.91 1.81 1.72 1.86 1.7 1.77 1.89 1.86 1.66 1.89 lift
3.54 3.61 3.54 3.44 3.60 3.55 3.43 3.48 4.03 3.06 3.56 length
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Table 7.5: The p-values of log-rank tests based on the clustering of spectral clustering al-
gorithm for different data level combinations using extended EMT network. We highlighted
all p-values that are lower than 10e-5.
GE DM CNA GE+DM GE+CNA DM+CNA GE+DM+CNA
t-test 1.19e-5 1.18e-1 6.39e-2 8.16e-1 9.51e-7 3.85e-1 1.86e-5
Lasso 2.34e-4 6.78e-1 7.67e-1 4.92e-1 1.76e-5 1.85e-6 2.69e-6
NetLasso 3.36e-2 8.61e-1 5.25e-1 2.96e-1 2.46e-2 2.61e-1 8.03e-1
addDA2 2.16e-5 4.55e-1 3.00e-4 8.44e-13 3.09e-6 1.61e-7 1.45e-5
Netrank 4.89e-03 1.82e-01 8.85e-01 5.30e-02 2.11e-02 1.62e-02 1.15e-01
stSVM 1.64e-01 5.22e-01 5.77e-01 5.62e-01 2.20e-01 7.45e-01 7.92e-01
Cox 3.49e-03 1.36e-04 1.04e-02 4.45e-05 1.34e-04 1.49e-05 2.10e-01
RegCox 1.41e-04 6.53e-03 1.60e-03 1.20e-01 7.63e-02 2.89e-01 4.07e-01
MSS 1.72e-03 8.71e-01 1.12e-01 4.51e-03 6.32e-04 1.59e-01 1.44e-02
Survnet 3.89e-05 2.48e-02 2.30e-01 9.20e-04 6.13e-04 1.23e-03 2.14e-05
Ensemble 1.40e-03 9.75e-01 8.37e-02 3.95e-03 8.12e-07 2.42e-09 1.68e-08
allemt 5.78e-03 8.37e-01 3.46e-01 9.58e-01 9.36e-03 7.79e-01 4.02e-01
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Zusammenfassung
Netzwerke ko¨nnen als Vorwissen verwendet werden, um molekulare Signaturen zu identi-
fizieren. Die meisten Studien verwenden PPI-Netzwerke und Genexpressionsdaten, wobei
PPI-Netzwerke ha¨ufig verwendet werden, um die wichtige Features oder Unternetzwerke
als Signaturen zu finden. Da immer mehr der zahlreichen Arten von Omics-Daten zur
Verfu¨gung stehen, stellt sich die Frage, welche Art von Daten bessere molekulare Signa-
turen hervorbringen ko¨nnen und ob es vorteilhaft ist, mehrere Omics-Daten gleichzeitig zu
verwenden, um bessere Signaturen zu identifizieren. Dies sind die zwei Hauptfragen, die
in dieser Dissertation behandelt werden.
Wir untersuchen dieses Thema mit dem Anwendungsfall der Vorhersage von Kreb-
sprognosen. Nach einer umfassenden Literaturrecherche zu Feature Selection Algorith-
men wa¨hlen wir 10 Algorithmen aus. Fu¨nf von diesen integrieren Netzwerkinformationen,
die anderen betrachten die Omics-Daten ohne Zunahme eines Netzwerks. Auf Einzeld-
atenebene fu¨hren wir die Feature Selection alternativ auf drei Datenebenen durch - mRNA-
und miRNA-Expression, DNA-Methylierung und Kopienzahlvariation aus. Dann ana-
lysieren wir die Vorhersageleistung dieser Features auf ihre Stabilita¨t, Netzwerkeigenschaften
und biologische Interpretation. Um Multi-Omics-Signaturen zu erhalten, kombinieren wir
zuerst die ausgewa¨hlten Features aus einzelnen Datenebenen und testen deren Vorhersageleis-
tung. Dann erweiterten wir netzwerkbasierte Feature Selection Algorithmen, um mehrere
Datenebenen unter Verwendung einer Multiplexstruktur zu integrieren. Die Feature Se-
lection Algorithmen ohne Netzwerk hingegen werden auf kombinierten Daten angewendet.
Schließlich untersuchen wir die Vorhersageleistung von Single-Omics- und Multi-Omics-
Signaturen an einer Reihe unabha¨ngiger Stichproben mit zwei Omics-Datenebenen.
Das kritische Thema bei der Entdeckung von Biomarkern ist sog. Curse of dimen-
sionality, der eine geringe Reproduzierbarkeit der molekularen Signaturen verursachen
kann. Selbst mit netzwerkbasierten Feature Selection Algorithmen wurden signifikante
Verbesserungen nicht erreicht, da die Netzwerke oft groß sind. Um dieses Problem zu lo¨sen,
schlagen wir vor, Pha¨notyp-relevante Genregulationsnetzwerke basierend auf epithelial-
mesenchymale Transition (EMT) zu benutzen, die sich als a¨ußerst relevant fu¨r Krebsmeta-
stasen und -prognosen erweisen. Dann haben wir verschiedene Arten von Omics-Daten
in das Netzwerk integriert, um prognostische Signaturen zu finden. Obwohl die Dimen-
sionalita¨t auf weniger als 2,5% des Originals reduziert ist, bieten EMT-Funktionen eine
bessere Vorhersageleistung als die aus den Originaldaten ausgewa¨hlten Features. Ha¨ufig
ausgewa¨hlte Features erreichen durchschnittliche Vorhersage-AUC-Werte von u¨ber 0,8.
Diese Features sind in der Lage, Stichproben in signifikant unterschiedliche prognostische
Gruppen sowohl auf den Trainingsdaten als auch auf den unabha¨ngigen Testdaten zu strat-
ifizieren. Die Verwendung kombinierter Features aus mehreren Omics-Ebenen und die
Verwendung einer multiplexbasierten Feature-Auswahl verbessern die Vorhersage weiter.
Daru¨ber hinaus haben wir relationale und NoSQL Datenbanken zur Integration in die
Multi-Omics-Datenanalyse verglichen. Da biologische Daten große Volumen, hohe Dy-
namik und große Vielfalt aufweisen, ist es notwendig, ein Datenbanksystem zu haben,
das Daten effizient speichern und abrufen kann. Basierend auf den Ergebnissen haben
wir notwendige Bedingungen zum Aufbau eine skalierbaren Omics-Dateninfrastrukturen
abgeleitet.
